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ABSTRACT 
While Human Leukocyte Antigen (HLA) typing remains the central means of 
selecting stem cell donors and determining stem cell transplantation (SCT) outcome, 
non-HLA molecules are also involved in the process. HLA compatibility is the main 
factor determining the occurrence of graft-versus-host disease (GvHD) in patients. It 
has also been shown that minor histocompatibility antigen differences as well as 
genetic polymorphisms that are not sequenced by standard methodology for HLA 
typing can play a role.  
As early predictive markers for the occurrence of GvHD are still lacking and a better 
understanding of the mechanisms and pathways involved are still needed to provide 
insight into the pathogenesis of the disease, this study aims to identify novel targets 
for identifying allogeneic responses predictive of such a serious complication of this 
therapeutic treatment. 
The mixed lymphocyte culture (MLC) model was used under different conditions in 
order to identify potential genetic markers associated with allogeneic responses. 
Initially, this model using the mononuclear cell fraction of blood samples from 
mismatched individuals was validated by comparing cell activation and proliferation 
and time course studies, as well as using irradiation of cells and lipopolysaccharide 
(LPS) in an effort to mimic the in vivo conditions occurring during the infusion of 
allogeneic cells to patients during SCT. 
Through a limited gene expression analysis of immune related genes, of both HLA-
matched and HLA-mismatched mononuclear cell fractions, we further validated the 
time and conditions used for global gene expression profiling and observed different 
gene expression changes between the two HLA settings. 
  
The investigation of global gene expression changes, of the HLA matched and HLA 
mismatched MLC, enabled us to identify differentially regulated genes and pathways. 
A great number of these genes were related to immune function. These genes were 
also found to be associated with GvHD and graft rejection in previous studies. By 
investigating global gene expression changes in mismatched MLC we aimed to 
identify genes that may constitute good targets to study further as markers for donor-
recipient alloresponses. The most highly upregulated genes were IDO1, CXCL9, 
CXCL10 and CCL8. The majority of differentially regulated genes were IFN-γ 
inducible genes and IFN-γ neutralisation in MLCs abrogated their induction. The 
microRNA-155, a recently identified target for GvHD, was also found to be 
significantly induced in HLA mismatched MLC but not in the matched setting and its 
induction was not diminished by IFN-γ blockade. 
In this proof-of-principle study we show gene expression changes in mismatched 
MLC that represent alloreactive responses and correlate with markers involved in 
GvHD and can potentially be useful in further studies of the biological processes 
involved in this disease but also in the search of early predictive markers for the 
disease. 
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General Introduction 
 
1.1. Allogeneic stem cell transplantation 
For half a century allogeneic stem cell transplantation (ASCT) in humans has been 
used as a therapeutic method to cure malignant and non-malignant haematologic 
diseases but also non-hematological diseases. Stem cells from a histocompatible 
donor, which can be a sibling, an unrelated volunteer donor (UVD) or cord blood, are 
infused into a recipient/patient following a conditioning regiment. In many cases 
ASCT is the only curative option available. The first transplantation was performed 
shortly after the discovery of the Human Leukocyte Antigen (HLA) system in 1968 (1) 
and involved a young child with severe combined immunodeficiency (SCID) (2), a 
genetic disorder in which there is no B cell and T cell production in the body (3). 
Bone marrow was transplanted from his HLA-identical sister and led to the deficiency 
being corrected.  
 
Since the first transplantation the procedure has been developed and a steady 
increase in the number of transplantations performed can be observed. Significant 
changes in the procedure include the shift from bone marrow to peripheral blood as 
the source of stem cells as well as the use of cord blood (4), better conditioning 
treatments and improved HLA typing methods among other. The main reported 
indications for ASCT are leukaemia, lymphoproliferative diseases, myelodysplasia 
and non-malignant diseases such as thalassaemia and severe aplastic anaemia (5). 
However, the availability of more therapeutic options in some cases has led to a 
change in the major indications. For example, the availability of Tyrosine kinase 
inhibitors for the treatment of patients affected by chronic myelogenous leukaemia 
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(CML) (6) has led to a dramatic decrease in the number of transplantations in this 
disease, despite the fact that CML was formerly the main indication for ASCT. 
 
The intention of ASCT, as a therapeutic approach, is to reconstitute the recipient’s 
defective haematopoietic system, which has been ablated by conditioning and in this 
way eradicate disease. However, disease is not eradicated simply by the virtue of 
the diseased cells being replaced with healthy cells from the donor. Indeed, the 
uniqueness of ASCT is that it involves potential immune recognition and attack 
between donor and recipient. It is now generally accepted that the way that ASCT 
leads to cure, relies primarily on the ability of immunocompetent transplanted cells to 
mount sustained responses directed towards malignant recipient cells. These 
responses are collectively termed graft-versus-tumour (GvT) effects (7,8). Host-
versus-graft (HvG) effects represent the other side of the coin, which can lead to 
graft rejection. Finally, graft-versus-host (GvH) effects arise when immunocompetent 
transplanted cells of the donor can recognize and attack healthy tissues of the 
recipient, a situation termed Graft-versus-host disease (GvHD) which represents a 
major complication of transplantation (9,10). 
 
ASCT can be a highly successful therapeutic approach (more than 50% cure rate 
when performed in the early phases of disease in young patients) but it also has 
some important limitations. The first limiting factor is the lack of availability of 
histocompatible grafts, which results in patients not being able to find the most 
suitable graft. This in turn, increases the contribution of the second limiting factor 
which is the development of GvHD in transplanted patients. As described above 
there are a number of immunological reactions that can occur in a transplanted 
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patient and the success of ASCT as a therapeutic approach relies in the balance 
between HvG, GvH and GvT reactions. Overcoming these limitations would lead to 
the application of this life-saving procedure in more patients. Improving HLA-typing 
techniques (11) and developing donor registries are obviously important. At the 
same time, transplant-related mortality could be reduced through a better 
understanding of the mechanisms driving GvHD, which can lead better ways of 
predicting, diagnosing and treating this disease.  
 
1.2. The major histocompatibility complex 
The Major Histocompatibility complex (MHC) is a 7 megabase region located on 
chromosome 6 in humans and chromosome 17 in mice. This region is particularly 
gene-rich containing more than 200 genes, the majority of which are involved in 
immune responses (12). Genes within this region were firstly identified to determine 
whether tumours transplanted from one strain of mice to another were accepted or 
rejected. Experiments were extended to humans receiving skin grafts. For their 
pioneering work that lead to the discovery and understanding of the importance of 
MHC genes in transplantation Frank Macfarlane Barnet and Peter Medawar received 
the Nobel Prize in 1960.  
The most critical genes for transplantation within the MHC region, encode the α 
chains of MHC class I molecules and the α and β chains of MHC class II (13). In 
humans these genes are known as Human Leukocyte Antigens or HLA as they were 
first discovered as antigenic differences of white blood cells across different 
individuals. In the mouse system MHC genes are known as the Histocompatibility-2 
(H-2) genes. The general organization of the MHC class I and II genes in humans is 
shown in Figure 1. The class I antigens which include HLA A, B and C, are hetero 
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dimmers composed of a heavy chain with polymorphic regions and a β2 
macroglobulin as a non-polymorphic light chain. The genes for β2-microglobulin and 
the invariant chain are on different chromosomes (chromosomes 15 and 5, 
respectively, in humans and chromosomes 2 and 18 in the mouse). Class I antigens 
are expressed on almost all nucleated cells. Class II antigens are HLA-DRB, -DQ 
and -DP and are only expressed on antigen presenting cells (APCs) such as 
dendritic cells, B cells and macrophages but can also be expressed on other cell 
types during inflammation; for example IFN-γ can induce the expression of Class II 
MHC. Class II antigens are also hetero dimmers, made of α and β chains, both 
polymorphic except for DP antigens which share the same invariant α chain. The 
MHC region also includes MHC class III genes that have completely different roles 
than MHC I and II genes (14).  
 
 
Figure 1. Gene map of the human leukocyte antigen (HLA) region. The HLA region 
spans 4 × 10
6
 nucleotides on chromosome 6p21.1 to p21.3, with class II, class III 
and class I genes located from the centromeric (Cen) to the telomeric (Tel) end.  
(Adapted from http://www.expertreviews.org/ in molecular medicine) 
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The function of HLA Class I and II molecules is to present peptides to T cells; this 
function is critical for the immune system as, unlike B cells, T cells cannot recognize 
antigenic epitopes on the surface of soluble antigens. T cells can only be activated 
by antigenic peptides that have been processed and are presented by HLA 
molecules on the surface of antigen presenting cells (15, 16). If an antigen cannot be 
processed and presented in a complex with an HLA molecule, it cannot be 
recognised by T cells, so as to activate and hence mount an immune response 
against it. Molecules encoded within the HLA Class III region do not participate in 
antigen presentation, but their function is related to the immune system. Important 
gene products of this region include complement proteins such as C2 and C4, 
cytokines such as Tumour Necrosis Factor and heat –shock proteins such as HSP70 
(17).  
 
1.2.1 Major histocompatibility complex class I antigen processing and 
presentation 
The class of MHC used to present antigen is dictated by the type of antigen. 
Endogenous antigens are presented by MHC class I whereas exogenous antigens 
are presented by MHC class II (12, 18, 19, 20). MHC class I present endogenous 
peptides that are expressed within the cell, are hence present in the cytosol, and are 
processed in the cytosolic pathway (21). Endogenous antigens could be proteins 
derived from viruses that have infected the cell or other intracellular parasites but 
can also be endogenous modified self-proteins for example mutated proteins 
expressed by cancerous or aged cells that have accumulated mutations. These 
antigens are tagged for degradation by the addition of the small protein ubiquitin and 
are led to the proteasome (22). Proteasomes which are protein complexes, serve to 
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degrade unneeded or damaged proteins by proteolysis of the protein peptide bonds. 
The proteasome is not a structure dedicated to the immune system process of 
antigen processing and presentation but is part of a major mechanism by which cells 
regulate the concentration of particular proteins and degrade misfolded proteins. 
Degradation of proteins in the proteasome yields peptides which can then be further 
degraded into shorter amino acid sequences and can be used as building blocks for 
the synthesis of new proteins. Peptides from the degraded endogenous antigen can 
be selectively transported from the cytosol into the lumen of the endoplasmic 
reticulum through the transporter associated with antigen processing (TAP), a 
heterodimer membrane receptor consisting of TAP1 and TAP2 (23). Translocation of 
peptides through TAP requires energy in the form of ATP and has the highest affinity 
for peptides that are between 8 and 12 amino acids long, which constitutes the most 
appropriate sized peptide to fit in the closed antigen binding pocket of MHC class I 
molecules. 
 
Once in the lumen of the endoplasmic reticulum, the peptides will encounter the 
newly synthesized MHC class I molecules and will be loaded to their binding site. 
This process requires the co-operation of several other proteins including tapasin, 
calreticulin, calnexin and Erp57 that act as molecular chaperones and assist with 
peptide loading (24). Calnexin acts to stabilize the α chain of the class I MHC prior to 
the association of the β2-microglobulin and dissociates following complete assembly. 
Without the peptide bound to it, the class I molecule is still unstable and requires the 
assistance of chaperones calreticulin and Erp57. Finally tapasin is a protein that is 
linked to the TAP receptor and facilitates peptide loading by bringing class I 
molecules in close proximity to the TAP receptor (25). Once the peptide is loaded 
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onto the MHC class I molecules the complex leaves the endoplasmic reticulum 
through the secretory pathway to reach the cell surface. MHC I antigen presentation 
There, it can be recognized by CD8+ T cells and is the first signal generated by the 
interaction between the TCR and MHC plus antigenic peptide complex on APCs. But 
in order for antigen presentation to elicit cell activation a secondary costimulatory 
signal is required. The second signal is delivered by “positive” costimulatory 
molecules expressed on APCs that interact with their cognate receptors on T cells 
(26). The CD28:B7 signaling is the best characterised and perhaps the most 
important costimulatory pathway for the activation of naive T cells. Interaction of 
CD28, constitutively expressed on T cells, with B7-1 and B7-2, expressed on APCs, 
provides the second positive signal that results in full T cell activation including 
cytokine production, clonal expansion, and prevention of anergy and T cell survival 
(27,28 29).  However, it is now clear that some costimulatory molecules deliver 
negative signals that down-regulate T cell responses in vitro and in vivo. The 
CD28/CTLA-4:B7 pathway is the best characterized T cell costimulatory pathway 
and is critical for T cell activation and peripheral tolerance (30, 31). CD28 
costimulation is necessary for the initiation of most T cell responses. Once activation 
occurs, T cells can develop into effectors and/or memory cells that are important in 
mediating the immune response. CTLA-4 is expressed on activated T cells and 
interacts with B7 to deliver a negative costimulatory signal to T cells inhibiting TCR- 
and CD28-mediated signal transduction (32, 33). The critical role of CTLA-4 as a 
negative regulator of T cell activation was illustrated in CTLA-4-deficient mice, which 
died within 3–4 weeks of birth from massive lymphoproliferation (34, 35). 
Activated CD8+ T cells can differentiate to cytotoxic T cells (CTLs), which are 
effectors cells with the ability to directly kill targets (36). Since nearly all nucleated 
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cells express MHC class I, all of them can potentially present foreign antigens and 
activate CTLs (36). The importance of this fact is that any cell of the body can be 
detected and destroyed if it is infected or transformed and thus, it is presenting such 
antigens on its surface.  
 
1.2.2 Major histocompatibility complex class II antigen processing and 
presentation 
MHC class II molecules present exogenous peptides derived from bacteria and 
parasites that are internalised by antigen presenting cells through the process of 
phagocytosis or receptor-mediated endocytosis (38). Such exogenous materials are 
processed in the endocytic pathway in lysosomes by the action of various proteolytic 
enzymes and low pH (39). The processing breaks antigens down to antigenic 
peptides that are 10 to 20 amino acids long, longer than antigenic peptides that bind 
to class I MHC molecules. The antigen binding pocket of class II MHC molecules can 
accommodate longer peptides because they are open as both ends. Loaded 
antigenic peptides are transported to the surface of antigen presenting cells 
complexed with class II MHC molecules and are presented to CD4+ T cells and 
activate them (39, 40).  
 
Similar to class I MHC molecules the α and β chains of class II MHC molecules are 
also expressed and assembled in the lumen of the endoplasmic reticulum however 
these molecules do not bind to antigenic peptides of the cytosolic pathway found in 
this cellular compartment. This is because the MHC class II chains are complexed 
with a special polypeptide, called the invariant chain, which effectively blocks the 
peptide-binding cleft (41). In that way binding of peptides found in the lumen of the 
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endoplasmic reticulum is hindered since these peptides are destined to be bound to 
class I MHC molecules. The invariant chain also facilitates the export of class II 
molecules from the endoplasmic reticulum to the Golgi and subsequently to late 
endosomes that contain the endocytosed, degraded antigenic peptides (42).  
Loading of the antigenic peptides is allowed because the invariant chain is 
progressively degraded leaving at first a small fragment known as CLIP which is 
finally removed by an MHC class II related molecule, HLA-DM. MHC class II 
molecules complexed with antigenic peptides are finally transported and presented 
on the cell surface. 
 
Since class II MHC molecules present antigenic peptides derived from extracellular 
antigens their role is to survey the extracellular space for pathogens for example 
bacteria infecting a wound or found in the blood. Class II molecules present and 
activate CD4+ T helper cells the main function of which is the production of cytokines 
that support the activation of B cells and T cytotoxic cells (43). Nevertheless 
secondary costimulation is also required as well as explained earlier in Section 1.2.1. 
In this way an appropriate immune response can be orchestrated in response to 
extracellular invaders which may involve localised inflammation due to recruitment of 
phagocytes as well as the induction of both the humoral and cell-mediated adaptive 
responses. 
 
1.2.3 Major histocompatibility complex polymorphism 
HLA is the most polymorphic genetic locus in humans (44). HLA polymorphism 
refers to   the fact that multiple ‘version’ of the HLA genes i.e. A, B, C, DQ, DP, DR 
exist, which are known as alleles. This fact was identified early in the study of HLA 
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molecules and polymorphisms within the HLA system and new ones are constantly 
being discovered. In addition, the need for a systematic nomenclature and 
documentation was recognised. The naming of new HLA genes and allele 
sequences is the responsibility of the WHO nomenclature Committee for Factors of 
the HLA System, which sets the nomenclature criteria and rules since 1968. 
Currently, there are more than 12,000 known HLA alleles comprised of 9,437 Class I 
and 3,105 Class II alleles (Table 1.).  
Table 1. Known HLA Class I and Class II alleles 
(Adapted from HLA nomenclature http://hla.alleles.org/nomenclature/stats.html) 
HLA Class I 
Genes A B C 
Alleles 2,995 3,760 2,553 
Proteins 2,112 2,789 1,799 
Nulls 140 122 80 
 
HLA Class II 
Gene DRA DRB DQA1 DQB1 DPA1 DPB1 
Alleles 7 1,740 52 734 38 489 
Proteins 2 1,276 32 486 19 402 
Nulls 0 42 1 17 0 13 
 
HLA polymorphisms dictate the repertoire of antigens that can be bound and 
therefore presented to T cells. In other words, it determines the repertoire of antigens 
that can induce an immune response. Indeed, one of the main factors that determine 
the immunogenicity of antigens is the MHC genes of each individual; consequently 
within a population different individuals will have a different ability to recognise and 
mount immune responses to different antigens. The vast majority of HLA 
polymorphisms has been maintained among the human population because it 
ensures, that at least, some individuals will be able to respond to a certain antigenic 
challenge and survive, providing therefore a competitive advantage (45). 
Interestingly, a number of studies have suggested that HLA polymorphism may 
affect mate choice at least in mammals, with data showing that mice prefer to mate 
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with individuals of different MHC types, than mice that had the same HLA (46).  Such 
mate selection would of course be beneficial for the population as it would increase 
allelic diversity and thus increase the ‘fitness’ of a population. Finally, It is considered 
that MHC-based sexual selection involves olfactory mechanisms with some data 
even coming from studies with human subjects.   
The extensive polymorphism of the HLA system might be evolutionarily beneficial for 
the survival of populations but also means that finding matching grafts for patients in 
need of transplantation is a difficult task to perform. As mentioned above, 
polymorphisms within the HLA system are still being discovered and over 12,000 
alleles have been identified worldwide. Nevertheless, the discovery of the HLA 
system revolutionised the approach of using transplantation as a therapeutic method 
and the matching of donor and recipient for HLA serves as the gold standard. This 
significantly improved the outcome of ASCT. The introduction of better typing 
techniques for HLA typing has revealed that antigen typing is not sufficient for 
determining histocompatibility and that high-resolution allelic HLA matching generally 
improves transplant outcome but has the disadvantage of somewhat limiting the 
donor pool (47,48). The effects of HLA disparity between donor and recipient are 
well documented for their cause of morbidity and mortality to the recipient (49, 50) 
and will be further discussed below with regards to GvHD. 
 
1.3. Graft versus host disease 
GvHD is unique in ASCT, as the transplanted tissue-donor T cells, recognise the 
genetically disparate and immunosuppressed recipient as non-self. The result of this, 
leads to organ damage, with deleterious events that can be lethal. Acute GVHD 
(aGvHD) primarily affects the skin, liver and gastrointestinal tract and typically occurs 
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within the first two months after ASCT (9), but also can occur later. Generally, 
disease occurring up to 100 days after transplantation is classified as aGvHD 
whereas disease occurring after 100 days of transplantation is classified as chronic 
GvHD (cGvHD). The development of GvHD depends on the presence of three 
conditions (51). First, immunocompetent cells have to be present in the graft. 
Second, genetic disparity between the recipient and donor is required in order to 
activate the transplanted immunocompetent cells. And finally, the recipient must not 
be able to clear the donor’s activated immunocompetent cells.  
 
1.3.1 Immunobiology of graft-versus-host disease 
The classical model of GvHD development divides its progression into three distinct 
phases.  
First Phase 
Preparative transplant regiments include chemotherapy and sometimes total body 
irradiation and the first phase of the disease in recognised as the tissue injury 
caused by these regiments in the mucosal and epithelial surfaces especially in the 
gastrointestinal tract of the recipient patient (51,52). This damage results to tissue 
inflammation and the release of immune stimuli such as pro-inflammatory cytokines 
such as tumor necrosis factor-α (TNF-α) and interleukin-1 (IL-1) (55). Tissue damage 
also leads to increased intestinal permeability and release of gut-derived endotoxin 
lipopolysaccharide (LPS), a glycolipid component of the outer membrane of Gram-
negative bacteria of normal gut flora which enters the circulation.  LPS, which acts as 
a ligand for Toll-like receptor-4 (TLR-4), triggers the release of inflammatory 
cytokines (mostly TNF-α) by monocytes and macrophages, further mitigating the 
inflammatory process (56). The consequence of this immune stimulation in the 
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recipient, there is upregulation of co-stimulatory and MHC molecules. In agreement 
with the importance of this phase in GvHD development, intensive conditioning 
regimens, history of viral infections and advanced stage leukaemia are associated 
with increased incidence of GvHD (57,58). Furthermore, the connection between 
severity of GVHD and expression of inflammatory cytokines along with conditioning 
intensities is further supported by animal model studies. The increase in MHC 
expression along with adhesion molecules results in an enhanced recognition of host 
APCs by donor T cells (59). On the other hand, reduced intensity conditioning 
regimens result in reduced occurrence of GVHD. 
 
Second Phase 
In the second phase, the donor graft is infused and the immunocompetent 
alloreactive donor T cells recognise major and minor histocompatibility antigens 
presented by activated host APCs as foreign. The alloreactive T cells, are become 
activated, differentiate, and proliferate and their subset differentiation is determined 
by the alloantigen composition of the host. Using mouse models, it has been shown 
that CD4+ cells induce GVHD in response to MHC class II variances, while CD8+ 
cells induce GvHD in response to MHC class I variances. The greater the disparity 
between the donor and recipient MHC the greater the T cell response will be. In the 
case of mismatched transplantation the alloreactive T cell frequency is at least five-
fold higher than the frequency of peptide-specific T cells reacting to an autoantigen 
(60). In HLA identical pairs, the donor T cells recognise differences of the minor 
histocompatibility antigens miHAgs, presented on the host APCs. Under the 
influence of the pro-inflammatory cytokine environment, clonal T cell expansion and 
differentiation occurs into effector cells.   
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Although in theory APC from either the host or the donor could interact with and 
activate alloreactive T cells, experimental evidence strongly supports that host-
derived APC are the most crucial (61,62). The most potent APC are considered to be 
the dendritic cells. These cells are activated by necrotic cells, which are the result of 
chemotherapy or radiotherapy to the patient, microbial products such as LPS that 
leak from damaged intestinal mucosa, and inflammatory cytokines. A key event in 
the second phase of GVHD is the secretion of cytokines by activated T cells that 
include IL-2, IL-15, and IFN-γ. An interesting observation relating to IFN-γ is that the 
expression of this cytokine in animals with GvHD peaks prior to the appearance of 
clinical symptoms, suggesting that this molecule plays a role in the early stages of 
the disease (63).  
 
Third Phase 
The third phase of GvHD is the efferent phase of acute GvHD involving a complex 
cascade of cellular and inflammatory effectors, resulting in the attack and damage of 
healthy tissues in the graft recipient. The main cellular effectors of acute GvHD are 
CTL and NK cells (63). The main inflammatory effectors involved in GvHD are the 
cytokines TNF-α and IL-1 that are produced by stimulated monocytes and 
macrophages. These immune cells may be activated by microbial products such as 
LPS.  The TNF-α cytokine contributes to GvHD by inducing the presentation of 
alloantigens by dendritic cells, the recruitment of immune cells into target organs, 
and by damaging tissue directly through its ability to induce apoptosis (64).   
The ‘cytokine storm’ that takes place during this phase, which includes TNF-α, IL-1 
and IL-2, also activates Natural Killer cells (NK cells) which along with cytotoxic T 
lymphocytes, perpetuate the damage by the engagement of the Fas/Fas ligand and 
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perforin/granzyme dependent mechanisms (65, 66). The induction of apoptosis in 
the target tissues further contributes to the process by the release of inflammatory 
mediators. The main tissues affected are the GI tract, the liver and the skin. 
However, the exact pathogenic mechanisms involved remain unstudied.  
 
1.3.2 Risk factors for graft-versus-host disease HLA disparity 
The classic HLA genetic loci, encoded by the MHC, are the best characterised and 
most influential determinants for GvHD (67). Class I HLA proteins (A, B and C) are 
expressed in various densities on almost all nucleated cells, while Class II molecules 
(DR, DQ and DP) are primarily expressed on B cells, dendritic cells and monocytes 
which represent the antigen presenting cells. As the likelihood of GvHD development  
is directly related to the degree of HLA disparity between recipient and   donor, donor 
selection for transplantation is based on matching for HLA by DNA typing for HLA-
class I (HLA-A, -B, -C) and II (HLA-DRB1, -DQB1) loci. The intent is to identity at 
least an 8/10 antigen match in order to proceed with transplantation. Studies using 
large patient cohorts confirm that if patient and donor have less than 8/8 identity at A, 
B, C and DRB1 loci this leads to increased risk for GvHD in the absence of T-cell 
depletion (68, 69, 70, 71). 
The contribution of the individual HLA loci has also been investigated. A study by the 
Center for International Blood and Marrow Transplant Research (CIBMTR) showed 
that mismatching at HLA-B or C conferred less risk than mismatching at HLA-A or 
DRB1 (72). With regards to the use of growth factor-mobilised peripheral blood stem 
cells, in a cohort of 1933 patients Woolfrey et al. identified that among all 
mismatches, donor HLA-C antigen mismatching was associated with worse 
outcomes compared to HLA-A, B or DRB1 mismatching (73). The contribution of DP 
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and DQ loci mismatches is less clear with different studies showing conflicting 
results. It has been shown that there is no increase in risk for DQ mismatches (73) 
while in another study, DQB1 mismatching significantly increased risk together with 
another mismatching at HLA-A, C, B or DRB1 (74). Although, it is understood that 
mismatching at each HLA locus increases risks, heterogeneous findings make it 
challenging to precisely understand the relative impact of each loci. Understandably, 
these relative risks, are important when no HLA-matched donor is available and 
transplantation from a mismatched donor is considered. Nevertheless, data from 
many studies have collectively led to the establishment of HLA matching guidelines 
for the selection of unrelated donors for bone marrow transplantation (75). In 
addition, several important concepts have emerged from international experience 
including that the negative effects of HLA mismatching are additive to one another, 
HLA-DQB1 locus mismatches appear to confer the least risk, except when they 
occur in combination with mismatching at other HLA loci, HLA-C mismatches are 
highly deleterious and finally that mismatching at certain epitopes are risky (76).  
 
Clinical factors of the recipient and donor 
Even in the setting of HLA-matched ASCT moderate to severe aGvHD occurs in 
roughly 40% of patients (78). Many additional factors that contribute to the 
subsequent development of aGvHD following ASCT have been identified. Some 
examples are clinical factors of the recipient/patient and donor, pre-transplant 
conditioning and GvHD prophylaxis are associated with increased GvHD occurrence 
as well as non-HLA genetic factors that correlate with increased risk. The risk for 
acute GVHD rises with increasing patient age (78); animal models of ASCT suggest 
that in older recipients the antigen presenting cells have increased allostimulatory 
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activity (79). Large studies also show that the underlying diagnosis of the recipient 
contributes in the development of GvHD. Using multivariate analysis it was observed 
that CML is conveying the highest risk for GvHD as compared to other diseases (70, 
71).  ABO antigen disparity has also been suggested to contribute with a study 
showing minor ABO incompatibility increasing the risk for aGvHD (78), although this 
association was not confirmed in larger studies (71) 
 
Minor histocompatibility antigens 
As mentioned above aGVHD occurs in roughly 40% of patients receiving HLA-
identical grafts (68), and can occur in the HLA matched sibling and syngeneic twin 
setting. The biggest contributors to these alloreactions are undetected antigen 
differences between individuals which can be recognised by donor T cells following 
transplantation and lead to the disease. The minor Histocompatibility antigens 
(miHAgs) are not coded by the MHC but are peptides derived from intracellular 
proteins of restricted polymorphisms by autosomal or Y chromosome genes. These 
peptides are presented by HLA Class I or Class II molecules. miHAgs have been 
correlated with GvHD (80, 81). T cell clones recognizing miHAgs were first isolated 
following ASCT in patients with GVHD or graft rejection. In the HLA matched 
transplant setting, GvHD is mounted against miHAgs (81), with some miHAgs 
causing a more severe reaction than others. One example is the case of a male 
receiving a graft from a female donor with multiple reports showing that such donor 
selection increases GvHD risk (82), particularly when the female individual has been 
allo-immunised as a result of a previous pregnancy. The source of miHAgs is the HY 
antigens which have a ubiquitous distribution and account for the increased GvHD in 
male recipients of female allografts (83).  
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Stem Cell Source 
Graft properties have also been identified as risk factors for the development of 
aGvHD. The stem cell source can vary depending on availability. The donor would 
ideally be a genetically identical sibling i.e. a monozygotic twin. Since such a donor 
is rare to find, HLA-identical siblings are the next best possible donors for graft 
acquisition. Patients without suitable sibling donors use grafts from UVD or cord 
blood units or even haploidentical donors. This has led to the setup of HLA-typed 
volunteer donor pools reaching today more than twenty seven million donors 
registered worldwide (84).  
In the case of haploidentical transplantation, T cell depletion or aggressive 
immunosuppressive GvHD prophylaxis have been used to minimize the risk for 
developing GvHD. Despite the fact that these strategies make such transplantations 
possible, they predispose the recipients to delayed immune reconstitution therefore 
increasing the risk of infection or disease relapse. Generally it has been 
demonstrated that cord blood transplant disparities are better tolerated as compared 
to bone marrow or peripheral blood as a stem cell source making cord blood grafts a 
better option, when similar HLA-matched units are available. The predominance of 
naïve T cells in cord blood grafts may explain the fact that they are better tolerated. 
 
In this perspective with the diversity of HLA types, it may not be realistic to aim for a 
perfectly HLA matched unrelated donor. Future donor selection could be based on 
functional matching i.e. the donor’s immune system to minimally react with the 
recipient’s immune system and vice versa. 
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Non-inherited maternal antigens effects in cord blood transplantation 
Pregnancy represents a unique immunological situation whereby individuals are 
chronically exposed to foreign HLA. The offspring is exposed to the maternal 
haplotype, which was not inherited from the mother or non-inherited maternal 
antigens (NIMA). On the other hand, the mother is chronically exposed to the 
paternal HLA haplotype possessed by the child or non-inherited paternal antigens 
(NIPA). Interestingly, evidence supports that these exposures during pregnancy 
influence the outcome of transplantation that can occur much later in life (85). In the 
case of the child, the exposure to NIMA may lead to the development of 
immunological tolerance towards that haplotype. It has been found that exposure to 
maternal HLA molecules during fetal life induces B cell unresponsiveness to these 
antigens (86) and improves graft survival where the HLA mismatch is the same 
haplotype as the one non-inherited from the mother (87). In addition, lower risks of 
aGvHD and cGvHD and mortality have been observed following haploidentical 
marrow transplantation from mother to child in contrast to higher incidence after 
transplantation from father to child. Due to the beneficial effect of NIMAs on the 
patient, currently cord blood registries have begun typing mothers in addition to cord 
blood units and match the cord blood unit’s mother’s non-inherited HLA antigens with 
the patients.   
In contrast, for the mother the exposure to non-inherited paternal antigens (NIPA) 
can lead to immunization and the formation of antibodies against the paternal HLA 
molecules. Indeed, antibodies against paternal HLA molecules are found in 15-30% 
of women who have been pregnant (88, 89). The immunization of the mother to the 
paternal HLA haplotype present in her child during pregnancy can be expected to 
affect alloimmune reactions following transplantations from husband-to-wife or from 
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offspring-to-mother (85). The influence of pregnancy on clinical transplantation is a 
further confounding factor that needs to be considered.  
 
Conditioning and GvHD prophylaxis  
Tissue damage caused during preparatory regiments, i.e. GI tract damage has a 
significant role in GVHD pathophysiology. Increased risk in patients with high 
damage in the GI tract is supported by clinical observations of higher GvHD 
incidence in patients experiencing prolonged periods without oral intake or severe 
diarrhea after transplantation (90, 91). The inclusion of total body irradiation in 
conditioning regimens has also been shown to reproducibly increase aGvHD risk 
(78). The contribution of conditioning damage is also demonstrated by the decrease 
in the incidence of GvHD associated with the use of reduced-intensity conditioning 
regiments that results in less damage in the GI tract.  
 
1.3.3 The role of T regulatory cells 
About 5-10% of CD4+ T cells co-express the CD25 antigen, without previous 
activation of their T cell receptor (TCR) (92). This subset of T cells, termed as natural 
regulatory T cells (Tregs), has the role of preventing potentially harmful autoimmune 
responses and suppresses immune activation. Tregs are characterised by a specific 
transcription factor Foxp3 (93). Recent studies have evaluated the effect of Tregs in 
GVHD development. The severity of GvHD has been associated with a decrease in 
Foxp3 gene expression in transplanted patients (94).  
In the murine model, Cohen et al observed that in a Treg depleted transplant 
situation, GvHD onset was faster than with unmanipulated graft (95). An inverse 
relationship between the number of Tregs in the graft and risk of GvHD was 
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observed in HLA-identical SCT in humans; high graft Treg content has been shown 
to decrease aGvHD risk (96). Also, Tregs were found to be deficient in the intestinal 
mucosa of patients with GvHD (97). Some promise has been shown by initial trials 
aiming at enriching Treg numbers to prevent GvHD (98) but further studies are 
required to evaluate the full potential of this approach. 
 
1.3.4 The role of the Th17 cells 
This subset of T cells, termed Th17 because of their ability to produce pro-
inflammatory cytokines such as IL-17A, IL-17F, IL-21 and IL-22 as well as 
chemokines such as CXCL1, CXCL2 and CXCL8, are considered to contribute to the 
development of GvHD by the recruitment of Th1 cells in lymphoid organs during the 
early phase of transplant. This was shown in pre-clinical (99,100) and clinical studies 
(101,102), especially on cutaneous and chronic GvHD. 
 
1.3.5 The role of natural killer cells 
Natural Killer (NK) cells are cytotoxic lymphocytes that possess perforin- and 
interferon-γ-dependent effector functions acting as part of the innate immune 
system. According to the “Missing Self Hypothesis” NK cells act to eliminate cells 
that do not express self-MHC Class I molecule and this activity is a crucial defense 
mechanism against viral infection and anti-tumor activity (103). Due to the potent 
effects of NK cells as effectors of the innate immune system, their activity is tightly 
regulated requiring the integration of multiple activating and inhibitory receptors. 
Unlike B and T lymphocytes, the NK cells express a variety of germline combinations 
that do not undergo somatic recombination.  A large family of inhibitory NK cell 
receptors in humans is the killer Ig-like receptors (KIR), the known ligands of which 
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are MHC class I molecules. The KIR gene family is highly variable in gene number 
and content, while also exhibiting allelic polymorphism (104,105). Examples of 
known ligands for KIRs are tabulated in Table 1.3.5.   
 
KIRs inhibit the cytolytic actions of NK cells when they come across cells that 
express the self HLA repertoire. On the other hand, KIRs activate NK cells to 
eradicate cells that lack or have a lower expression of self-HLA. Following 
transplantation, NK cells are rapidly formed by differentiation of transplanted HSC. It 
is now recognized that NK cells are another important determinant of GvHD 
incidence (106, 107, 108). This role of NK cells arises from the ability of donor 
derived NK cells to eliminate leukaemic cells remaining in the host. Once NK cells of 
donor origin recognise the lack of specific HLA alleles on the recipient 
haematopoietic cells, they express cytolytic activity. NK cells, via the granzyme –
perforin pathway, eradicate the recipient’s remaining haematopoietic as well as 
tumour cells. Thus, they are involved in the promotion of engraftment and the GvT 
effect. With respect to GVHD they suppress the disease (106, 107, 108). Their 
alloreactivity is dependent on mismatch between KIR and MHC class I of the donor 
and the recipient. The mismatching of KIR and HLA alleles was exploited in the HLA 
haploidentical SCT with impressive results for acute myeloid leukeamia (AML) 
patients (109,110). Since the KIR genes are located in chromosome 19 while the 
HLA genes are located on chromosome 6 these two gene families segregate 
independently and matching for HLA does not match for KIR during transplants. 
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Table 1.3.5 Inhibitory NK Receptors and their ligands 
Inhibitory NK Receptors 
 
Ligand 
2DL1 
 
Cw2,Cw4,Cw5,Cw6 
2DL2/3 
 
Cw1,Cw3,Cw7,Cw8 
3DL1 HLA-B alleles containing the Bw4 e.g. 
B5,B13,B17,B27,B44,B52 
3DL2 
 
HLA-A3, -A11 
 
 
1.3.6 The role of cytokine gene polymorphisms 
As cytokines have a primary role in the pathogenesis of GvHD, different gene 
polymorphisms that modulate the activity and expression of these cytokines has 
been evaluated in a number of studies. The presence of polymorphisms that lead to 
low production of the anti-inflammatory cytokine interleukin-10 (IL-10) in recipients 
leads to increased incidence of GvHD after transplantation (111). The contribution of 
IL-10 promoter polymorphisms GCC (high production), ATA (intermediate 
production) and ACC (low production) has also been evaluated. The presence of the 
GCC haplotype correlates with decreased aGvHD incidence in recipients (112).  
 
Pro-inflammatory cytokines such as IL-1, TNFα, IL-6 and INF-γ have a significant 
role in GvHD. Due to the role of interleukin-1 (IL-1) in promoting GvHD 
pathophysiology; polymorphisms in IL-1A, IL-1B and IL-1Ra have been evaluated. 
While polymorphisms in IL-1A and IL-1B have not been associated with GvHD risk 
(113,114), donor cytokine polymorphism IL-1Ra (IL-1RN*2) is considered to have a 
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protective role in GvHD (115). Increased TNF-α production is associated with d3/d3 
and d4/d4 genotypes and some studies have suggested that patients carrying the 
d3/d3 genotype have higher GvHD incidence (116). In contrast, increased GvHD risk 
has been shown in patients carrying the d4/d4 but not the d3/d3 genotype (117). 
With regards to IL-6, homozygosity for IL-6 -174 (G/G) polymorphism, which is 
associated with increased IL-6 serum levels, in donors or recipients correlates with 
higher rates of GvHD (118). Finally, several studies have investigated the 
contribution of INF-γ polymorphisms. IFNG*3 polymorphism in the recipient may 
increase the risk of aGvHD while IFNG*2, which is associated with higher expression 
levels than IFNG*3, may be protective (119,120). 
 
1.3.7 The role of other genetic polymorphisms 
The MHC region harbours approximately 200 genes, many of which have immune-
related functions and several single nucleotide polymorphisms within the MHC (of 
the donor or recipient) that are not sequenced by standard SBT for HLA typing 
confer higher risk for aGvHD (121). In addition, non-MHC variants are miHAgs that 
could contribute to GvHD and the cytokine polymorphisms described previously, also 
other polymorphisms like that of the Nucleotide-binding oligomerisation domain-
containing protein 2 (NOD2) (122) and cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4) (123) play a role in GvHD manifestation. NOD2 encodes for an intracellular 
receptor that binds bacterial cell wall components and leads to the upregulation of 
Nuclear Factor kappa B (NFκB). NOD2 is one of the most frequently studied genetic 
predictors of aGvHD with several variants which result in decreased induction of 
inflammatory cytokines in response to bacterial cell components. NOD2 variants 
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SNPs 8, 12 and 13 in donors and recipients have been identified as risk factors for 
GvHD (122).  
 
1.4 Current treatment and prediction of the occurrence of graft-versus-host 
disease 
Presently limited progress has been achieved in the treatment of acute GvHD. 
Consequently, acute GvHD is still the leading cause of patient morbidity and 
mortality following HCT transplantation. Treatment with glucocotricoids is the 
accepted primary therapy for GvHD. The mechanisms by which corticosteroids affect 
GvHD remain unclear, although different mechanisms of action have been proposed 
including the direct suppression of cytotoxic lymphocytes (124) and altered secretion 
of proinflammatory cytokines (125). Glucocorticoids provide an inadequate therapy 
for acute GvHD, with about half the patients not responding to the treatment (126). 
Consequently, diverse approaches are being pursued that include novel 
pharmaceuticals or upcoming cellular therapeutics (127). 
Nevertheless, the lack of adequate treatment for acute GvHD at present increases 
the urgency of identifying reliable predictors for this disease (128). Identification of 
such markers would allow the pre-emptive treatment of patients after HCT transplant 
prior to the development of symptoms. Early attempts to identify biomarkers for 
GvHD focused on inflammatory cytokines such as IL-2, which proved to be non-
specific to GvHD. A different approach has utilised high-throughput transcriptomic 
and proteomic investigation of tissues from GvHD patients in an effort to identify 
novel biomarkers for the condition. One candidate identified by the proteomic 
examination of 1000 samples from HCT patients was REG3α (129). This protein 
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normally acts downstream of IL-22 to protect the epithelial barrier in the intestinal 
mucosa. By a similar approach Elafin was identified as another potential biomarker 
for acute GvHD (129). Elafin which is an elastase inhibitor is over-expressed in the 
inflamed epidermis. Both promising biomarkers do not relate to aberrant activation of 
the immune system but are instead activated in response to inflammation in the gut 
(REG3α) and skin (elafin) respectively. It is hoped that in the future combination of 
biomarkers with clinical and other information would lead to improvements in the 
earlier and more reliable identification of acute GvHD in HCT patients. 
 
1.5 Cellular assays for the prediction of graft-versus-host disease 
Cellular tests such as the mixed lymphocyte culture (MLC) or the frequency analysis 
of alloreactive helper and cytotoxic T lymphocyte progenitors (HTLp and CTLp 
respectively) were established as functional assays representing the cellular 
response to antigenic determinants and hence the possibility of alloreactions 
between donor-recipient. MLC, in particular, is a test involving the coculturing-mixing 
of lymphocytes isolated from two different individuals, usually a transplant recipient 
and a potential donor (130). The different major and minor antigens present in the 
immune cells from the two individuals result in the activation of lymphocytes within 
the mixed culture, termed mixed lymphocyte response (MLR). The traditional 
endpoint for this assay is the measurement of lymphocyte proliferation. The central 
idea behind the development of this test was that the strength of the MLR relates to 
the immunological mismatch between the individuals and can be informative of the 
risk of GvHD development (131). MLC is also a widely used research tool for 
investigating the molecular pathways involved in the activation of the immune system 
and the incidence of GvHD.  
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The MLC as currently performed is not considered to be a test of sufficient sensitivity 
and specificity for GvHD (132). In addition to measuring cell proliferation some 
researchers have tried to investigate cytokine production as a more sensitive readout 
that could reveal incompatibility between donor-recipient. A study by van der Meer et 
al. attempted to decipher whether levels of IFN-γ in MLC, as a marker for deleterious 
Th1 responses, are sensitive to HLA incompatibility but also whether they correlate 
with GvHD occurrence when the donor-recipient pairs tested proceeded with 
transplantation (133).  Indeed, previous studies have shown the central role of IFN-γ 
in the cytokine network following alloantigen recognition as well as the generation 
and maintenance of alloresponses associated with the induction of GvHD. In murine 
models of GvHD IFN-γ is elevated early, peaking before clinical symptoms appear 
(134) and T cells isolated from patients with GvHD have higher levels of IFN-γ (135). 
GvHD results from the recognition of host antigens by donor T cells following 
allogeneic transplantation and these alloreactive donor T cells are the primary 
source of IFN-γ. Therefore, IFN-γ can be used as a surrogate of T cell response and 
many studies have explored the use of IFN-γ as a marker for donor selection 
(133,136), transplantation-related complications (137) and GvHD (138). It was 
shown that high levels of INF-γ in MLC of donor-recipient coincided with severe 
aGvHD in unrelated bone marrow transplantation, whereas low levels were largely 
associated with grades 0-I. In addition, levels of IFN-γ in MLC reflected HLA class II 
differences but not isolated class I differences or mismatches other than HLA 
(identical siblings), suggesting that measuring IFN-γ alone cannot be employed for 
the detection of class I mismatches (133).  
The MLC, HTLp and CTLp assays rely on measuring cell proliferation or production 
of cytokines, employ radioactive agents and are very laborious and time consuming. 
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In addition, these tests have not been consistently shown to correlate well with the 
occurrence of aGvHD (139,140,141). Since the total number of transplantation 
antigens encoded within the MHC region remains unknown, Petersdorf et al.(142) 
have suggested that haplotype matching for unrelated HSCT is beneficial to 
decrease GvHD morbidity , but still this approach does not provide functional clues 
for alloresponses between donor recipient and does not account for non-MHC 
determinants. Therefore selection procedures in ASCT would greatly benefit from the 
development of simpler and faster functional assays, for example measuring gene 
expression as a marker of alloreactivity. Gene expression profile in an HLA 
mismatched setting could be indicative of high-risk donor-recipient pairs and would 
allow better donor selection in cases where more than one suitable donor is 
available for AHCT; for example haploidentical siblings of a patient. 
One study, using gene expression profiling, suggested that some donors may be 
‘stronger alloresponders’ and consequently more likely to elicit GvHD than others 
(143). By investigating the gene expression profiles of CD4+ and CD8+ cells of 50 
AHCT donors, Baron et al, could segregate those whose recipients went on to 
develop GvHD from those who did not. A limitation of this study however, was that it 
looked at the donor cells in isolation and thus did not take into consideration the 
interactions between the donor and recipient. In addition to genetic background, 
leading to quantitative or qualitative differences in immune responses; environmental 
factors and donor/recipient immune system history may contribute to how they will 
react; hence a functional assay is more favourable than simply sequencing gene 
variations or viewing donor cells in isolation. 
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1.6 Hypothesis and aims of this study 
Donor selection relies on HLA typing that offers no information about functional 
responses of the donor and recipient whereas functional tests such as the MLC can 
complement HLA typing and serve as a more relevant representation of these 
responses. This makes MLCs valuable not only in matching but also in studying how 
differential gene expression and other surface antigens can play a role in donor T 
cell activation and ultimately GvHD. By using gene expression profiling as a more 
sensitive tool to study global differences in the HLA mismatched MLC compared to 
the HLA matched setting we can investigate gene expression profiles that can reveal 
mechanisms involved in GvHD and graft rejection; this can potentially serve to better 
our understanding of the mechanisms involved in the alloresponses during these 
diseases and reveal therapeutic targets.  
Since there are a number of parameters that play a role on the outcome of ASCT 
that involve allorecognition between donor and recipient, we followed the hypothesis 
that immune system related gene responses could predict donor-recipient 
compatibility. We are proposing that measuring gene expression in MLC could be a 
simpler and faster method of identifying functional incompatibilities between potential 
donor-recipient pairs that are not detected by DNA typing techniques or compared to 
the traditional cellular assays. 
The aim of this study is to potentially identify genetic markers that correlate with 
published data related to GvHD. In order to achieve this we aim firstly to identify the 
optimum conditions to be used for the MLC experiments in the context of gene 
expression studies. This would be achieved through the identification of conditions 
that will be closer to the in vivo situation, so as to elicit the higher possible 
alloreaction of HLA-mismatched cell populations in co-culture. In order to achieve 
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this, activation as well as proliferation markers would be studied. Performance of a 
limited number of immune related gene expression studies would be used to identify 
potential differences in the different MLC settings and to identify possible immune 
related transcripts which change in response to donor-recipient incompatibility in the 
MLC. Global gene expression profiling under the selected conditions should provide 
information that could be correlated with and potentially identify genetic markers that 
could be used in further in vitro and in vivo studies of GvHD. 
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CHAPTER 2 
Materials and Methods 
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2.1 Materials  
 
2.1.1 Samples  
Written consent was obtained from volunteers after approval by the National 
Bioethics Committee of Cyprus (No. 224/2007) and peripheral blood samples, up to 
45ml in EDTA were collected.  All samples were collected by trained personnel at the 
Karaiskakio Foundation (Nicosia, Cyprus) and were used for the purposes of the 
study within one hour from collection. 
 
2.2 Methods 
2.2.1 Subject characterisation studies 
The reagents shown in Table 2.1 were used in subject characterisation. Namely 
blood drawn from volunteers as described in 2.1.1, was typed for HLA class I and II, 
to examine the presence or absence of common HLA alleles, cytokine genotyped to 
ascertain the absence of polymorphisms that could potentially affect the scope of the 
MLC experiments, KIR typed to examine the KIR repertoire and immunophenotyped 
to ascertain the presence of normal cell populations.  
 
Table 2.1 Reagents used in subject characterisation 
 
Reagent Manufacturer 
Qiagen QIAmp Mini kit for DNA extraction 
 
Qiagen, Velno, Netherlands, cat. no 29104 
DYNAL kit for HLA typing DYNAL, ThermoFisher Scientific Inc, NY, 
USA, cat. no  810.00 
LIFECODES kit for cytokine genotyping Tepnel Lifecodes Corporation, Stamford, CT, 
USA cat no 345110 
PEL-FREEZ kit for KIR typing PEL-FREEZ Clinical Systems LLC, WI, USA 
cat. no 78930-3 
Simultest IMK Plus kit for 
immunophenotyping 
Becton Dickinson and Co, BD Biosciences, 
CA, USA 
 47 | P a g e  
 
2.2.2 DNA extraction 
DNA was extracted using QIAamp Mini Blood Kit (QIAGEN, Cat. No. 29104) 
according to the manufacturer’s instructions. DNA was eluted in buffer to an average 
concentration of 12 μg of total DNA from 400 μl of whole blood.   
DNA was adsorbed onto the QIAamp silica membrane during a brief centrifugation 
step and removal of residual contaminants was achieved by washing the adsorbed 
DNA in two centrifugation steps. Purified DNA was eluted from the spin column in a 
concentrated form in AE Buffer. 
 
2.2.3 HLA typing 
Subjects were typed for HLA class I and II with the polymerase chain reaction 
sequence-specific oligonucleotide priming (PCR-SSOP) by DYNAL (cat no 810.00) 
according to the manufacturer’s instructions. Specifically, HLA-A, -B, -Cw, -DRB and 
-DQB were assessed. The method is based on three major processes, polymerase 
chain reaction (PCR) target amplification, hybridisation of the amplified products to 
specific oligonucleotide probes, and the detection of the probe-bound amplified 
product by colour formation.  
 
(i) PCR target amplification 
The DNA-containing specimens and reagent mixture were heated to 95˚C to 
separate the double-stranded DNA and expose the target sequences to the primers. 
As the mixture cooled, the biotinylated primers annealed to their targets. The 
thermostable recombinant Taq DNA polymerase, in the presence of excess 
deoxynucleoside triphosphates (dNTPs), extended the annealed primers along the 
target templates to produce a biotinylated DNA sequence termed an amplicon. This 
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process was repeated for a number of cycles, each cycle effectively doubling the 
amount of target DNA. 
 
(ii) Hybridisation and Detection 
After the PCR amplification process, the amplicons were chemically denatured to 
form single strands, which were then added to a well of a typing tray that contained 
nylon membrane with bound, sequence-specific, oligonucleotide probes. The biotin-
labelled amplicons were captured onto the membrane strip by binding to the 
sequence-specific probes. After the membrane strip was washed to remove unbound 
material, a streptavidin-horseradish peroxidase conjugate was added to the well of 
the tray. The streptavidin was then bound to the biotin-labelled amplicons captured 
by the membrane-bound probe. After washing the unbound conjugate, the bound 
streptavidin-horseradish peroxidase conjugate was reacted with hydrogen peroxide 
and tetramethylbenzidine to form a colour complex. The reaction was stopped by 
several water washes. The probe intensities were compared to the internal control 
and the typing pattern was recorded. 
 
2.2.4 Cytokine Genotyping 
Cytokine genotyping was performed using the DNA extracted, using the SSO 
technique (LIFECODES, cat no 34511) according to the manufacturer’s instructions. 
The LIFEMATCH System for cytokine genotyping is based on the simultaneous 
detection of multi-coloured beads in suspension. Identically sized polystyrene beads 
are dyed with two fluorophores in different concentrations. Each different coloured 
bead set can carry a different sequence-specific oligonucleotide (SSO) probe. 
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The Lifecodes HLA SSO Typing procedure is based on the hybridisation of labelled 
single stranded PCR product to SSO probes. Amplification of DNA using PCR 
employs equimolar amounts of forward and reverse primers to generate a double-
stranded DNA product. The initial cycles of the Lifecodes amplification step result in 
the generation of double-stranded DNA.  After the limiting primer is exhausted, the 
remaining primer uses the double-stranded product as template for single-stranded 
DNA generation. Therefore, both single-stranded and double-stranded DNA is 
generated that after denaturation participates in the hybridisation reaction. 
The probes are designed so that they can preferentially hybridise to a 
complementary region, which may be present in or absent from the amplified DNA. 
Additionally, the amplified DNA is hybridised to one or more consensus probes 
homologous to sequences present in all the alleles of a given locus (control). The 
probes in the Lifecodes cytokine genotyping procedure are attached to Luminex 
microspheres designed for use by the Luminex instrument.  
 3μl of DNA was hybridised with probes, amplified and conjugated with colour 
substrate and results were read using the Luminex platform. 
 
2.2.5 KIR Genotyping 
KIR genotyping was performed using the PCR-sequence–specific priming (PCR-
SSP) method (PEL-FREEZ, Cat. No. 78930-3) according to manufacturer 
instructions and the presence or absence of KIR genes was detected. This method is 
based on the principle that a completely matched primer will be more efficiently used 
in the PCR reaction than a primer with one or several mismatches in its 3’-end, 
especially in the first few critical cycles, During PCR amplification, a perfectly 
matched primer pair results in amplification. Briefly, DNA samples were mixed with 
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reaction buffer and Taq DNA polymerase and amplified. After amplification the PCR 
products were loaded on an ethidium bromide stained agarose gel and 
electrophoresis was performed. At the end of the procedure, the gel was 
photographed and interpreted using a specific company interpretation-worksheet for 
the amplification patterns. 
 
2.2.6 Immunophenotyping 
The two colour direct immunofluorescence method was employed (Simultest IMK 
Plus, Becton Dickinson cat. no 349217) to enumerate the percentages of human 
lymphocyte subsets. This included T cells, activated T cells, B lymphocytes, 
helper/inducer CD4+ cells, suppressor/cytotoxic CD8+ cells and natural killer (NK) 
cells. 100µl of whole blood were added to tubes containing 20 μl of each 
fluorochrome-labelled monoclonal antibody (mAb). After a thorough mixing of each 
tube the fluorochrome-conjugated mAb and blood containing tubes were incubated, 
protected from light, for 20 minutes at room temperature. After incubation, the red 
cells present in the incubation mixture were lysed by the addition of lysing solution, 
centrifuged and the supernatant was aspirated. The pellet was re-suspended and 
washing steps with 1xPBS/0.1% sodium azide followed. The washed cells were kept 
in the dark at 2-8°C until analysis. The different cell populations were evaluated 
using flow cytometry (FACScan Becton Dickinson). The gating strategy employed 
gating on lymphocytes based on typical forward and the side scatter characteristics 
and used isotype negative controls provided in the kit to exclude non-antigen specific 
binding of mAbs. The software used for the analysis was the SimulSET v3.1. The 
mAb used for immunophenotyping are shown in the Table 2.2. 
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Table 2.2 Lymphocyte populations and identification markers used for                 
Immunophenotyping 
 
Lymphocyte population Identification Marker-Fluorochrome 
Leucocytes 
 
Mouse anti-human CD45-FITC, clone 
2D1 
Monocytes 
 
Mouse anti-human CD14-PE, clone 
MφP9 
T and B lymphocytes 
 
Mouse anti-human CD3-FITC, CD19-PE 
Helper/Cytotoxic T cells 
 
Mouse anti-human CD4-FITC, CD8-PE  
T lymphocytes/Activated T lymphocytes-
B lymphocytes 
Mouse anti-human CD3-FITC, HLA-DR-
PE 
T lymphocytes/NK cells 
 
Mouse anti-human CD3-FITC, 
CD16/CD56-PE 
 
 
 
2.3 Mixed lymphocyte cultures  
Mixed lymphocyte cultures (MLC) were set up as follows: lymphocytes from 20ml of 
freshly drawn anticoagulated (EDTA) blood were separated using the density 
gradient (ficol-histopaque) method (118,119). Lymphocytes were incubated at a final 
concentration of 1x106 cells/ml (0.5x106 from each subject) in culture medium 
consisting of RPMI-1640 supplemented with 10% FBS and 1% 
penicillin/streptomycin, in 12-well flat-bottomed plates.  They were incubated at 37˚C 
in a 5% CO2 humidified atmosphere. This kind of MLCs is referred to as bidirectional. 
Cells from each subject at a concentration of 1x106 cells/ml incubated under the 
same conditions served as controls. 
MLCs were also set up with one cell population irradiated with 25,000Gy and vice 
versa. This kind of MLCs is referred to as unidirectional. One well of both cell 
populations irradiated served as control. 
LPS of final concentration 1μg/ml culture medium was added to an otherwise 
identical set of cultures. 
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MLCs and controls, containing 1x106 cells/ml, (MLCs contained 0.5x106/ml from 
each subject) in each plate well were incubated for up to 6 days. On day 4, 0.5ml of 
culture medium was added to each well. LPS stimulated cultures were supplemented 
with LPS at 1μg/ml. 
For cell plating IWAKI 12-well flat-bottomed plates were used, cat. no 3815-012 and 
cultured in a SANYO CO2 incubator, model MCO-18AIC. For irradiation of cells the 
GAMMACELL 1000Elite, MDS Nordion was used for providing 25,000Gy in 3.5 
minutes, as this is the acceptable radiation for blood products for transfusion. Flow 
cytometric analysis was performed using FacsScan by Becton Dickinson. 
Haematological parameter counting was performed using SYSMEX K1000 analyser. 
 
Table 2.3 Reagents used in setting the MLCs 
 
 
2.4 Cell activation and proliferation studies 
The reagents shown in Table 2.4 were used for activation and proliferation studies 
performed on cells harvested during the MLC validation experiments, in order to 
examine whether cells become activated, the time of the highest activation and 
Reagents Manufacturer 
Ficoll Hypaque 
 
Amersham Pharmacia Biotek, GE 
Healthcare Medical Diagnostics, L. 
Chalfort, U.K. cat. no 17-144-02 
RPMI 1640 Solution GIBCO, ThermoFisher Scientific Inc, NY, 
USA, cat. no  21875 
Fetal Bovine Serum GIBCO, ThermoFisher Scientific Inc, NY, 
USA, cat. no  10108-165 
Penicillin/Streptomycin, 10,000U/ml GIBCO, ThermoFisher Scientific Inc, NY, 
USA, cat. no  2815 
LPS GIBCO, ThermoFisher Scientific Inc, NY, 
USA, cat. no  24506 
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whether cells proliferate in culture. The setting up of MLCs was as described in 
section 2.3. 
Table 2.4 Markers used for MLC analysis 
Marker Monoclonal Antibody Manufacturer 
CD25 Mouse anti-human 
CD25/FITC 
DakoCytomation 
Denmark A/S, DK-2600 
Glostrup, Denmark, 
Product No. F080101 
HLA-DR, DP, DQ/CD3 Mouse anti-human HLA- 
DP,DQ,DR/FITC, 
CD3/RPE 
DakoCytomation 
Denmark A/S, DK-2600 
Glostrup, Denmark, 
Product No.FR86750 
Ki-67 Mouse Anti-human 
Ki-67/RPE 
DakoCytomation 
Denmark A/S, DK-2600 
Glostrup, Denmark, 
Product No.72648 
 
Cells were analysed by flow cytometry at 1, 2, 3 and 6 days for the expression of the 
markers shown in Table 2.4. 
The method employed for CD25 positive cell counting was the following: 10µl of the 
fluorochrome-stained mAb were added to 100μl of cells harvested from the 
incubation plates used in the MLCs and control cells. After incubation of the cells and 
the fluorochrome-stained monoclonal antibody at 4°C in the dark for 30 minutes, the 
cell-antibody mixture was twice washed with 1xPBS/0.1 sodium azide, and the pellet 
re-suspended. The CD25 positive cells were evaluated using flow cytometry 
(FAcsScan, Becton Dickinson). Parallel to the staining procedure negative control 
was used. The gating strategy employed used the isotype negative control so as to 
set the fluorescent-1 (FL1) voltage and exclude non-antigen specific binding. The 
software used for the analysis was the CellQuest. 
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The method employed for HLA-DR-DP-DQ/CD3+ cell counting was the following: 
10µl of the fluorochrome-stained monoclonal antibodies were added to 100μl of cells 
harvested from the incubation plates used in the MLCs and control cells. After 
incubation of the cells and the fluorochrome-stained monoclonal antibody at room 
temperature, in the dark for 10 minutes, the cell antibody mixture was twice washed 
with 1xPBS/0.1 sodium azide, and the pellet re-suspended. The HLA-DR-DP-
DQ/CD3 positive cells were evaluated using flow cytometry (FacsScan, Becton 
Dickinson). Parallel to the staining procedure negative control was used. The gating 
strategy employed used the isotype negative control so as to set the fluorescent-1 
(FL1) and fluorescent-2 (FL2) voltages and exclude non-antigen specific binding of 
fluorochromes. The software used for the analysis was the CellQuest. 
 
The method employed for the Ki-67 positive cell counting was the following: cells 
harvested from the incubation plates were pelleted by centrifugation and the 
supernatant aspirated. While re-suspending the cells by vortexing, 3ml of cold 70% 
ethanol were added drop by drop. The cells were then incubated at -20°C for 1 hour. 
The next step was to wash the cells three times with PBS/1%FBS/0.09% NaN3 and 
aspirate the supernatant. Cells were then washed once more with PBS and the 
supernatant aspirated. The cell pellet was re-suspended with 500 µl PBS and 100µl 
of sample was added to 20µl of fluorochrome-conjugated mAb, and incubated in the 
dark for 30 minutes. Then, two washing steps followed with PBS and cells were 
analysed by flow cytometry. The gating strategy employed used the isotype negative 
control so as to set the fluorescent-1 (FL2) voltage and exclude non-antigen specific 
binding. The software used for the analysis was the CellQuest. 
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2.5 The real time polymerase chain reaction 
So as to perform real time PCR experiments, RNA extracted from the MLCs was 
used. Table 2.5 shows the reagents used. 
Table 2.5. Reagents used for the real time polymerase chain reaction 
Reagent Manufacturer 
Qiagen RNeasy Mini kit for RNA extraction Qiagen, Velno, Netherlands, 
cat. no 28205 
SuperArray’s RT2 First Strand Kit 
 
SABioscience Corporation, Qiagen, Velno, 
Netherlands cat. no PA 012-24 
RT2qPCR SYBR Green Master Mix SABioscience Corporation, Qiagen, Velno, 
Netherlands cat. no PA 010-24 
SuperArray’s RT2 Th1-Th2-Th3 Array, 
version 3.0 
SABioscience Corporation, Qiagen, Velno, 
Netherlands cat. no PAHS-344-24 
 
2.5.1 RNA extraction 
Cells were harvested and RNA was extracted using the Qiagen RNeasy Mini Kit as 
per manufacturer’s instructions: 
1. 6 million cells of each sample (either MLC or control cells) were 
centrifuged at 400g for 10 minutes and the supernatant was completely 
discarded. 
2. 600 μl of Buffer RLT was added to the pelleted leukocytes and vortexed to 
mix and remove any clumps 
3. The lysate was pipetted directly into a QIAshredder spin column sitting in a 
2-ml collection tube and centrifuge for 2 min at maximum speed to 
homogenize. The QIAshredder spin column was discarded and the 
homogenized lysate saved. 
4. 600 μl of 70% ethanol  was then added to the homogenized lysate and 
          mixed by pipetting.  
5. The sample was then pipetted into a new QIAamp spin column sitting in a 
2-ml collection tube and centrifuged for 15 sec at 8,000 x g.  
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6. The QIAamp spin column was then transferred into a new 2-ml collection 
tube. 700 μl Buffer RW1 was applied to the QIAamp spin column and 
centrifuged for 15 sec at 8000 x g to wash. 
7. Then, the QIAamp spin column was placed in a new 2-ml collection tube 
and  500 μl of Buffer RPE was pipetted into the QIAamp spin column and 
centrifuged for 15 sec at 8000 x g 
8. 500 μl of Buffer RPE was added the cap closed and centrifuged at full 
speed for 3 min.  
9. The QIAamp spin column was transferred into a 1.5-ml microcentrifuge 
tube and 30–50 μl of RNase-free water was pipetted directly onto the 
QIAamp membrane and centrifuged for 1 min at 8000 x g to elute.  
 
RNA concentration and purity was assessed by UV spectrophotometry. Purity was 
considered satisfactory when the A260:A280 was greater than 2.0 and the A260:A230 
greater than 1.7. After the assessment of purity the RNA was stored at -60˚C until 
further use. 
 
2.5.2 Gene expression studies of a panel of 84 immune related genes 
Real-Time PCR technologies allow detection of ﬂuorescence emission during the 
PCR reaction from one (TaqMan) internal oligonucleotide probe, the detected 
ﬂuorescence being proportional to the amount of target present in the sample. 
The TaqMan assay uses a single internal oligonucleotide probe bearing a reporter 
ﬂuorophore (e.g. 6-carboxy-ﬂuorescein) and quencher ﬂuorophore (e.g. 6-carboxy-
tetra-methyl-rhodamine). During the extension phase, the TaqMan probe is 
hydrolysed by the nuclease activity of the Taq polymerase, resulting in separation of 
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the reporter and quencher ﬂuorochromes and consequently in an increase in 
ﬂuorescence. In the TaqMan technology, the number of PCR cycles necessary to 
detect a signal above the threshold is called the cycle threshold (Ct) and is directly 
proportional to the amount of target present at the beginning of the reaction. The 
DRn corresponds to the increase in ﬂuorescence intensity when the plateau phase is 
reached. Using standards or calibrators with a known number of molecules, a 
standard curve and the determination of the precise amount of target present in the 
test sample can be established.  The theoretical slope of the standard curve is 3.32 
for a PCR reaction with maximum efficiency. Using a known amount of DNA 
molecules for the standard curve, the intercept point on the Y-axis deﬁnes the 
number of cycles theoretically needed to detect one molecule. Alternatively the 
relative expression levels can be calculated by comparing the levels of the test 
transcript levels to the levels of an internal control gene such as Abelson. 
 
The “SuperArray’s RT2” template was chosen as it contains 84 immune-related 
genes, such as genes that are inducible by INF-γ, involved in antigen presentation, 
leukocyte trafficking, lymphoid effectors, myeloid and inflammatory effectors and 
apoptosis. Six control genes were included in each plate, shown in Table A1, while 
Table A2 lists the genes tested (see Appendix).  
 
Genomic DNA in the RNA samples was eliminated using the “SuperArray’s RT2 First 
Strand Kit” (Cat. No. C-03), as follows: in a sterile tube for each RNA sample, the 
following mixture was prepared: 400ng RNA, 2μl GE (5X gDNA Elimination Buffer) 
and RNase-free H2O to a final volume of 10μl. The mixture was briefly centrifuged 
and incubated at 42˚C for 5 minutes. Then the mixture was immediately chilled for 
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more than one minute. For each sample the RT cocktail as shown in Table 2.8 was 
prepared. 
 
Table 2.8 Real Time cocktail used in gene expression studies 
BC3(5X RT buffer 3) 4μl 
P2(Primer &External Control Mix) 1μl 
RE3(RT Enzyme Mix 3) 2μl 
RNase-free H2O 3μl 
Final Volume 10μl 
 
The 10μl of the RT cocktail was added to the 10μl Genomic DNA elimination mixture, 
mixed gently and incubated at 42˚C for 15 minutes. Then the mixture was heated to 
95˚C for 5 minutes to cause RNA degradation and inactivation of the reverse 
transcriptase. Then, 91μl of ddH2O was added to each 20μl of cDNA synthesis 
reaction and mixed well. The first Strand cDNA Synthesis reaction was stored at -
20˚C until ready for analysis. 
Each sample was analysed for the gene expression of 84 immune related genes 
using 96-well plates by “SuperArray” Th1-Th2-Th3 plate.  
For each sample to be analysed the master mix cocktail shown in Table 2.9 was 
prepared. 
 
Table 2.9. Master Mix cocktail used in gene expression studies 
2X SuperArray RT2 qPCR Master Mix 1275μl 
Diluted first strand cDNA synthesis reaction 102μl 
ddH2O 1173μl 
Total volume 2550μl 
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25μl of the above cocktail was added to each well on the “SuperArray” plate and the 
plate was covered tightly with optical thin-wall 8-caps and centrifuged briefly to 
remove air bubbles from the added cocktail. The plate was immediately loaded on 
the ABI 7000 instrument for analysis. 
The ABI instrument 7000, used for detection, was set to follow the program in Table 
2.10 below: 
 
 
Table 2.10. Program used in gene expression studies 
Cycles                       Duration                    Temperature 
   1                            10 minutes                      95˚C 
   40                          15 seconds                     95˚C 
                                 1 minute                          60˚C 
 
The readings were then analysed using the web based “RT2 Profiler PCR Array Data 
analysis” web program by SuperArray. Gene expression change was measured as 
fold change or Δct. All samples and controls were tested in triplicate and only the 
changes in gene expression with a p-value <0.05 were considered for further 
analysis. 
 
 
2.6 Microarray gene expression profiling 
The microarray study was performed in collaboration with Dr George Vassiliou at the 
Welcome Trust Cancer Institute, Cambridge, UK, using the Illumina Whole-Genome 
Gene Expression analysis platform. Each array on the HumanHT-12 v4 Expression 
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BeadChip targets more than 47,000 probes derived from the National Center for 
Biotechnology Information Reference Sequence (NCBI) RefSeq Release 38 
(November 7, 2009) and other sources (http://www.illumina.com). In brief, 1µg total 
RNA extracted as described in 2.5.1 from MLCs and controls prepared as described 
2.3, was reverse transcribed to synthesize first- and second- strand complementary 
DNA (cDNA), followed by in vitro transcription to synthesize biotin-labelled 
complementary RNA (cRNA) using the TotalPrep-96 RNA amplification kit (Ambion) 
or the TargetAmp-Nano Labeling Kit for Illumina Expression BeadChip (Epicentre). 
Biotin-labelled cRNA from each sample was then hybridised to the Human HT12 v4 
BeadChips (Illumina Inc., San Diego, CA) at 58°C for 18 hours. The hybridised 
BeadChips were washed, labelled with streptavidin-Cy3 and then scanned with 
Illumina BeadScan and images imported into GenomeStudio version 1.5.4 (Illumina 
Inc) for data extraction. Analyses were performed using BRB-Array Tools and MeV 
(34). Data were log2 transformed and quantile normalised using the lumi package 
from Bioconductor (http://www.bioconductor.org/) and genes with low variability (less 
than 20% of expression data values have at least a 1.5-fold change in either 
direction from the gene’s median value) were filtered out from further analysis. 
Genes with significantly altered expressions were identified by one-way ANOVA with 
Benjamini-Hochberg multiple testing correction, with p<0.01.  The entities satisfying 
the significance analysis were passed on for the fold change analysis. For a given 
gene its change in expression was calculated by subtracting its average normalised 
intensity in individuals from the average normalised intensity in MLCs (144,145). 
For real-time reverse transcription PCR inventoried TaqMan® Gene expression 
Assays for IDO1 (Hs00984148_m1), CCL8 (Hs041877715_m1), CXCL9 
(Hs001771065_m1) and CXCL10 (Hs01124251_g1) were used (Applied 
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Biosystems) with SuperScript® III Reverse Transcriptase (Invitrogen) and TaqMan 
Universal PCR Master Mix (Applied Biosystems). 
 
 
2.7 Statistical analysis of results 
For statistical analysis of results, other than those mentioned for web based software 
by SuperArray and t BRB-Array Tools mentioned in section 2.5 and 2.6 respectively, 
the GraphPad Prism 6 software was used, provided by the University of Surrey. 
One-way Anova and t-test methods were used.  Only p values less than 0.05 were 
considered statistically significant.  
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CHAPTER 3 
 
Verification of the Mixed Lymphocyte 
Culture Method in the Context of Gene 
Expression 
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Rationale and Aims 
Mixed lymphocyte cultures have long been used for the study of allogeneic response 
(146) and are commonly used as an investigative tool in the immunology of 
transplantation and for assessing immunologic reactions that might arise 
(147,148,149,150). Investigations related the standardisation of the method were 
also attempted (149), as well as examination of cell response to compounds was 
attempted (150) has been made. 
 
The aim of the set of experiments described in this Chapter was to verify the use of 
this model in the HLA-mismatched setting. The use of mismatched subjects was 
attempted so as to elicit the largest possible immunological reaction of cells that 
could be examined in gene expression studies in the co-culture model. In order to 
ascertain this, the subjects chosen were unrelated and of different gender so as to 
take into consideration the minor histocompatibility antigens. Also, a number of other 
investigations were considered important in the choice of subjects. Firstly, the 
subjects were typed for HLA and if they possessed two or less common antigens 
were considered mismatched. Secondly, the subjects were immunophenotyped to 
ensure that they possessed normal percentage of cell populations. The presence of 
a wide KIR repertoire and lack of aberrant cytokine polymorphisms were also 
considered through genotyping as described in Chapter 2, Section 2.2.4 and Section 
2.2.5.  
 
For the detection of activation of cells at the end of culturing distinct cell markers 
were employed: 1) HLA-DR,-DP,-DQ, which are considered as activation markers for 
haematopoietic cells, and 2) CD25, which when up-regulated is  expressed at high 
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levels in stimulated T and B cells and on monocytes and macrophages stimulated 
with lipopolysaccharide (LPS).  
The extent of activation responses that could be measured in different time frames 
was also investigated so as to ascertain the best possible time frame for gene 
expression studies that would follow. In order to achieve this, cells harvested at 
different times were analysed for the same activation markers. 
 
Since patients undergoing stem cell transplantation are immunosuppressed prior to 
graft infusion, due to chemotherapy and/or total body irradiation, MLCs in which one 
cell population was irradiated were also set up as well as MLCs supplemented with 
LPS, which is a well described inflammatory factor during stem cell transplants and 
graft versus host disease manifestation (150,151). 
 
Another important issue for the use of this model was to investigate proliferation of 
cells in culture so as to ensure that the incubation conditions applied and the culture 
media used facilitated cell responses. To achieve this, the Ki-67 protein was used as 
a proliferation marker (152).  
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3. Results 
 
3.1 HLA typing of individuals used for the mismatched lymphocyte cultures 
3ml of blood were drawn from six unrelated volunteers and were typed for HLA. DNA 
was extracted and purified as described in Chapter 2, Section 2.2.2 and typed for 
Class I and II as described in Chapter 2, Section 2.2.3.  The results of this procedure 
are shown in Table 3.1. Individuals that did not share more than two antigens were 
considered to be mismatched regarding histocompatibility. Samples from individuals 
1 and 2 were chosen for further characterisation. 
 
Table 3.1 The HLA typing results of six peripheral blood samples of 
volunteers. 
 HLA-A HLA-B HLA-Cw HLA-DRB1 HLA-DQB1 
1 *01xx,*02xx *52xx,*44xx *05xx,*12xx *15xx,*04xx *06xx,*03xx 
2 *02xx,*24xx *44xx,*50xx *06xx,*16xx *11xx,*07xx *02xx,*03xx 
3 *02xx,*24xx *18xx,*35xx *04xx,*07xx *11xx,*07xx *02xx,*03xx 
4 *24xx,*33xx *51xx,*14xx *14xx,*08xx *01 xx,*03xx *05xx,*02xx 
5 *02xx,*35xx *50xx,*35xx *04xx,*06xx *16xx,*07xx *05xx,*02xx 
6 *24xx,*32xx *18xx,*35xx *12xx,*05xx *11xx,*13xx *03xx,*03xx 
 
In HLA antigen nomenclature, four digits are used. The first two denote the allele 
group. “xx” represents low resolution typing and denotes the presence of any allele 
within the allele group specified by the first two digits. 
“*” denotes that the typing was performed using molecular based techniques (153).  
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3.2 Cytokine genotyping 
Cytokines are a group of immunomodulatory proteins or glycoproteins, which are 
secreted in response to various stimuli and bind their receptors resulting in signal 
transduction pathways. Genetic variations that result in altered structure or 
expression of a cytokine could have evident pathological consequences. As specific 
cytokine polymorphisms are correlated with cytokine production levels, samples from 
subjects 1 and 2 were further genotyped for cytokine polymorphisms. As described 
in Chapter 2, Section 2.2.2, DNA was extracted using the SSO technique, hybridized 
with probes, amplified and conjugated with colour substrate. The results are shown 
in Table 3.2. The production levels corresponding to the genotyping results were 
inferred from previously published studies on the subject (154, 155,156). The 
cytokine gene haplotypes that resulted from the results shown in Table 3.2 are 
displayed in Table 3.3.  Homozygosity for the ATA haplotype of the IL-10 cytokine 
produced the lower IL-10 production in LPS stimulated blood samples (156,). As can 
be seen from these results none of the subjects tested possessed the IL-10 ATA 
homozygocity, which is associated with low IL-10 production.  
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Table 3.2 Cytokine genotyping results of Subjects 1 and 2 from Table 3.1 
 Subject 1 Subject 2 
Cytokine 
Position 
Genotype Production 
Level 
Genotype Production 
Level 
IFNγ-874 A/T Intermediate A/A Low 
IL10-592 C/C  A/C  
IL10-819 C/C High C/T Intermediate 
IL 10-1082 A/G  A/G  
IL6-174 G/G High C/G Low 
TNFα-238 G/G  G/G  
TNFα-308 G/G Low G/A High 
IL12β-1188 A/A Low A/A Low 
IL1α-889 C/C Low T/T High 
IL1β+3962 C/C  T/T  
IL1β-511 C/T  C/C Low 
IL1R1970 C/C  C/T  
IL1Rα 11100 C/C  T/T  
  
Table 3.3 Cytokine gene haplotypes of Subject 1 and 2 from Table 3.1 
Haplotype Subject 1 Subject 2 
IL-10 ACC/GCC ATA/GCC 
TNF-α GG/GG GG/GA 
IL-1β CC/CT CT/CT 
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3.3 KIR genotyping 
Samples drawn from Subjects 1 and 2 were genotyped for KIR as described in 
Chapter 2, Section 2.2.5, using the PCR-SSP method. Both subjects 1 and 2 had an 
inhibitory (DL) and activating (DS) KIR repertoire as can be seen in Table 3.4. KIR 
factors correlate with parameters of human health and disease, in which the 
observed associations have mostly been with individual or groups of activating KIR 
(109). In HCT, a variety of KIR associations have been observed. Increased aGvHD 
was correlated with donor KIR2DS3 in HLA-matched unrelated transplants and with 
donors having more than four activating KIR in haploidentical transplants (158). 
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Table 3.4 KIR genotyping results of the subjects 1 and 2 from Table 3.1 
Allele Subject 1 Subject 2 
2DL1*001-005 + + 
2DL2*001-004 + + 
2DL3*001-006 + + 
2DL4*00101/00102/00201/11202/003-007 + + 
2DL5A*001 - + 
2DL5B*002-004 - - 
2DS1*001-004 - - 
2DS2*001-005 + - 
2DS3*00101-00103 - + 
2DS4*00101/00102/002 + + 
2DS4*003 + + 
2DS5*001-003 - - 
3DL1*00101/00102/002/003/00401/00402/005-009 + + 
3DL2*001-012 + + 
3DL3*001/00201/00202/003/004 + + 
3DS1*010-014 - - 
2DP1*001/002 + + 
3DP1*001/002 + - 
3DP1*00301/00302 - + 
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3.4 Immunophenotyping 
Based on their function human lymphocytes are divided into three main types: T 
cells, B cells and Natural Killer cells (NK). These distinct populations can be 
identified by their cell surface antigen expression. A method for the identification of 
these antigens is flow cytometry. T lymphocytes, which participate in antigen -
specific cell mediated immunity and regulate secretion of immunoglobulins by B 
lymphocytes, and NK cells. T lymphocytes can be further differentiated into helper, 
suppressor or cytotoxic T lymphocytes. In this method, whole blood was used and 
cells were incubated with fluorochrome-conjugated monoclonal antibodies as 
described in Chapter 2, Section 2.2.6. Samples were analysed using flow cytometry 
and as it can be seen in Table 3.5, both subjects possessed cell populations within 
normal ranges as defined by the manufacturer and were considered suitable for 
further use in the following experiments. 
 
Table 3.5 Immunophenotyping of peripheral blood lymphocytes from Subjects 1 and 2 
Cell Type Cell Surface 
Marker 
Subject 
1 
Subject 
2 
Normal 
Range 
T Lymphocytes % CD3+ 62 73 59-85 
B Lymphocytes % CD3-/CD19+ 13 18 6-22 
Cytotoxic Lymphocytes % CD3+/CD8+ 28 24 12-38 
Helper Lymphocytes % CD3+/CD4+ 51 54 31-59 
Activated T lymphocytes % CD3+/HLA-DR+ 7 4 3-26 
NK lymphocytes % CD3-
/CD16+/CD56+ 
13 9 5-33 
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3.5 Activation marker studies 
Activation markers such as HLA-DR,-DP,-DQ, and CD25 were used in the following 
set of experiments in order to test whether cells from mismatched individuals when in 
co-cultured under the conditions described in Chapter 2, Section 2.3, are altered. 
     
3.5.1 HLA-DR, -DP, -DQ expression 
The activation marker HLA-DR,-DP,-DQ was used to investigate possible cell 
activation in different MLC settings. MLCs were prepared as described in Chapter 2, 
Section 2.3 from mismatched individuals chosen as described earlier in this chapter 
under three different cell conditions. 
The following types of MLCs were prepared and harvested at 3 and 6 days of culture 
for analysis: 
I. Cells in culture medium, with cells originating from both subjects in equal 
amounts 
II. Cells in culture medium, with cells originating from both subjects in equal 
amounts. Cells originating from one subject of the two, were  irradiated with 
25,000Gy (in these experiments, 2 set of cultures were prepared at the same 
time, each with a different one of the two cell populations irradiated) 
III. Cells in culture medium, with cells originating from both subjects in equal 
amounts supplemented with LPS (six day incubation only) 
IV. Cells in culture medium. Cells from each subject were cultured  (for each 
experiment both cell populations were cultured alone and served as controls) 
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Cells from MLCs and controls were harvested and analysed at three days of culture 
as well as a different set was harvested and analysed at six days of culture. Cells 
that were kept in culture for six days, on day four, were supplement with culture 
media as described in Chapter 2, Section 2.3. In Figure 3.1, there is a comparison of 
the percentage of HLA-DR,-DP,-DQ positive cells present in different settings and 
time of cell harvest. Triplicate MLCs and control cells were set up in each 
experiment. The HLA-DR,-DP,-DQ positive cells detected at different time points and 
conditions were only compared at control cells at that specific time and conditions. 
Results from MLCs and controls at time zero were not considered as the goal was to 
observe differences between MLCs and control cells under the same conditions.   
Flow cytometry analysis of harvested cells from three day cultures showed that the 
highest increase in the percentage of HLA-DP, -DQ,-DR positive cells reaching 
25.67% was observed in the bidirectional setting (p<0.001), while in the irradiated 
bidirectional setting as well as the unidirectional setting proved to produce no 
statistically significant difference with the control cells (p=0.65 and 0.163 
respectively). After six days of incubation the percentage of positive cells was higher  
in the unidirectional MLC setting reaching 18.88% (p=0.0001) compared to 12.01% 
of the bidirectional MLC (p=0.0005) when compared to the respective control  The 
bidirectional irradiated setting again showed no statistically significant change from 
the respective control cells (p=0.2981). The addition of LPS to the MLCs showed 
resulted in an increase in the percentage of cells upregulating HLA-DP, -DQ,-DR, 
with the bidirectional MLC reaching 34.08% (p=0.0001), with the unidirectional 
upregulating only 9.09% cells (p=0.0007), when taking the control cells into account. 
The bidirectional irradiated MLC setting showed no statistically significant change 
from the control cells (p=0.2981). 
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Fi Figure 3.1. Comparison of the HLA-DR,-DP,-DQ positive cells (%) in different 
MLCs and controls of mismatched subjects at three and six days of incubation  
Each bar represents the results of three different experiments performed in triplicate.  
Error bars present the standard deviation. MLCs were prepared as described in 
Chapter 2, Section 2.3 and HLA-DR,-DP,-DQ expression was evaluated as 
described in Chapter 2 Section 2.4. Cells were harvested on the completion of day 
three and on day six of incubation. CC: Bidirectional MLC results CR: Unidirectional 
MLC results, where the mononuclear cell suspension from one of the two individuals 
was irradiated with 25,000Gy prior to culture (results present the collective results of 
cultures with one cell population irradiated at a time) and RR: Bidirectional MLCs, 
with both cell populations irradiated with 25,000Gy prior to culture. C: single cell 
population cultures prepared from each subject (results present the collective results 
of cultures from both single cell populations used).  
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Comparison of the change in the percentage HLA-DR, -DP,-DQ positive cells of the  
bidirectional MLC settings and unidirectional provides a clearer picture as shown in 
Figure 3.2. The addition of LPS in the culture medium proved that HLA-DR, -DP, -
DQ further increased expression as compared to the day six bidirectional cultures 
without LPS as well as compared to the three day bidirectional setting, when taking 
into account the expression in the controls.  
0 1 0 2 0 3 0 4 0
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C C (6 D A Y  L P S )
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i                  Figure 3.2 Comparison of the HLA-DR,-DP,-DQ positive cells (%) of different 
bidirectional and unidirectional MLCs of mismatched subjects, normalised to 
the respective controls.  
Each bar represents the results of three different experiments performed in triplicate. 
Error bars present the standard deviation. MLCs were set up as described in 
Chapter 2 Section 2.3 and HLA-DR,-DP,-DQ expression was evaluated as described 
in Chapter 2 Section 2.4. Cells were harvested on the completion of day three and 
on day six of incubation. CC: Bidirectional MLC results CR: Unidirectional MLC 
results, where the mononuclear cell suspension from one of the two individuals was 
irradiated with 25,000Gy prior to culture (results present the collective results of 
cultures with one cell population irradiated at a time) and RR: Bidirectional MLCs, 
with both cell populations irradiated with 25,000Gy prior to culture. C: single cell 
population cultures prepared from each subject (results present the collective results 
of cultures from both single cell populations used). CC(6 DAY LPS) and CR(6DAY 
LPS), represent the results of cultures after 6 days of incubation but with the addition 
of 1μg/ml LPS on day 0, as described in Chapter 2, Section 2.3.  
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3.5.2 CD25+ expression 
CD25, otherwise named the IL-2 receptor alpha chain, is expressed on stimulated T 
cells, B cells stimulated with anti-IgM antibody and on monocytes and macrophages 
stimulated with LPS. CD25 upregulation is considered to be a measure of 
haematopoietic cell activation and indicates possible proliferation of T lymphocytes.  
In order to examine cell activation using theCD25 as a marker, the following types of 
MLCs were prepared: 
I. Cells in culture medium, with cells originating from both subjects in equal 
amounts 
II. Cells in culture medium, with cells originating from both subjects in equal 
amounts. Cells originating from one subject of the two, were  irradiated 
with 25,000Gy (in these experiments, 2 set of cultures were prepared at 
the same time, each with a different one of the two cell populations 
irradiated) 
III. Cells in culture medium, with cells originating from both subjects in equal 
amounts supplemented with LPS (six day incubation only) 
IV. Cells in culture medium. Cells from each subject were cultured (for each 
experiment both cell populations were cultured alone and served as 
controls) 
 
Cells were harvested and analysed on the completion of three days of culture, as 
well as a different set was analysed, on the completion of six days of culture. Cells 
that were kept in culture for six days and on day four were supplemented with 0.5ml 
of culture medium as described in Chapter 2, Section 2.3. The harvested cells were 
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conjugated with mouse anti-human CD25/FITC and analysed by flow cytometry as 
described in Chapter 2, Section 2.4. 
CD25 expression showed the highest increase in the bidirectional setting after three 
days of incubation, reaching  18.66 % (p<0.0001) as compared to the unidirectional 
setting, where one of the cell population was irradiated, that reached 7.53% of CD25 
positive cells (p=0.011) when taking into account the increase in the respective 
control cells.  It is also observed that the bidirectional setting with both cell 
populations irradiated showed no statistically significant difference from the control 
cells (p=0.2694). A similar pattern to the three day MLC changes is observed with 
the six day MLCs. The bidirectional six day setting showed the higher increase in the 
percentage of the CD25 positive cells, reaching 9.13% (p=0,0003)  as compared to 
the unidirectional setting that showed a 5.21% increase (p=0.0007) when taking into 
account the change in the control cells. The bidirectional irradiated MLCs again 
produced no statistically significant change compared to the control cells again 
(p=0.0618).  
For the six day MLCs supplemented with LPS again the bidirectional setting 
produced the higher percentage increase in CD25 cells (1.7%, p=0.043), while the 
unidirectional MLCs showed a decrease of -1.06% (p=0.0007) when taking into 
account the changes in the control cells. The bidirectional irradiated six day setting 
supplemented with LPS proved that the percentage of CD25 cells decreased by 
1.99% (p=0.024) when compared to the control cells. 
A schematic representation of the results is shown in Figure 3.3 and Figure 3.4. 
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Figure 3.3 Comparison of the CD25 positive cells (%) in different MLCs and 
controls of mismatched subjects  
Each bar represents the results of three different experiments performed in triplicate. 
Error bars present the standard deviation. MLCs were prepared as described in 
Chapter 2, Section 2.3 and cells were harvested and analysed as in Chapter 2, 
Section 2.4. Cells were harvested on the completion of day three and day six of 
incubation. Results are from three kind of MLCs were compared: the bidirectional 
CC, which consisted of final concentration of 1x106 cells in equal amounts from both 
subjects, the unidirectional, CR, were the mononuclear cell suspension from one of 
the two individuals was irradiated with 25,000Gy prior to culture (results indicate the 
collective results of cultures with one cell population irradiated at a time) and the 
bidirectional RR, MLCs with both cell populations irradiated with 25,000Gy prior to 
culture. As controls, C, single cell population cultures were prepared (results indicate 
the collective results of single cell cultures from both subjects. CC(6 DAY LPS), 
CR(6DAY LPS), RR(6DAY LPS) and C(6DAY LPS) represent the results of cultures 
after 6 days of incubation but with the addition of 1μg/ml LPS on day 0, as described 
in Chapter 2, Section 2.3.  
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F                      Figure 3.4   Comparison of the CD25 positive cells (%) in different bidirectional 
and unidirectional MLCs of mismatched subjects, normalised to the respective 
controls.  
Each bar represents the results of three different experiments performed in triplicate. 
Error bars present the standard deviation. MLCs were prepared as described in 
Chapter 2, Section 2.3 and cells were harvested and analysed as in Chapter 2, 
Section 2.3 on the completion of day six of incubation. Results from three MLC 
experiments with different settings were compared: the bidirectional CC, which 
consisted of final concentration of 1x106 cells in equal amounts from both subjects, 
the unidirectional, CR, where the mononuclear cell suspension from one of the two 
individuals was irradiated with 25,000Gy prior to culture and the bidirectional RR, 
MLCs with both cell populations irradiated with 25,000Gy prior to culture. As 
controls, C, single cell population cultures were prepared. The harvested cells were 
conjugated with mouse anti-human CD25/FITC fluorochromes and analysed by flow 
cytometry as described in Chapter 2, Section 2.4. CC(6 DAY LPS), CR(6DAY LPS), 
represent the results of cultures after 6 days of incubation supplemented with 1μg/ml 
LPS on day 0, as described in Chapter 2, Section 2.3.  
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3.6 Investigation of cell proliferation in culture 
Presence of cell proliferation was investigated so as to verify that the conditions used 
in these experiments facilitate cell responses. In order to examine this, Ki-67 
expression was assessed.    
 
3.6.1 Do cells enter the proliferation cycle in culture? The Ki-67 expression. 
Associated with cell proliferation is the expression of the Ki-67 protein and this is 
widely used in tumour cell studies, mainly relating to breast and prostate tumour cell 
proliferation and correlation to disease prognosis (151, 152).  Ki-67 is a protein that 
is tightly regulated by the proliferative state of the cell, is detected in the nucleus of 
all cells during the cell cycle such as the G1, S and G2 phase, as well as during 
mitosis, but not during the resting phase G (159). Since this set of experiments 
aimed to investigate the proliferative state of the cells in these culturing conditions, 
mixed lymphocyte cultures were set up and harvested after 6 days of incubation with 
and without LPS addition. 
In order to investigate any changes in Ki-67 expression, and thus cell proliferation 
using the MLC model the following type of MLCs were set up: 
I. Cells in culture medium, with cells originating from both subjects in equal 
amounts 
II. Cells in culture medium. Cells from each subject were cultured (for each 
experiment both cell populations were cultured alone and served as controls) 
III. Cells in culture medium, with cells originating from both subjects in equal 
amounts supplemented with LPS 
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IV. Cells in culture medium supplemented with LPS. Cells from each subject were 
cultured (for each experiment both cell populations were cultured alone and 
served as controls) 
Cells were harvested and analysed on the completion of 6 days of culture (on day 4 
cultures were supplemented with 0.5ml of culture medium as described in Chapter 2, 
Section 2.3). The harvested cells were conjugated with mouse anti-human Ki-
67/RPE and analysed by flow cytometry as described in Chapter 2, Section 2.4. 
In three triplicate experiments, Ki-67 protein expression of cells was increased in the 
bidirectional MLCs after 6 days of incubation, as compared to the controls for both 
subject cells supplemented. Cells in the presence of LPS though, showed a greater 
increase in their proliferative state in the MLC setting after six days of incubation, 
reaching an increase of 23.66% (p=0.0014) as compared to the respective control 
cells. The increase in Ki-67 observed in the MLCs after six days incubation but 
without the presence of LPS reached 13.08% (p=0.0065) as compared to the control 
cells. MLCs in LPS showed an almost double increase in the proliferative state of 
cells as compared to the MLCs without LPS. Thus, it is evident that the presence of 
LPS affected the proliferative state of the cells, by decreasing the number of cells 
that are in the resting phase G. Nevertheless, Ki-67 protein expression assesses 
whether cells enter the cycling process, but not whether they actually divide.  
Figure 3.5 provides a schematic representation of the results of Ki-67 expression. 
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Fi Figure 3.5 Ki-67 protein expression in controls and MLCs of mismatched 
subjects after 6 days of incubation.  
Each bar represents the results of three different experiments performed in triplicate. 
Error bars present the standard deviation. MLCs were prepared as described in 
Chapter 2, Section 2.3 and cells were harvested and analysed as in Chapter 2, 
Section 2.4 on the completion of day 6 of incubation. The harvested cells were 
analysed by flow cytometry for Ki-67. MLC: bidirectional MLC which consisted of final 
concentration of 1x106 cells in equal amounts from both subjects. MLC+LPS: 
bidirectional MLC   which consisted of final concentration of 1x106 cells in equal 
amounts from both subjects, supplemented with 1μg/ml LPS on day 0.  Single cell 
population cultures from both cell populations were prepared, C and C+LPS, the 
latter supplemented with 1μg/ml LPS, on day 0 and served as controls.  
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3.7 Discussion 
The objective of this chapter was to establish the MLC conditions under which future 
gene expression studies would be investigated. This included subject 
characterisation in the HLA system to establish disparity, the absence of aberrant 
cytokine gene polymorphisms and diversity of KIR receptors.  Also, the aim of these 
experiments was to identify the conditions and time course that yielded the higher 
cell activation so as to ascertain the conditions of the MLCs to be used in the gene 
expression studies that would follow. 
In an attempt not to exclude any white cell population, and thus try to mimic the in 
vivo situation of SCT, where the cells of both the recipient and the donor coexist, the 
white cell layer from the blood collected was used in the MLCs examined. 
Two cell activation markers (MHC class II [HLA-DR, DP and DQ] and CD25) were 
evaluated in the MLC setting using different time points and conditions. MHC Class II 
(HLA-DR, -DQ, -DP) which is considered an activation marker for hematopoietic cells 
in the MLC and CD25, otherwise named the IL-2 receptor alpha chain, which is 
expressed at high levels on stimulated T cells, B cells that are stimulated with anti-
IgM antibody and on monocytes and macrophages stimulated with 
lipopolysaccharide (LPS). CD25 upregulation is considered to be a measure of 
haematopoietic cell activation and indicates possible proliferation of T lymphocytes.  
Both activation markers examined were up-regulated during the mismatched MLC. 
The HLA-II showed a more marked increase of 25.67% in the three day bidirectional 
MLC setting, while the CD25 showed an increase of 18.66%. The increase in 
expression for both markers did not increase with time. A decrease was observed 
when comparing the 3 and 6 day MLCs for both markers which may mean that to 
sustain the activation process addition of an activating agent like IL-2 might be 
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important. The only exception to this was the 6 day cultures in the presence of LPS, 
where HLA-DR,-DP,-DQ appeared to be upregulated more than the three and six 
day cultures without LPS reaching 34.08%. 
The measurement of cell proliferation in culture was also examined, which allows for 
the optimisation of culture conditions, revealed an increase in the proliferative state 
of cells in the presence of LPS, which correlated with published data (150,160) has 
been well established by observing increases in Ki-67 expression. Ki-67 being a 
protein that is tightly regulated by the proliferative state of the cell and is detected in 
the nucleus of all cells during the cell cycle such as the G1, S and G2 phase, as well 
as during mitosis, but not during the resting phase G (159). In these set of 
experiments Ki-67 expression was increased in MLCs analysed at 6 days of 
incubation, showing a marked increase in the presence of LPS. An increase of 
23.66% in Ki-67 expression was observed in the presence of LPS, while without LPS 
only 13.08% when taking into account the respective controls.     
 
Through the above set of experiments, the conditions and time courses used, 
indicated that the bidirectional MLC at three days of culture could be used for further 
gene expression studies. Since activation and proliferation of cells was confirmed at 
3 days of culture of HLA-mismatched cells, this time point, as well as the earlier time 
point of 24 hours, could be employed, since gene activation would invariably occur 
earlier than activation marker expression, At the three day time point of cell culture, 
no further culture media addition took place as compared to the six day incubation of 
cells and thus parameters that may alter cell concentration and possible alteration of 
results would be avoided. Also, the bidirectional MLCs proved to elicit the higher cell 
activation and thus would probably show the higher change in gene expression. 
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Gene Expression Studies of  
Immune Related Genes  
in  
Mixed Lymphocyte Cultures
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Rationale and Aims 
Following the successful establishment of the MLC culture conditions, as described 
in Chapter 3, the aim of this Chapter was to detect changes in expression in a range 
of immune-related genes in both HLA-mismatched and HLA-matched MLCs, in order 
to identify potential differences in gene expression between these two different kinds 
of MLCs. If distinct differences in gene expression would be observed between the 
two settings, then a global gene expression analysis would provide us with a genetic 
signature of the effect of mismatch of subjects in the MLC model.  
 
As the three day culture of HLA-mismatched cells was confirmed in Chapter 3 by the 
examination of activation and proliferation markers, as eliciting the higher cell 
activation marker response, this time point was also used in this set of gene 
expression experiments. The earlier time points of 24 and 48 hours were also 
examined in order to detect gene expression that occurs earlier in the activation 
process.    
 
Real time PCR was used to assess expression of a panel of 84 immune-related 
genes.  These genes were related to the three classes of CD4+ T-lymphocytes, TH1, 
TH2 and Tregs since these cells play a vital role in GvHD as described in Chapter 1. 
For the TH1 subset of T cells, cytokine and related genes analysed included: CCR5, 
CD28, CSF2, CXF2, CXCR3, HAVCR2, INFG, IGSF6, IL12B, IL12RB2, IL18, 
IL18R1, IL2, IL2RA, IL6R, IRF1, SOCS1, SOCS5, STAT1, STAT4, TBX21, TLR4, 
TLR6 and  TNF. 
For the TH2 T cell subset cytokine and related genes included: CCL11, CCL5, 
CCL7, CCR2, CCR3, CCR4, CEBPB, NFATC21P, GATA3, GFI1, GPR44, ICOS, 
IL10, IL13, IL13RA, IL1R1, IL1R2, IL4, IL4R, IL5, IL9, IRF4, JAK1, MAF, NFATC1, 
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NFATC2, PCGF2, STAT6 and TMED1. For the Th17 cells IL17A and IL23A were 
available. In addition genes involved in immune cell activation of T cells such as 
CD28, CD4, CD80, CD86, GLMN, IL10, IL18, IL2, IRF4, SFTPD, SOCS5, SPP1 and 
CD27 and for B cell activation such as CD40LG, IL10, IL4, INHA, INHBA and CD27 
were part of the panel. Finally the expression of some general CD4+ T cell markers 
such as CD40LG, , CREBBP, CTLA4, FASLG, IL15, IL16, IL7, JAK2, LAG3, LAT, 
MAP2K7, MAPK8, PTPRC, TFCP2, TGFB3, CD27, TNFRSF8, TNFRSF9, TNFSF4, 
TNFSF6, TYK2, YY1 were also analysed. Thus, with the use of this panel, a wide 
range of genes that play a role in the immune reaction process were evaluated as T 
cells play a major role in GvHD manifestation. 
 
 
 
 
Results 
4.1. Selection of HLA-mismatched and HLA-matched subjects and MLC set-up 
Volunteers, different to those described in Chapter 3, were HLA typed as previously 
described in Chapter 2, Section 2.2.3. Subjects of different gender with two or less 
common antigens were considered mismatched. Matched subjects were considered 
those that shared the same HLA antigens and were siblings of the same gender. The 
subjects were HLA typed as described in Chapter 2, Section 2.2.3 and the results 
are shown for HLA mismatched and matched pairs in Tables 4.1 and 4.2, 
respectively. 
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Table 4.1 HLA types of Mismatched pairs used in the gene expression studies. 
 
    HLA-A     HLA-B   HLA-Cw   HLA-DRB1  HLA-DQB1 
1-Male *01:01,*02:01 *52:01,*44:05 *05:01,*12:02 *15:02,*04:02 *06:01,*03:03 
2-Female *24:02,*32:01 *18:01,*35:01 *12:03,*05:01 *11:04,*13:05 *03:01,*03:01 
      
1-Male *32:01,*33:01 *14:02,*40:02 *08:02,*02:02 *01:02,*16:02 *05:01,*05:02 
2-Female *24:02,*32:01 *18:01,*35:01 *12:03,*05:01 *11:04,*13:05 *03:01,*03:01 
      
1-Male *02:01,*24:02 *44:02,*50:01 *06:02,*16:04 *11:04,*07:01 *02:02,*03:01 
2-Female *24:02,*32:01 *18:01,*35:01 *12:03,*05:01 *11:04,*13:05 *03:01,*03:01 
 
HLA typing results of the pairs used in the mismatched MLCs. Each pair consisted of 
subjects that do not share more than two HLA antigens, are not related and are of 
different gender. In HLA antigen nomenclature 4 digits are used. The first two denote 
the allele group and the last two denote the presence of an allele within the allele 
group specified by the first two digits. 
“*” denotes that the typing was performed using molecular based techniques (153).  
 
 
Table 4.2 HLA types of Matched pairs in the gene expression studies. 
 
    HLA-A     HLA-B   HLA-Cw   HLA-DRB1   HLA-DQB1 
Sibling 
Pair 1 
*24:02,*02:02 *08:01,*35:01 *07:02,*04:01 
 
*03:01,*13:02 
 
*02:01,*06:04 
 
Sibling 
Pair 2 
 
 
*32:01,*32:01 *40:02,*18:01 *02:02,*12:03 *06:01,*07:01 *05:02,*02:02 
Sibling 
Pair 3 
*32:01,*02:01 *35:03,*51:01 *04:01,*14:02 *11:04,*04:03 *03:01,*03:05 
Each pair of subjects was siblings of the same gender and shared the same HLA 
typing. In HLA antigen nomenclature 4 digits are used. The first two denote the allele 
group and the second two the allele within the allele group specified by the first two 
digits.  
“*” denotes that the typing was performed using molecular based techniques (153).  
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4.2 Immune related gene expression studies in the mismatched MLC setting 
MLCs were set up as described in Chapter 2, Section 2.3 and incubated for 24, 48 
and 72 hours. Upon completion of the incubation period, cells were harvested and 
RNA was extracted as in Chapter 2, Section 2.5.1. According to the manufacturer’s 
instructions, cDNA was synthesised and using the TaqMan technology, the 84 
immune related gene plates were plated as described in Chapter 2, Section 2.5.2. 
The results were analysed using the RT2 Profiler PCR Array Analysis program and 
are shown below. Three different experiments repeated in triplicate were set up as 
follows: 
 Mismatched MLCs incubated for 24, 48 and 72 hours 
 Cell cultures from both subjects cultured alone incubated for 24, 48 and 72 
hours 
 Mismatched MLCs incubated for 24 and 48 hours, supplemented with LPS 
 Cell cultures from both subjects cultured alone, incubated for 24 and 48 
hours,  supplemented with LPS 
The results in the mismatched MLC setting, at the three set time points of 24, 48 and 
72 hours,  are shown in Table 4.3, Table 4.4 and Table 4.5 respectively (see 
Appendix I). The results indicate changes in gene expression when normalised to 
the respective control cell cultures (single cell cultures of each subject). Only the 
results with p-value less than 0.05 were considered as statistically significant.  
Observation of these data reveals that, at the 24 hour incubation point, only the IFN-
γ inducible gene of signal transducer and activator of transcription 1 (STAT-1),  
showed an increase in expression of 2.43 fold with a p value of 0.034. After 48 hours 
of incubation, STAT-1 is still observed to be upregulated reaching 3.64 fold 
(p=0.0007). Also, two other genes, belonging to the same group, i.e. IFN-γ inducible 
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group, the interferon regulatory factor 1 (IRF1) and the protein tyrosine phosphate 
receptor type C (PTPRC) genes showed an increase in expression by 2.34 fold 
(p=0.0041) and 1.23 fold (p=0.041), respectively. 
The suppressor of cytokine signaling 1 (SOCS1) gene was upregulated at the 72 
hour time point by a 1.85 fold increase (p=0.024) along with the STAT-1, which 
showed a further increase in expression to 4.78 fold (p=0.0009). At this time point of 
72 hours, the IRF1 and the PTPRC reverted to normal while the genes coding for 
interleukin-10 (IL-10) (-1.83 fold, p=0.0344) and secreted phosphoprotein 1, early T-
cell activation 1, (SPP1) (-3.27 fold, p=0.024) appeared to be down regulated. The 
gene coding for the Tumour Necrosis Factor superfamily 8 receptor (TNFRSF8)   (-
4.06 fold, p=0.011) was also shown to be downregulated. 
Figures 4.1, 4.2 and 4.3 provide a schematic representation of the observed gene 
expression changes from the obtained results with mismatched MLC. 
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Figure 4.1 Fold increase in the expression of STAT-1 gene over time of MLC 
incubation normalised to the controls. Experiments were performed in triplicates 
and the mean value is shown on the graph. Error bars represent the standard 
deviation. Results shown are from analysis of MLCs set up using mismatched 
subject pairs as described in Section 4.1. MLCs were set up, as previously described 
in Chapter 2, Section 2.3. At 24, 48 and 72 hours, cells were harvested and plated 
as described in Chapter 2, Section 2.5.2 using the SuperArray Th1-Th2-Th3 plate kit. 
After the real time polymerase chain reaction data was analysed using the 
SuperArray software for this type of plate. Controls were single cell cultures from 
each subject incubated in the same conditions. (24 hours p=0.034, 48 hours 
p=0.007, and 72 hours p=0.009). 
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Figure 4.2. Fold increase in the expression of STAT1, IRF1, PTPRC genes at 48 
hours incubation of mismatched MLC normalised to the controls. Experiments 
were performed in triplicates and the mean value is shown on the graph. Error bars 
represent the standard deviation. Results shown are from analysis of MLCs set up 
using mismatched subject pairs as described in 4.1. MLCs were set up as previously 
described in Chapter 2, Section 2.3. At 48 hours, cells were harvested and plated as 
described in Chapter 2, Section 2.5.2 using the SuperArray Th1-Th2-Th3 plate kit. 
After the real time polymerase chain reaction data was analysed using the 
SuperArray software for this type of plate. Controls were single cell cultures from 
each subject incubated in the same conditions.  (STAT1 p= 0.007, IRF1 p= 0.004, 
TPRC p=0.04). 
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Figure 4.3 Fold change in the expression of genes after 72 hours incubation of 
mismatched MLCs normalised to the controls. Experiments were performed in 
triplicates and the mean value is shown on the graph. Error bars represent the 
standard deviation. Results shown are from analysis of MLCs set up using 
mismatched subject pairs as described in Section 4.1. MLCs were set up as 
previously described in Chapter 2, Section 2.3. At 72 hours, cells were harvested 
and plated as described in Chapter 2, Section 2.5 using the SuperArray Th1-Th2-
Th3 plate kit. After the real time polymerase chain reaction data was analysed using 
the SuperArray software for this type of plate. Controls were single cell cultures from 
each subject incubated in the same conditions. (STAT1 p=0.009, IL-10 p=0.03, 
SOCS1 p=0.02, SPP1 p=0.004, TNFRSF8 p=0.011). 
 
4.3 Investigation of the effect of LPS on the gene expression in the 
mismatched MLC setting  
MLCs and controls supplemented with 1µg/ml LPS on day 0 were analysed using the 
SuperArray Th1, Th2, Th3 plate kit as described in Chapter 2, Section 2.5, after 24 
and 48 hour incubation. This was performed according to the MLC verification 
process (see Chapter 3) where it was observed that addition of LPS, altered 
expression of activation markers such as HLA-DP, DQ, DR and CD25.  
At 24 hours, the inducible T-cell co-stimulator, ICOS (1.72 fold) and the suppressor 
of cytokine signaling, SOCS1 (1.62 fold) as well as the IRF1 gene (1.74 fold) were 
upregulated while the interleukin (IL) 13 receptor A1, IL-13RA1 gene were down-
regulated (-2.6 fold) when normalised to the responses of the control cells. The 
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mentioned genes were considered as they presented statistically significant results 
i.e p values less than 0.05. Specifically, the p value for SOCS1 was 0.021, for ICOS 
0.003, for IRF1 0.043, for IL13RA1 0.043, and for IL6R 0.022. Data is shown in 
Table 4.6 (see Appendix I). 
At the 48 hour time point under the same conditions, there was a great number of 
genes coding mainly for anti-inflammatory cytokine receptors, and growth factors 
that showed downregulation when normalized to the response of control cells. Data 
is shown in Table 4.7 (see Appendix ). 
Schematic representation of the data of Table 4.6 and 4.7 are shown in Figure 4.4 
and Figure 4.5 respectively. Only gene fold changes that have a p value lower than 
0.05 were considered.  
The addition of LPS affected the gene expression changes in the mismatched MLCs 
as compared to the mismatched MLCs without LPS as shown in Section 4.2. In the 
presence of LPS at 24 hours incubation a different set of genes appear to change 
their expression, like ICOS, IRF1 and SOCS1 which upregulate their expression 
while IL13RA1 shows a downregulation. STAT-1 that remained upregulated both at 
the 24 and 48 hours in the mismatched MLCs without LPS, appears not to be 
affected, while the IRF1, that altered its expression at the 48 hours of MLCs without 
LPS, is observed to be upregulated 24 hours earlier in the presence of LPS. A 
similar observation can be done with SOCS1 upregulation. In the presence of LPS, 
SOCS1 is upregulated at 24 hours, while in the absence of LPS at 72 hours.  
The effect of LPS to the MLCs at 48 hours affects a greater number of genes by 
downregulating their expression. Of the Th1 cytokines and related genes, TBX21 
decreases its expression by -2.3 fold (p=0.045), IGSF6 by -1.36 fold (p=0.043) and 
IL6R by -1.58 (p=0.036). A number of other genes related to the Th2 cells like 
STAT6 (-1.34 fold p=0.021), NFATC21P (-2.03 fold p=0.019), NFATC21P (-2.03 fold  
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p=0.038), IL4R (-1.29 fold p=0.045), IL1R1 (-1.67 fold p=0.045), GFI1 (-2.25 fold 
p=0.044), CEBPB (-1.79 fold p=0.048) were also downregulated in the presence of 
LPS. Of the CD4 cell marker genes examined, TYK2 was downregulated by -1.90 
fold (p=0.001), TFCP2 by -1.62 fold (p=0.045), IL15 by -1.64 (p=0.034) and FASLG 
by -1.93 fold (p=0.011). 
The only T cell activation marker gene that altered its expression was GLMN that 
appeared to be down-regulated by 1.92 fold (p= 0.045). GLMN is a negative 
regulator of T-cell proliferation (162).  
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Figure 4.4 Fold change in gene expression of mismatched MLCs 
supplemented with LPS at 24 hours incubation normalised to the controls.  
Results shown are triplicate results of 3 different experiments. Error bars present the 
standard deviation. Results shown are from analysis of MLCs set up using 
mismatched subject pairs as described in Section 4.2. MLCs were set up as 
previously described in Chapter 2, Section 2.3. At 24 hours, cells were harvested 
and plated as described in Chapter 2, Section 2.5 using the SuperArray Th1-Th2-
Th3 plate kit. After the real time polymerase chain reaction completion, data were 
then analysed using the SuperArray software for this type of plate. Controls were 
single cell cultures from each subject incubated in the same conditions. (ICOS 
p=0.003, IRF1 p=0.043, SOCS1 p=0.021, IL13RA1 p=0.043, IL6R p=0.022). 
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Figure 4.5 Fold change in the expression Th1, Th2 cytokines and related genes 
and CD4+T cell marker genes of mismatched MLCs supplemented with LPS at 
48 hours incubation normalised to the controls.                              
Experiments were performed in triplicates and the mean value is shown on the 
graph. Error bars present the standard deviation. Results shown are from analysis of 
MLCs set up using mismatched subject pairs as described in Section 4.2. MLCs 
were set up as previously described in Chapter 2, Section 2.3. At 48 hours, cells 
were harvested and plated as described in Chapter 2, Section 2.5 using the 
“SuperArray Th1-Th2-Th3” plate kit. After the real time polymerase chain reaction 
completion, data were analysed using the “SuperArray” software for this type of 
plate. Controls were single cell cultures from each subject incubated in the same 
conditions. A: represents fold change in gene expression of Th1 cytokine and related 
genes. (IL6R p=0.036, GSF6 p=0.043 TBX21 p=0.045). B: represents fold change in 
CD4 cell marker genes FASLG p=0.011, IL15 p=0.034, TFCP2 p=0.045, TYK2 
p=0.001) and C: represents fold change in expression of Th2 cytokine and related 
genes (STAT6 p=0.021, NFATC2IP p=0.038, NFATC2 p=0.019, IL4R p=0.045, 
IL1R1 p=0.045, GFI1 p=0.044, CEBPB p=0.048) 
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 4.4 Immune related gene expression studies in the Matched MLC setting 
MLCs with samples from HLA-matched individuals as described in Section 4.1 were 
set up, as described in Chapter 2, Section 2.3 and incubated for 72 hours. Upon 
completion of the incubation period, cells were harvested and RNA was extracted as 
in Chapter 2, Section 2.5.1 According to the manufacturer’s instructions, cDNA was 
synthesised and using the TaqMan technology, the 84 immune related gene plates 
were plated as described in Chapter 2, Section 2.5.2. The readings were analysed 
using the RT2 Profiler PCR Array Analysis program.  
Table 4.8 shows the data as analysed by the RT2 Profiler PCR Array Analysis 
program (see Appendix I). Observation of these data reveals that no genes like 
STAT1 and the other IFN-ɣ inducible genes that were identified in the mismatched 
MLC setting altered their expression. In the following Figure 4.6 there is a schematic 
presentation of the results of matched subjects MLCs according to gene category. 
Only fold changes with p value less than 0.05 are considered statistically significant 
and presented. 
The matched MLC setting proves that genes related to Th1, Th2 and CD4 and cell 
activation are up regulated. From the panel used no gene shows down regulation. 
When comparing these results with the 72 hours mismatched MLC there are no 
common upregulated genes. SPP1 and TNFRSF8 that showed a down regulation in 
the mismatched MLC, appear to be upregulated in the matched setting, SPP1 by 
2.58 fold and TNFRSF8 by 3.42 fold.   
 
 
 96 | P a g e  
 
0 2 4 6
C D 2 8
C S F 2
H A V C R 2
IN F G
IL 2
T L R 6
F o ld -c h a n g e
0 5 1 0 1 5
C C R 2
IL 2 3 A
G F I1
G P R 4 4
IL 1 R 2
IL 9
P C G F 2
F o ld -c h a n g e
0 2 4 6
F A S L G
IL 7
M A P 2 K 7
T G F B 3
T N F R S F 8
T N F R S F 9
T N F S F 4
F o ld -c h a n g e
0 2 4 6
C D 2 8
C D 8 0
IL 2
S P P 1
F o ld -c h a n g e
A B
C D
Figure 4.6 Fold change in gene expression of matched MLCs after 72 hours 
incubation, normalised to the controls Experiments were performed in triplicates 
and the mean value is shown on the graph. Error bars represent the standard 
deviation. Results shown are from analysis of MLCs set up using matched subject 
pairs as described in Section 4.1. MLCs were set up as previously described in 
Chapter 2, Section 2.3. At 72 hours, cells were harvested and plated as described in 
Chapter 2, Section 2.5 using the SuperArray Th1-Th2-Th3 plate kit. After the real 
time polymerase chain reaction data was analysed using the SuperArray software for 
this type of plate. Controls were single cell cultures from each subject incubated in 
the same conditions. A: represents fold changes of Th1 cytokines and related genes 
(TLR6 p=0.047, IL2 p=0.038, IFNG p=0.028, HAVCR2 p= 0.033, CSF2 p= 0.044, 
CD28 p= 0.039), B: represents fold changes of Th2 cytokines and related genes 
(PCGF2 p=0.036, IL9 p=0.048, IL1R2 p=0.045, GPR44 p=0.022, GFI1 p=0.030, 
IL23A p=0.0007, CCR2 p=0.033), C. represents fold changes in CD4+T cell marker 
genes (TNSF4 p=0.023, TNFRSF9 p=0.015, TNFRSF8 p=0.018, TGFB3 p=0.037, 
MAP2K7 p=0.019, IL7 p=0.034, FASLG p=0.036) and D: represents fold changes in 
T cell activation genes (SPP1 p=0.003, IL2 p=0.038, CD80 p=0.0007, CD28 
p=0.039). 
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4.5 Discussion 
The aim of this Chapter was to investigate gene expression using a panel of immune 
related genes using the MLC model evaluated in Chapter 3 and detect differences 
between the different conditions used.   
IFN-γ is a pleiotropic cytokine associated with both GvHD and GvL (162, 163). It is 
secreted by CD4+Th1 cells (164) and CD8+ cytotoxic T cells (165) as well as NK 
cells (166) upon antigen stimulation. IFN-γ induces major histocompatibility complex 
(MHC) class II expression and has also been implicated in the intestinal pathology of 
GvHD (167). This cytokine, through IL-12 and IL-18, which are potent inducers of its 
production, induces Fas expression and apoptosis of host-reactive donor cells T 
cells during the early stages of GvHD (162,168). 
Upon engagement of the IFN-γ receptor, which is composed of the INGR1 and 
INRG2 subunits on the cell surface, Jak1 and Jak2, INFGR1 and STAT-1 are 
phosphorylated, STAT-1 homodimers then translocates to the nucleus. In the 
nucleus, the STAT-1 homodimers bind to γ-activated sequences (GAS) elements 
and in collaboration of other transcription factors regulate gene expression (169). 
STAT-1 phosphorylation has been correlated with the induction of GvHD in the liver 
and spleen (167). Blockade of the phosphorylation pathway of STAT-1 proved to 
alter the biological activity of IFN-γ and diminished GvHD (170), The IFN-γ-STAT-1 
pathway is an apoptotic pathway and there is accumulating evidence that this 
cytokine downregulates immune responses. Through this pathway, activated T cells 
of the CD4+ and CD8+ lineage are eliminated by induction of apoptosis, thus it plays  
an important role in T cell homeostasis (163,171).  
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Hence, the finding that there is STAT-1 gene expression upregulation in the 
mismatched setting correlates with studies as to the relation of STAT-1 expression 
and GvHD and confirms the initial hypothesis that co-culturing of mismatched cells 
would elicit an immune response in the GvHD direction. All genes that were up-
regulated at the three day time point in the mismatched mixed lymphocyte cultures 
without LPS were regulated by IFN-γ. 
A different picture regarding gene expression appears to be evident by the addition 
of LPS in mixed lymphocyte cultures of mismatched individuals. LPS addition caused 
the upregulation of IRF1 and SOCS1, 24 hours earlier than in cultures without LPS. 
The upregulation of ICOS, which is associated with the initial expansion of activated 
Th1 and Th2 cells (172,173), is observed in the LPS setting, pointing towards an 
earlier increased activation of cells. Previous data showed that ICOS blockade could 
reduce alloreactive T cell interactions with antigen presenting cells responsible for 
graft versus host disease (174). The proteins coded by the SOCS gene family bind 
directly to cytokine receptors or to the catalytic domain of the Janus kinase (JAK) 
protein, thereby inhibiting the phosphorylation of tyrosine kinase and blocking 
cytokine signaling (175) while they act as negative regulators of the STAT family 
(176). Also, genes coding for receptors for cytokines such as IL-6, that regulates cell 
growth and differentiation and IL-4 that promotes Th2 differentiation and factors 
involved in transcription e.g. CEBPB, GFI1 and TFCP2 are downregulated at 48 
hours which is a completely different picture than the one without LPS. Although LPS 
is considered to be an important factor in the cytokine storm that takes place during 
GvHD, as discussed in Chapter 1, it does not require the presence of different cell 
population origins to cause activation as its effect is exerted prior to stem cell 
infusion due to tissue damage caused by the conditioning regiments that recipients 
undergo. Nevertheless, in these experiments, there appears to be a change from the 
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control cells cultured alone in the presence of LPS and the MLCs in the presence of 
LPS.  Taken together, the above observation might suggest that LPS causes the 
STAT-1, which is a gene associated with apoptosis of activated cells to revert to 
normal expression and also causes downregulation of anti-inflammatory factors with 
up-regulation of ICOS. Thus, these observations point to increased activation of 
immune cells and slowing of apoptotic pathways in the MLC. Nevertheless, 
consideration should also be given to the fact that response to LPS was proved to be 
dose dependent and a study with different LPS concentrations could provide a more 
definite sequence of events in gene activation in the MLC (150).    
 
The gene expression observed in the matched MLC setting was different than the 
one observed in the mismatched one. While in the mismatched setting at 72 hours 
the genes up-regulated were STAT1, IL-10 and SOCS1, while SPP1, TNFRSF8 
were down-regulated, in the matched setting the latter two genes wereup-regulated 
along with more CD4+T cell markers and T cell activation genes. STAT-1, IL10 and 
SOCS1, do not alter their expression in the matched setting, clearly distinguishing 
the two different kinds of MLCs related to HLA status of the subjects used. Also 
genes coding for Th1 and Th2 cytokines and related genes are observed to up- 
regulate their expression as in Figure 4.6, .in the matched setting. These differences 
observed in the matched and mismatched MLCs might suggest that the INF-related 
genes identified in the mismatched setting and the suggestion of cells driven to 
apoptosis is not observed in the matched case, as cells appear to become activated. 
In the matched MLCs, only the HLA typing of the individuals used was considered so 
as to be termed as ‘matched’, as it would be in the in vivo situation of SCT. 
Nevertheless, this does not imply that other factors, like miHLAs, cytokine 
polymorphisms, KIRs as well as other genetic polymorphisms are not involved in the 
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process. As it is well established and discussed in Chapter 1, other factors beyond 
the HLA type are involved in mounting allorecognition. Thus, unless the pairs used 
were identical twins and not being mere siblings, changes in gene expression would 
be observed even in the matched MLC. The important finding of the changes 
observed in the matched and mismatched MLC analysis is that the changes 
observed are distinct. 
 
Taken together, through this set of experiments using a limited number of immune 
related genes, we have observed distinct changes in the expression related to each 
MLC setting used. In the mismatched MLC setting, genes of the interferon family 
show changes pointing towards the apoptotic pathway that is correlated with GvHD. 
In the mismatched setting in the presence of LPS changes in expression may point 
to early cell activation but, as cell responses to LPS are dose dependent, evaluation 
of these findings may be required through new, earlier time course and different 
doses of LPS, in order to ascertain the gene expression changes observed. In the 
matched MLC setting, when compared to the respective mismatched MLC, quite a 
different kind and number of genes alter their expression by upregulation. Genes 
coding for Th1, Th2 cytokines and related genes as well as CD4 related genes and T 
cell activation genes as well alter their expression pointing towards cell activation. 
The important finding of these set of investigations was that the mismatched and 
matched MLCs showed completely different results, with the mismatched results 
correlating to previous findings in the GvHD direction of responses. 
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Abstract
Human leucocyte antigen (HLA) compatibility is the main factor determining the
occurrence of graft-vs-host disease (GVHD) in patients. It has also been shown that
minor histocompatibility antigen differences as well as genetic polymorphisms that
are not sequenced by standard methodology for HLA typing can play a role. We used
mixed lymphocyte cultures (MLCs) as a functional cellular test and investigated gene
expression changes driven by HLA incompatibility in an effort to better understand
the mechanisms involved in the disease. Gene expression profile of HLA matched
and HLA mismatched MLC identified differentially regulated genes and pathways.
We found that a great number of genes related to immune function were differentially
regulated; these genes were also found to be associated with GVHD and graft rejection.
The majority of differentially regulated genes were interferon-gamma (IFNγ)-inducible
genes and IFNγ neutralisation in MLCs abrogated their induction. The microRNA-155,
a recently identified target for acute GVHD (aGVHD), was also found to be significantly
induced in HLA mismatched MLC but not in the matched setting and its induction
was not diminished by blocking IFNγ. In this proof-of-principle study we show gene
expression changes in mismatched MLC that represent alloreactive responses, correlate
with markers involved in GVHD and can potentially be useful in the study of the
biological processes involved in this disease.
Introduction
Allogeneic haematopoietic stem cell transplantation
(allo-HSCT) can be a successful therapy for many haema-
tological malignancies and dysplasias but its success is limited
by graft rejection or the development of graft-vs-host disease
(GVHD), a major contributor to increased morbidity and
mortality of transplanted patients (1). The incidence of GVHD
and rejection is significantly lower in patients receiving a
graft from a sibling identical for human leucocyte antigens
(HLAs), compared with those receiving a graft from an HLA
phenotypically identical unrelated donor (2, 3). However, only
35% of patients have an HLA identical sibling donor hence,
for the majority of patients an HLA phenotypically identical
unrelated donor is the only option.
The classic HLA genetic loci are the best-characterised deter-
minants for GVHD (4) and donor selection for transplantation is
†These authors contributed equally to this work.
based onmatching donor and recipient for HLA byDNA typing
for HLA-class I (HLA-A, -B and -C) and II (HLA-DRB1 and
-DQB1) loci with an identity of at least 8 of 10 antigens required
to proceed with transplantation. However, aGVHD occurs in
roughly 40% of patients receiving HLA-identical grafts (5) due
to undetected antigen differences between unrelated individuals
which can be recognised by donor T cells following transplan-
tation and lead to the disease. The major histocompatibility
complex (MHC) region harbours approximately 200 genes
many of which have immune-related functions and several sin-
gle nucleotide polymorphisms within the MHC (of the donor
or recipient) that are not sequenced by standard methodology
for HLA typing confer higher risk for aGVHD (6). In addition,
non-MHC variants are minor histocompatibility antigens that
could contribute to GVHD such as CT 60 SNP in CTLA-4 (7),
SNP13 in NOD2 (8), or cytokines such as interferon-gamma
(IFNγ), interleukin-6 (IL-6), IL-10 and IL-1Ra (9–12). Finally,
the total number of transplantation antigens encoded within the
MHC region remains unknown. Petersdorf et al. have suggested
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 267
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that haplotype matching for unrelated HSCT is beneficial to
decrease GVHD-morbidity (13), but still this approach does
not provide functional clues for alloresponses between donor
and recipient and does not account for non-MHC determinants.
Cellular tests such as the mixed lymphocyte culture (MLC)
or the frequency analysis of alloreactive helper and cytotoxic
T lymphocyte progenitors (HTLp and CTLp, respectively)
were established as functional assays representing the cellular
response to antigenic determinants and hence the possibility
of alloreactions between donor–recipient. These assays rely
on measuring cell proliferation or production of cytokines, use
radioactive agents and are very laborious and time consuming.
In addition, these tests have not been consistently shown to
correlate well with the occurrence of aGVHD (14–17). There-
fore, selection procedures in HSCT would greatly benefit from
the development of simpler and faster functional assays for
example measuring gene expression as a marker of alloreac-
tivity. Gene expression profile in an HLA mismatched set-
ting could be indicative of high-risk donor–recipient pairs and
would allow better donor selection in cases where more than
one suitable donor is available for allo-HSCT; for example hap-
loidentical siblings of a patient.
One study using gene expression profiling suggested that
some donors may be ‘stronger alloresponders’ and conse-
quently more likely to elicit GVHD than others (18). By
investigating the gene expression profiles of CD4+ and CD8+
cells of 50 allo-HSCT donors Baron et al. could segregate
those whose recipients went on to develop GVHD from those
who did not. A limitation of this study, however, was that it
looked at the donor cells in isolation and thus did not take into
consideration the interactions between the donor and recipient.
In addition to genetic background, leading to quantitative or
qualitative differences in immune responses, environmental
factors and donor/recipient immune system history may con-
tribute to how they will react; hence a functional assay is more
favourable than simply sequencing gene variations or viewing
donor cells in isolation.
The study presented here was conducted as a proof-of-
principle that gene expression signatures in MLC of a poten-
tial donor–recipient pair could be predictive of incompatibility.
To this end we used gene expression microarrays to investi-
gate the genes and pathways differentially regulated in bidi-
rectional MLC from HLA matched vs mismatched pairs. We
found that a great number of genes related to immune function
were differentially regulated; these genes were also found to
be associated with GVHD. The most highly upregulated genes
were IFNγ-inducible genes and IFNγ neutralisation in MLCs
abrogated their induction. The microRNA-155 (miR-155) was
also found to be significantly induced in the mismatched set-
ting but its induction was not diminished by blocking IFNγ.
We are proposing that measuring gene expression in MLC
could be a simpler and faster method of identifying functional
incompatibilities between potential donor–recipient pairs that
are not detected by DNA typing techniques, compared with the
traditional cellular assays.
Methods
Materials and reagents
Peripheral bloodmononuclear cells (PBMCs) were prepared by
density gradient centrifugation from healthy volunteer donors.
All samples were obtained with written informed consent and
the study was approved by the Cyprus National Bioethics
Committee. IFNγ neutralising antibody and isotype control
were purchased from R&D systems, Abington, UK. Human
recombinant IFNγ as well as IFNγ ELISA (enzyme-linked
immunosorbent assay) kits were from PeproTechInc., Rocky
Hill, NJ. For real-time RT-PCR inventoried TaqMan® Gene
expression Assays for IDO1 (Hs00984148_m1), CCL8
(Hs041877715_m1), CXCL9 (Hs001771065_m1), CXCL10
(Hs01124251_g1) and MIR155HG (Hs01374569_m1) and
inventoried TaqMan® MicroRNA Assays for miR-155
(000479) and RNU (001006) were used (Applied Biosystems,
Foster City, CA) with SuperScript® III Reverse Transcriptase
(Invitrogen Corp., Carlsbad, CA) and TaqMan Universal PCR
Mastex Mix (Applied Biosystems, Foster City, CA) and run on
an ABI 7500 Real Time PCR System. All other reagents were
purchased from Sigma-Aldrich UK Ltd, Dorset, UK unless
otherwise stated.
Mixed lymphocyte cultures
Bidirectional MLCs were set up in roswell park memorial insti-
tute (RPMI) media supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin/streptomycin at a 1:1 ratio and main-
tained in a humidified incubator at 37∘C and 5% CO2. All HLA
matched pairs were genotypically matched siblings while all
HLA mismatched pairs had at least four out of six mismatches
considering HLA-A, -B and -DRB1 loci. The HLA types of all
individuals included in this study are shown in Table S1, Sup-
porting Information. Typing was performed by combination of
standard sequence specific oligonucleotide probes (SSOP) and
sequence-specific primers (SSP) typing methods routinely used
for bone marrow transplantation purposes in our european fed-
eration for immunogenetics (EFI) accredited laboratory. Uni-
directional assays were also performed using three individuals
who were either homozygous or heterozygous for the two most
frequent haplotypes in the Cypriot population (Table S2). Cells
were irradiated with 25Gy. Cell culture supernatants were har-
vested at different time points, centrifuged to remove cell debris
and stored at −20∘C until their use in ELISA assays. Cultures
were harvested at different time points for RNA isolation.
Gene expression proﬁling
The microarray study was performed using the
IlluminaHumanHT-12 v4 Expression BeadChips (Illumina
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Inc., San Diego, CA). In brief, 1 μg total RNA was reverse
transcribed to synthesise first- and second-strand comple-
mentary DNA (cDNA), followed by in vitro transcription
to synthesise biotin-labelled complementary RNA (cRNA)
using the TotalPrep-96 RNA amplification kit (Ambion,
Austin, TX). Biotin-labelled cRNA from each sample was then
hybridised to the BeadChips at 58∘C for 18 h. The hybridised
BeadChips were washed, labelled with streptavidin-Cy3 and
then scanned with Illumina BeadScan and images imported
into GENOMESTUDIO version 1.5.4 (Illumina Inc.) for data
extraction. Analyses were performed using BRB-Array
Tools and MeV (19). Data were log2 transformed and quan-
tile normalised using the lumi package from Bioconductor
(http://www.bioconductor.org/) and genes with low variabil-
ity (less than 20% of expression data values have at least a
1.5-fold change in either direction from the gene’s median
value) were filtered out from further analysis. Genes with
significantly altered expressions were identified by one-way
analysis of variance (ANOVA) with Benjamini–Hochberg multi-
ple testing correction, with P< 0.01. The entities satisfying the
significance analysis were passed on for the fold change anal-
ysis. For a given gene its change in expression was calculated
by subtracting its average normalised intensity in individuals
from the average normalised intensity in MLCs (MLCs were
plated at a ratio of 1:1) (20).
Results
Matched and mismatched MLCs have distinct
expression proﬁles
To investigate the differences between matched and mis-
matched MLC we carried out a whole genome gene expression
microarray. We isolated PBMC from a pair of HLA identical
siblings (S4 and S5) and a third HLA mismatched individual
(S6) which were either cultured alone or in bidirectional
matched (S1= S4+ S5) and mismatched MLCs (S2=S5+ S6
and S3=S4+ S6), all in triplicate. After culturing for 72 h
RNA was extracted and used for the whole genome expression
microarray. Prior to the microarray analysis, it was verified
that in the mismatched MLC setting there was increased
proliferation as determined by carboxyfluorescein succin-
imidyl ester (CFSE) dilution assay and upregulation of T-cell
activation markers CD25 and HLA-DR (data not shown).
Unsupervised hierarchical clustering using the set of genes
with the most variable mRNA expression (SD> 0.75) showed
that the expression profile of mismatched MLC (S2 and S3)
was distinct from the matched MLC (S1) defined by two
major clusters formed (Figure 1A). Furthermore, the expres-
sion profile of the matched MLC (S1) clustered together
with the matched individuals (S4 and S5), whereas the mis-
matched MLC (S2 and S3) was more closely related to the
third individual (S6) (Figure 1A). Genes with significantly
altered expressions between matched and mismatched MLC
were identified by one-way ANOVA with Benjamini–Hochberg
multiple testing correction, with P< 0.01 and the entities
satisfying the significance analysis were subsequently used for
fold change analysis. Fold change was calculated comparing
average normalised intensity of matched or mismatched MLCs
to the mean of their respective individuals cultured alone. We
identified 193 genes that were differentially regulated between
matched and mismatched MLC by at least twofold, of which
142 were upregulated (Tables S3 and 1) and 51 downregulated
(Tables 4 and 2). Heatmap of the fold-changes of regulated
genes shows that major differences in gene expression exist
in the mismatched MLC as compared with the individuals
[S2− (S5+ S6) and S3− (S4+S6)]. Conversely, as shown
on the Tables and heatmap no significant differences can
be seen in gene expression of the matched MLC compared
with the matched individuals cultured alone [S1− (S4+ S5)];
co-culturing does not lead to any change in gene expression
(Figure 1B).
The genes differentially regulated in matched vsmismatched
MLCwere classified ontologically using PANTHER classifica-
tion system pathways which also statistically determines over-
or under-representation of genes in a particular pathway.Within
regulated genes there was significant over-representation of
genes related to immune system response (Table 3). Other
significantly represented pathways were angiogenesis and
interleukin signalling pathways, transforming growth factor
(TGF)-β signalling pathway, cytoskeletal regulation by Rho
GTPase and Toll-like receptor signalling pathway. Using
KEGG pathways these genes were also shown to be signif-
icantly associated with GVHD and graft rejection (Table 4).
According to the fold change analysis the immunosuppressive
enzyme indoleamine 2,3-dioxygenase (IDO) and chemokines
CXCL9, CXCL10 and CCL8 were the most highly upregulated
genes in mismatched MLC whereas they were not induced in
the matched MLC (Table 1). As validation of the microarray
results the expression levels of these four genes were deter-
mined by qPCR in the same RNA samples (Figure 1C) and
found to be highly correlated to their expression changes as
calculated by the microarray (Pearson’s correlation r= 0.9216,
P< 0.0001) (Figure 1D).
IDO1, CXCL9, CXCL10 and CCL8 are induced
in mismatched MLC
As IDO1, CXCL9, CXCL10 and CCL8 were the most highly
upregulated genes in mismatched MLC we chose to further
investigate these four genes as theywould bemore likely to have
higher discriminatory value. The temporal regulation of IDO1,
CXCL9, CXCL10 and CCL8 in bidirectional mismatchedMLC
was investigated at 24 h, 48 h, 72 h and day 6 of culture. The
mRNA levels of all genes increasedwith time reaching a peak at
72 h and declining after that (Figure 2A). The induction of these
four genes was shown to be a reproducible effect in further HLA
mismatched pairs (Figure 2B), while in further pairs of matched
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Figure 1 (A) Hierarchical clustering using the set of genes with the most variable mRNA expression (SD>0.75) deﬁning two major clusters. Clustering
was performed using centered correlation and average linkage in BRB-Array Tools. S1=S4+S5matchedmixed lymphocyte culture (MLC), S2=S5+S6
and S3=S4+S6 mismatched MLC, S4 and S5 matched siblings, S6 mismatched individual. (B). Heatmap of fold-changes of regulated genes in the
mismatched MLC [S2− (S5+S6) and S3− (S4+S6)] and the matched MLC [S1− (S4+S5)]. CLUSTER 3.0 and TREEVIEW software were used. Genes with a
fold change of ±5 are presented. Red colour indicates upregulated genes, green colour downregulated genes and black colour indicates no change. (C)
Upregulation of IDO1, CCL8, CXCL9 and CXCL10 was veriﬁed using qPCR shown as fold change in the MLC vs the mean expression of the individuals
(MLCs were at a 1:1 ratio). (D) Correlation between fold changes for IDO1, CXCL9, CXCL10 and CCL8 calculated by microarrays and qPCR; Pearson’s
correlation is shown.
MLCs there was no induction of IDO1, CXCL9, CXCL10 or
CCL8 showing that these genes are only induced in an HLA
mismatched setting (Figure 2B). Across all the 15 different mis-
matched pairs investigated the induction of the four genes was
consistent albeit of different magnitudes probably representing
the biological variation of the individuals (Figure 2C).
To investigate whether the four genes can show directional
response we performed selected unidirectional assays using
irradiation to complement our findings. We chose three indi-
viduals A, B and C based on their HLA haplotypes that were
either homozygous or heterozygous for the two most frequent
haplotypes in the Cypriot population (Table S2) and performed
both bidirectional and unidirectional MLC (AB, BC and AC).
Both directions of the unidirectional MLCs were performed by
irradiating (ir) the cells from one or the other individual prior
to MLC, i.e. AB= bidirectional MLC, irAB= unidirectional
MLC were cells from A were irradiated, AirB= unidirectional
MLC were cells from B were irradiated. In these assays we
found a trend of directional response in the induction of IDO,
CCL8, CXCL9 and CXCL10 (Figure S2), although further val-
idation is required.
IFN𝛄 is responsible for IDO1, CXCL9, CXCL10 and CCL8
induction in mismatched MLC
Among the differentially regulated genes in matched and
mismatched MLC there was a strong IFNγ signature; indeed
IDO1, CXCL9, CXCL10 and CCL8 are IFNγ inducible genes.
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Table 1 Upregulated genes in matched vs mismatched MLCa
S2− (S5+S6) mismatched S3− (S4+S6) mismatched S1− (S4+S5) matched
Gene symbol FC Corrected P FC Corrected P FC Corrected P
INDO 23.20 0.0106 21.02 0.0100 1.14 0.9726
IDO1 22.78 0.0101 22.08 0.0074 1.00 1.0003
CXCL9 15.31 0.0026 12.57 0.0073 −1.07 1.0076
CXCL10 14.78 0.0060 16.56 0.0106 −1.12 1.0131
CCL8 14.42 0.0107 15.21 0.0112 −1.07 1.0069
MT1G 13.33 0.0001 10.78 0.0002 1.49 0.5269
ANKRD22 11.67 0.0065 11.36 0.0070 −1.01 1.0022
FAM26F 6.66 0.0221 4.74 0.0320 −1.03 1.0123
GBP1 6.64 0.0120 6.42 0.0182 −1.01 1.0061
GBP5 6.18 0.0025 7.11 0.0064 −1.09 1.0108
IFI27 6.00 0.0005 7.02 0.0008 −1.10 1.0076
WARS 5.98 0.0025 5.96 0.0020 −1.05 1.0177
MT1E 5.82 0.0008 4.65 0.0001 1.13 0.9669
MT2A 5.55 0.0006 6.27 0.0012 −1.06 1.0108
UBD 5.51 0.0044 4.67 0.0053 1.07 0.9852
CHI3L1 5.43 0.0584 5.54 0.0342 1.47 0.6315
SERPING1 5.00 0.0064 4.34 0.0112 −1.01 1.0047
IFIT3 4.89 0.0005 8.42 0.0053 −1.09 0.9901
IL1B 4.84 0.0128 6.07 0.0048 1.27 0.9556
GBP4 4.72 0.0070 5.86 0.0056 −1.11 0.9540
IFNG 4.46 0.0003 5.77 0.0016 −1.09 1.0131
ANOVA, analysis of variance; FC, fold change; MLC, mixed lymphocyte culture.
aGenes identiﬁed by microarray to be upregulated more than ﬁvefold in mismatched MLCs with corresponding fold change values in the matched MLC
presented for comparison. Genes with signiﬁcantly altered expressions were identiﬁed by one-way ANOVA with Benjamini–Hochberg multiple testing
correction, with P <0.01 and were passed on for the fold change analysis. For a given gene its change in expression was calculated by subtracting its
average normalised intensity in individuals from the normalised intensity in MLCs (P <0.01).
Table 2 Downregulated genes in matched vs mismatched MLCa
S2− (S5+S6) mismatched S3− (S4+S6) mismatched S1− (S4+S5) matched
Gene symbol FC Corrected P FC Corrected P FC Corrected P
SEPP1 −17.20 0.0036 −15.23 0.0009 1.03 1.0020
F13A1 −8.89 0.0003 −15.95 0.00001 1.06 1.0117
RNASE1 −7.81 0.1433 −19.80 0.0366 −1.02 1.0045
FOS −7.72 0.0101 −10.77 0.0073 −6.18 0.4073
LGMN −5.96 0.0108 −7.38 0.0074 −1.14 0.5846
LGMN −5.54 0.0066 −6.85 0.0030 −1.22 0.4033
DUSP1 −5.47 0.0157 −4.59 0.0327 −3.99 0.5231
FOSB −5.08 0.0551 −3.79 0.0956 −5.70 0.5291
ADORA3 −4.83 0.0047 −6.53 0.0072 1.05 1.0130
HS3ST2 −4.61 0.0723 −5.33 0.0441 −1.14 0.8104
CHST13 −4.50 0.0029 −5.66 0.0019 −1.05 0.9255
ANOVA, analysis of variance; MLC, mixed lymphocyte culture.
aGenes found to be downregulated more than ﬁvefold in mismatched MLCs in the microarray study together with corresponding fold change values in
the matched MLC presented for comparison. Genes with signiﬁcantly altered expressions were identiﬁed by one-way ANOVA with Benjamini–Hochberg
multiple testing correction, with P <0.01 and were passed on for the fold change analysis. For a given gene its change in expression was calculated
by subtracting its average normalised intensity in individuals from the normalised intensity in MLCs (P <0.01).
In addition, IFNγ is known to be an important regulator in T
cell alloreaction, extensively studied in the mismatch MLC
setting and also as a marker for alloreaction between HLAmis-
matched donors and recipients. All the significantly regulated
genes identified by the microarray in the mismatched MLC
were investigated using the INTERFEROME tool, a database
of interferon regulated genes (21), revealing that 116 of 193
genes submitted are regulated by IFNγ. Among them were
IDO1, CXCL9, CXCL10 and CCL8 as well as other known
IFNγ inducible genes such as STAT1 and SOCS1.
We found increased levels of IFNγ in our mismatched MLC
peaking at 72 h, which probably accounts for the induction of
these genes (Figure 3A). To verify that IFNγ drives the induc-
tion of IDO1, CXCL9, CXCL10 and CCL8 in the mismatched
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Figure 2 (A) Expression of IDO1, CXCL9, CXCL10 and CCL8 measured by qPCR in bidirectional mismatched mixed lymphocyte cultures (MLCs) at
24 h, 48 h, 72 h and 6 days. (B) Expression of IDO1, CXCL9, CXCL10 and CCL8 in matched and mismatched bidirectional MLCs and (C) in further 16
mismatched MLCs. Gene expression is shown as fold change in the MLC vs the mean expression of the individuals.
MLC we sought to investigate the expression of these genes
in the presence of IFNγ neutralising antibody. IFNγ neutrali-
sation significantly decreased the induction of IDO1, CXCL9,
CXCL10 and CCL8 in bidirectional mismatched MLCs as
compared with isotype matched control (Figure 3B). This
finding indicates that the induction of IDO1, CXCL9, CXCL10
and CCL8 in the mismatched MLC setting depends on IFNγ.
The miR-155 is induced in mismatched MLC
independently of IFN𝛄
Among the 77 genes that are not identified by the INTER-
FEROME database as IFNγ inducible genes the MIR155 Host
Gene (MIR155HG) was included. MIR155HG (also known as
BIC) consists of three exons and gives rise to miR-155 which
is encoded within exon 3. MIR155HG was identified by our
microarray to be induced by 2.55-fold (corrected P= 0.0009)
in the mismatched MLC (S2) (Table S2). MIR155HG induc-
tion in the mismatched but not the matched MLC was verified
by qPCR (Figure 4A). In the mismatched MLC the expression
of MIR155HG increased with time reaching roughly twofold at
72 h andmore that fourfold at 6 days of culture (Figure 4B). The
expression of miR155 was investigated in further mismatched
MLCs at three time points (72 h, day 6 and day 7) andwas found
to be induced and to be highly correlated toMIR155HG expres-
sion (Pearson’s correlation r= 0.8864, P= 0.0015, Figure 4C).
Even though the INTERFEROME database did not identify
MIR155HG as an IFNγ regulated gene there is data showing
that MIR155HG and miR-155 can be induced by IFNγ in vitro
(22). To investigate this, mismatched MLCs were repeated in
the presence of IFNγ neutralising antibody and the expression
of MIR155HG and miR-155 was measured. Neutralisation of
IFNγ did not abrogate the induction of MIR155HG or miR-155
in mismatched MLC (Figure 4D) and treatment of PBMC
with human recombinant IFNγ did not result in the induction
of MIR155HG or miR-155 while inducing IDO1 expression
(Figures 4E and S3). These findings suggest that MIR155HG
and miR-155 expression may be induced via alternative path-
ways in this setting.
Discussion
Donor selection relies onDNA typing that offers no information
about functional responses of the donor and recipient whereas
functional tests such as the MLC can complement HLA typing
and serve as a more relevant representation of these responses.
We used gene expression profiling to study global differences in
the HLA mismatched MLC compared with the HLA matched
setting and show that gene expression in MLC can reveal
mechanisms involved in GVHD and graft rejection; these can
potentially serve to better our understanding of the mechanisms
involved in the alloresponses during these diseases and reveal
therapeutic targets.
Gene expression changes driven by HLA incompatibility
were distinctly differentiated from the HLA matched setting
and were mostly related to immune function and immune
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Table 3 Overrepresented GO biological process pathways in matched vs mismatched MLCa
Pathways
Homo sapiens
genes
Regulated genes
twofold matched vs mismatched Expected P-value
Immune system process 2480 68 21.20 2.95E-17
Response to stimulus 1767 53 15.11 3.44E-14
Immune response 725 34 6.2 1.11E-13
Response to interferon-gamma 113 16 0.97 1.00E-12
Macrophage activation 325 21 2.78 1.88E-10
Cytokine-mediated signalling pathway 371 19 3.17 1.13E-7
Unclassiﬁed 6816 25 58.28 1.33E-6
Signal transduction 4019 62 34.36 1.21E-4
Cell communication 4224 64 36.12 1.37E-4
Cellular defence response 496 16 4.24 1.15E-3
Cell–cell signalling 1259 26 10.76 4.83E-3
Cellular process 6072 77 51.92 6.42E-3
Cell surface receptor linked signal transduction 2049 35 17.52 9.34E-3
JAK-STAT cascade 112 7 0.96 9.94E-3
JNK cascade 155 8 1.33 1.12E-2
Negative regulation of apoptosis 264 10 2.26 1.80E-2
MAPKKK cascade 454 13 3.88 2.79E-2
Extracellular transport 138 7 1.18 3.56E-2
Apoptosis 978 20 8.36 4.97E-2
GO, gene ontology; MLC, mixed lymphocyte culture; MAPKK, mitogen-activated protein kinase kinase kinase.
aGene ontology biological process pathways identiﬁed to be signiﬁcantly overrepresented within differentially regulated genes between matched and
mismatched MLC. Analysis was performed using the statistical overrepresentation tool of PANTHER classiﬁcation system. P values are corrected
using Bonferroni’s multiple testing correction and a cut-off of P <0.05.
Figure 3 (A) Interferon-gamma (IFNγ) levels in eight bidirectional mismatched mixed lymphocyte culture (MLC) measured by enzyme-linked
immunosorbent assay (ELISA) at 24 h, 48 h, 27 h, 6 days and 7 days. (B) Fold change expression of IDO, CCL8, CXCL9 and CXCL10 in mismatched
MLC in the presence of neutralising antibody to IFNγ or isotype control. Cumulative data of ﬁve independent experiments. Gene expression is shown
as fold change in the MLC vs the mean expression of the individuals. *P ≤0.05, **P ≤0.01.
response. The majority of genes regulated in the mismatched
setting were identified by the INTERFEROME tool to be IFNγ
inducible genes suggesting a very strong influence of INFγ in
MLC. Indeed many previous studies have shown the central
role of IFNγ in the cytokine network following alloantigen
recognition as well as the generation and maintenance of
alloresponses associated with the induction of GVHD. In
murine models of GVHD IFNγ is elevated early, peaking before
clinical symptoms appear (23) and T cells isolated from patients
with GVHD have higher levels of IFNγ (24). GVHD results
from the recognition of host antigens by donor T cells following
allogeneic transplantation and these alloreactive donor T cells
are the primary source of IFNγ. Therefore, IFNγ can be used as
a surrogate of T-cell response and many studies have explored
the use of IFNγ as a marker for donor selection (25, 26),
transplantation-related complications (27) and GVHD (28). A
study by van der Meer et al. attempted to decipher whether lev-
els of IFNγ in MLC, as a marker for deleterious Th1 responses,
are sensitive to HLA incompatibility and whether they correlate
with GVHD occurrence when the donor–recipient pairs tested
proceeded with transplantation. It was shown that high levels
of INFγ coincided with severe aGVHD in unrelated bone mar-
row transplantation, whereas low levels were largely associated
with grades 0 and I. In addition, levels of IFNγ inMLC reflected
HLA class II differences but not isolated class I differences or
mismatches other thanHLA (identical siblings), suggesting that
measuring IFNγ alone cannot be used for the detection of class
I mismatches (26).
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Figure 4 (A) Expression of MIR155HG in matched and mismatched bidirectional mixed lymphocyte cultures (MLCs) at 72 h. (B) Expression of
MIR155HG in mismatched MLCs at 24 h, 48 h, 72 h and 6 days. (C) Veriﬁcation of microRNA-155 (miR-155) induction in further mismatched MLCs
at three time points (72 h, day 6 and day 7) and correlation to MIR155HG expression, Pearson’s correlation is shown. (D) Fold change expression of
MIR155HG andmiR-155 in mismatchedMLC in the presence of neutralising antibody to interferon-gamma (IFNγ) or isotype control. Gene expression is
shown as fold change in theMLC vs the mean expression of the individuals. (E) Expression of miR-155, MIR155HG and IDO1 in human peripheral blood
mononuclear cell (PBMC) treated with 10 ng/ml of human recombinant IFNγ for 24 h. Fold changes relative to control of untreated PBMC. Cumulative
data of three separate experiments; *P ≤0.05.
By investigating global gene expression changes in mis-
matched MLC we aimed to identify genes that may constitute
good targets to study further as markers for donor–recipient
alloresponses. The most highly upregulated genes were IDO1,
CXCL9, CXCL10 and CCL8; the regulation of these genes
was confirmed by quantitative real-time PCR and in indepen-
dent HLA mismatched MLCs. The four selected genes have all
been invariably associated with GVHD or allograft rejection
(Table S5), supporting that in vitro responses can mirror the
in vivo situation. Indeed, gene expression profiling of early
changes in hepatic GVHD identified many targets similar to
the ones presented here (29). However, this does not exclude
the possibility that other genes may show more prominent
changes in different MLC, as compared with those studied by
microarray in this study, due to the presence of different HLA
combinations.
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Table 4 KEGG pathways overrepresented in matched vs mismatched
MLC regulated genesa
Pathways Count % P-value Benjamini
Cytokine–cytokine receptor interaction 17 1.4 7.6E-9 5.5E-7
Toll-like receptor signalling pathway 8 0.7 9.2E-5 3.3E-3
Chemokine signalling pathway 10 0.8 1.5E-4 3.6E-3
Haematopoietic cell lineage 7 0.6 2.9E-4 5.3E-3
Graft-vs-host disease 5 0.4 7.6E-4 1.1E-2
Type I diabetes mellitus 5 0.4 1.0E-3 1.2E-2
NOD-like receptor signalling pathway 5 0.4 4.3E-3 4.3E-2
Antigen processing and presentation 5 0.4 1.2E-2 1.0E-1
JAK-STAT signalling pathway 6 0.5 2.5E-2 1.8E-1
MLC, mixed lymphocyte culture.
aKEGG pathways found to be signiﬁcantly overrepresented within dif-
ferentially regulated genes between matched and mismatched MLC.
Gene set enrichment analysis was performed using the molecular signa-
tures database of DAVID Bioinformatics Resources (National Institute of
Allergy and Infectious Diseases, National Institutes of Health). P values
are corrected using Benjamini multiple testing correction and a cut-off of
P <0.05.
Representing an important immunoregulatory mechanism,
IDO catalyses the first and rate-limiting step of tryptophan
catabolism along the kynurenine pathway; decreased trypro-
phan and increased levels of its metabolites lead to inhibition of
T-cell activation and induce apoptosis (30). IDO is induced by
IFNγ in a variety of cells such as epithelial cells and antigen pre-
senting cells and there is extensive literature to support a role for
IDO in GVHD. Activation of the kynurenine pathway has been
reported in animal models of GVHD as well as in humans fol-
lowing allogeneic stem cell transplantation. Studies in animal
models suggest a protective role of IDO as deficiency leads to
accelerated GVHD in mice after allogeneic bone marrow trans-
plantation, while inability to induce IDO due to IFNγ deficiency
in recipients also leads to exacerbation of disease (31, 32). In
contrast to these findings, increased IDO activity and increased
levels of metabolites correlate with severity and worse outcome
in clinical studies (33, 34). Induction of IDO may represent a
counter acting mechanism as expression in host APCs leads to
the suppression of experimental GVHD through the induction
of regulatory T cells (35).
Chemokines and their receptors play a pivotal role in all
phases of GVHD by mediating the organ-specific homing and
activation of effector cells at sites of inflammation. CCL8 was
identified as a potential biomarker in murine GVHD using a
proteomics approach and was subsequently evaluated in human
samples where it was found to be increased during aGVHD and
to correlate with disease severity (36). CXCL9 and CXCL10
act through the same receptor CXCR3 and play a central role
in the pathogenesis of GVHD via the recruitment of CXCR3+
expressing T cells and natural killer (NK) cells at GVHD target
organs. CXCL9 and CXCL10 levels were increased in the liver,
intestine and lung of mice with aGVHD (37). CXCL10 and
CXCL9 were also markedly increased in the serum of patients
with aGVHD and chronic GVHD (cGVHD) (38), with CXCL9
levels suggested to be predictive of cGVHD occurrence (39).
Increased CXCL10 expression together with CXCR3+ cells
were shown in sections of skin biopsies from GVHD patients
(40), supporting an important role in the pathogenesis of skin
GVHD in humans.
A number of downregulated genes were also detected in
the mismatched MLC which are associated with immune
system function, for example, FOS, FOSB, legumain (LGMN),
dual specificity phosphatase 1 (DUSP1), CD9 and CD14
among others. It is possible that these genes are involved in
immune system regulation by dampening the immune response
or mediating tolerance. One example is DUSP1 which was
significantly downregulated by approximately fivefold in the
HLA mismatched MLC as compared with HLA matched MLC
(Table 2). DUSP1 specifically inactivates mitogen-activated
protein kinases (MAPKs) which are critically involved in the
immune response and in that way acts as a negative regulator
of inflammation (41).
One interesting target to arise from our study is miR-155. We
have shown that MIR155HG and miR-155 are induced during
alloresponses in the HLAmismatchedMLC but not in the HLA
matched setting. MiR-155 is currently receiving great interest
for its role in GVHD as shown in animal models and a clinical
trial is currently recruiting patients to investigate its involve-
ment (NCT01521039, clinicaltrials.gov). MiR-155 plays a cen-
tral role in the regulation of T and B cell responses; B and T
cells are known to upregulate miR-155 after B cell receptor
(BCR) and T cell receptor (TCR) activation (42, 43). MiR-155
also regulates T-cell responses as T cells from miR-155 knock-
out mice have an impaired response and lower levels of IL-2
and IFNγ in response to antigens (44, 45). A role for MiR-155
in the innate immune response is also supported by the abil-
ity of several TLR ligands to strongly induce its levels (22,
46). Such strong evidence of miR-155 regulation of immune
function prompted the investigations into its role in GVHD. It
has been shown that miR-155 is upregulated in T cells from
mice developing aGVHD while miR-155 deficient grafts had
markedly reduced lethal aGVHD (47). Furthermore, miR-155
blockade decreased aGVHD severity and prolonged survival.
Upregulation of miR-155 was also shown in specimens from
patients with pathologic evidence of intestinal aGVHD (47), as
well as significantly elevated in the serum of GVHD patients
where it correlated with disease severity (48).
Although one study reports the induction of miR-155 by
IFNγ in murine bone marrow derived macrophages (22),
our findings do not appear to support the same conclusion.
MIR155HG was not identified by the INTERFEROME
tool as an INFγ inducible gene, IFNγ neutralisation in
HLA-mismatched MLC did not abrogate its induction and
finally IFNγ did not induce MIR155HG or miR-155 expression
in human PBMC. IFNγ induction of miR-155 was shown
to require TNFα signalling in the murine macrophages (22),
suggesting that miR-155 may not be a direct target of the
canonical JAK/STAT pathway known to transactivate several
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hundred antiviral genes in response to IFN signalling. MiR-155
expression was shown to be induced through the JNK MAPK
pathway which activates the AP-1 complex and both human
and murine promoter regions of MIR155HG contain binding
sites for AP-1 and NF-κB family members.
In the absence of significant advances in the treatment of
GHVD, early diagnosis and early assessment of treatment
response have significant prognostic value for disease outcome
and considerable effort has beenmade to identify such biomark-
ers. However, predictive markers for the occurrence of GVHD
are still lacking and a better understanding of the mechanisms
and pathways involved are still needed to provide insight into
the pathogenesis of the disease and identify novel targets for
therapeutic intervention. We have identified gene expression
changes in HLA mismatch MLC which correlate with genes
and pathways involved in GVHD. These may be used to study
and monitor alloreactive responses in vitro and could also aid
in defining the biological processes and molecular cascade
involved in GVHD. Finally, they could potentially serve as pre-
dictive markers for GVHD but they should firstly be evaluated
in human studies to validate their predictive value.
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6.1 Final Discussion 
Donor selection relies on DNA typing that offers no information about functional 
responses of the donor and recipient whereas functional tests such as the MLC can 
complement HLA typing and serve as a more relevant representation of these 
responses. We studied cell expression using different MLC set ups and time points 
in order to validate the conditions to be used firstly in a limited gene expression study 
of 84 related immune related genes and then to study global differences in the HLA 
mismatched MLC, compared with the HLA matched setting. This showed that gene 
expression in MLC can reveal mechanisms involved in GVHD and graft rejection; 
these can potentially serve to better our understanding of the mechanisms involved 
in the alloresponses during these diseases and reveal therapeutic targets. 
In this study the mixed lymphocyte culture model was used in order to identify 
genetic markers that could be predictive of the most serious complication of SCT, 
graft-versus-host disease (GvHD).  Using the mononuclear cell fraction of samples 
from mismatched individuals this model was initially validated by comparing cell 
activation and proliferation and time course studies. Irradiation of cells and 
lipopolysaccharide (LPS) addition were included in an effort to mimic the in vivo 
conditions occurring during the infusion of allogeneic cells to patients during SCT.  
The complexity of responses due to LPS treatment in the MLC assay led to the 
selection of a simple bi-directional MLC assay without the inclusion of LPS. 
Through a limited gene expression analysis of immune related genes, of both HLA-
matched and HLA- mismatched mononuclear cell fractions, we further validated the 
time and conditions used for global gene expression profiling and observed different 
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gene expression changes between the two different HLA settings. The investigation 
of global gene expression changes of the HLA matched and HLA mismatched MLC 
using an expression arrays enabled us to identify differentially regulated genes and 
pathways. A great number of these genes were related to immune function. 
 
The role of interferon gamma 
Gene expression changes driven by HLA incompatibility distinctly differentiated from 
the HLA matched setting and were mostly related to immune function and immune 
response. The majority of genes regulated in the mismatched setting were identified 
to be IFN-γ inducible genes suggesting a very strong influence of IFN-γ in MLC. 
Indeed many previous studies have shown the central role of IFN-γ in the cytokine 
network following alloantigen recognition as well as the generation and maintenance 
of alloresponses associated with the induction of GvHD. In murine models of GvHD 
IFN-γ is elevated early, peaking before clinical symptoms appear (177) and T cells 
isolated from patients with GvHD have higher levels of IFN-γ (178). GVHD results 
from the recognition of host antigens by donor T cells following allogeneic 
transplantation and these alloreactive donor T cells are the primary source of IFN-γ. 
Therefore, IFN-γ can be used as a surrogate of T-cell response and many studies 
have explored the use of IFN-γ as a marker for donor selection (179,180), 
transplantation-related complications (181) and GvHD (182). A study by van der 
Meer et al. attempted to decipher whether levels of IFN-γ in MLC, as a marker for 
deleterious Th1 responses, are sensitive to HLA incompatibility and whether they 
correlate with GvHD occurrence when the donor–recipient pairs tested proceeded 
with transplantation.   It was shown that high levels of INF-γ coincided with severe 
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aGvHD in unrelated bone marrow transplantation, whereas low levels were largely 
associated with grades 0 and I. In addition, levels of IFN-γ in MLC reflected HLA 
class II differences but not isolated class I differences or mismatches other than HLA 
(identical siblings), suggesting that measuring IFN-γ alone cannot be used for the 
detection of class I mismatches (180). 
 
Markers of donor-recipient alloresponses 
By investigating global gene expression changes in mismatched MLC we aimed to 
identify genes that may constitute good targets to study further as markers for 
donor– recipient alloresponses. The most highly upregulated genes were IDO1, 
CXCL9, CXCL10 and CCL8; the regulation of these genes was confirmed by 
quantitative real-time PCR and in independent HLA mismatched MLCs. The four 
selected genes have all been invariably associated with GvHD or allograft   rejection, 
supporting that in vitro response can mirror the in vivo situation. Indeed, gene 
expression profiling of early changes in hepatic GvHD identified many targets similar 
to the ones presented here (183). However, this does not exclude the possibility that 
other genes may show more prominent changes in different MLC, as compared with 
those studied by microarray in this study, due to the presence of different HLA 
combinations.  
Representing an important immunoregulatory mechanism, IDO catalyses the first 
and rate-limiting step of tryptophan catabolism along the kynurenine pathway; 
decreased tryptophan and increased levels of its metabolites lead to inhibition of T-
cell activation and induce apoptosis (184). IDO is induced by IFN-γ in a variety of 
cells such as epithelial cells and antigen presenting cells and there is extensive 
117 | P a g e  
 
literature to support a role for IDO in GvHD. Activation of the kynurenine pathway 
has been reported in animal models of GvHD as well as in humans following 
allogeneic stem cell transplantation. Studies in animal models suggest a protective 
role of IDO as deficiency leads to accelerated GVHD in mice after allogeneic bone 
marrow transplantation, while inability to induce IDO due to IFN-γ deficiency in 
recipients also leads to exacerbation of disease (185,186). In contrast to these 
findings, increased IDO activity and increased levels of metabolites correlate with 
severity and worse outcome in clinical studies (187,188). Induction of IDO may 
represent a counter acting mechanism as expression in host APCs leads to the 
suppression of experimental GVHD through the induction of regulatory T cells (189). 
Chemokines and their receptors play a pivotal role in all phases of GVHD by 
mediating the organ-specific homing and activation of effector cells at sites of 
inflammation. CCL8 was identified as a potential biomarker in murine GVHD using a 
proteomics approach and was subsequently evaluated in human samples where it 
was found to be increased during aGvHD and to correlate with disease severity 
(190). CXCL9 and CXCL10 act through the same receptor CXCR3 and play a central 
role in the pathogenesis of GVHD via the recruitment of CXCR3+ expressing T cells 
and natural killer (NK) cells at GVHD target organs. CXCL9 and CXCL10 levels were 
increased in the liver, intestine and lung of mice with aGvHD (191). CXCL10 and 
CXCL9 were also markedly increased in the serum of patients with aGvHD and 
chronic GVHD (cGvHD) (192), with CXCL9 levels suggested to be predictive of 
cGvHD occurrence (193). Increased CXCL10 expression together with CXCR3+ 
cells were shown in sections of skin biopsies from GVHD patients (194), supporting 
an important role in the pathogenesis of skin GVHD in humans. 
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The role of MiR155 
One interesting target to arise from our study is miR-155. We have shown that 
MIR155HG and miR-155 are induced during alloresponses in the HLA mismatched 
MLC but not in the HLA matched setting. MiR-155 is currently receiving great interest 
for its role in GVHD as shown in animal models and a clinical trial is currently 
recruiting patients to investigate its involvement (NCT01521039, clinicaltrials.gov). 
MiR-155 plays a central role in the regulation of T and B cell responses; B and T 
cells are known to upregulate miR-155 after B cell receptor (BCR) and T cell 
receptor (TCR) activation (195,196). MiR-155 also regulates T-cell responses as T 
cells from miR-155 knock- out mice have an impaired response and lower levels of 
IL-2 and IFN-γ in response to antigens (197,198). A role for MiR-155 in the innate 
immune response is also supported by the ability of several TLR ligands to strongly 
induce its levels (199,200). Such strong evidence of miR-155 regulation of immune 
function prompted the investigations into its role in GvHD. It has been shown that 
miR-155 is upregulated in T cells from mice developing aGvHD while miR-155 
deficient grafts had markedly reduced lethal aGvHD (201). Furthermore, miR-155 
blockade decreased aGvHD severity and prolonged survival. Upregulation of miR-
155 was also shown in specimens from patients with pathologic evidence of 
intestinal aGvHD (202), as well as significantly elevated in the serum of GVHD 
patients where it correlated with disease severity (203). 
Although one study reports the induction of miR-155 by IFN-γ in murine bone 
marrow derived macrophages (199), our findings do not appear to support the same 
conclusion. MIR155HG was not identified by the INTERFEROME tool as an INF-γ 
inducible gene, IFN-γ neutralisation in HLA-mismatched MLC did not abrogate its 
induction and finally IFN-γ did not induce MIR155HG or miR-155 expression in 
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human PBMC.  IFN-γ  induction  of  miR-155  was shown to require TNF-α signaling 
in the murine macrophages (199), suggesting that miR-155 may not be a direct 
target of the canonical JAK/STAT  pathway known to transactivate  several hundred 
antiviral genes in response to IFN signalling. MiR-155 expression was shown to be 
induced through the JNK MAPK pathway which activates the AP-1 complex and both 
human and murine promoter regions of MIR155HG contain binding sites for AP-1 
and NF-κB family members. 
 
Conclusions and Future Directions 
With the use of the widely used technique of the MLC, it was attempted to 
investigate gene expression in matched and mismatched HLA pairs of individuals 
and examine any correlation with published data related to GvHD after ASCT. After 
the successful validation of the MLC model used for cell activation and proliferation 
and through an initial limited gene expression, we concluded that it would be 
possible to differentiate the responses in the matched and mismatched HLA pairs of 
individuals. Through global gene expression studies we concluded that mismatched 
and matched HLA pairs produced distinctly different genetic expression signatures. 
Four genes, IDO, CCL8, CXCL9 and CXCL10 were most upregulated in the 
mismatched setting and this upregulation was confirmed to be INF-ɣ dependant. The 
upregulation of miR-155 gene was also observed, which proved not to be INF-ɣ 
dependant. The five genes studied, have been invariably associated with GvHD or 
allograft rejection and support that our findings in vitro can mirror the in vivo 
responses as reported in hepatic GvHD. Thus, the goals of this work were attained 
and the findings can open the way to the testing of this model in vivo.  
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In the absence of significant advances in the treatment of GvHD, early diagnosis and 
early assessment of treatment response have significant prognostic value for 
disease outcome and considerable effort has been made to identify such 
biomarkers. However, predictive markers for the occurrence of GvHD are still lacking 
and a better understanding of the mechanisms and pathways involved are still 
needed to provide insight into the pathogenesis of the disease and identify novel 
targets for therapeutic intervention. We have identified gene expression changes in 
HLA mismatch MLC which correlate with genes and pathways involved in GvHD. 
These may be used to study and monitor alloreactive responses in vitro and could 
also aid in defining the biological processes and molecular cascade involved in 
GvHD. Finally, they could potentially serve as predictive markers for GvHD but they 
should firstly be evaluated in human studies to validate their predictive value. 
Prior to ASCT, actual recipient and donor pairs could be used  to set up MLCs and 
the expression of the five genes identified in this study, IDO, CCL8, CXCL9 and 
CXCL10  and miR-155 be examined. A number of parameters would need to be 
considered like: as patients/recipients undergo therapy prior to ASCT, the time point 
of sample collection from the patient might affect the gene expression of in the MLC 
setting, as there would be immunosuppression in the patient. Thus, this factor might 
need to be examined and different time points during the patient’s treatment could be 
used and studied. As patients and donors may not be in the same hospital or even 
country, it may not be possible to obtain fresh cells for the setting up of MLCs. Thus, 
the validation of the use of cryopreserved cells from the donor and/or patient could 
be attempted, in setting up MLCs so as examine whether this cell manipulation 
produces the same or similar results as compared to the use of fresh cells.   Also, 
after stem cell infusion, patient samples could be collected at different time points 
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and also examined for the expression of the above five genes. A correlation of the 
expression of the five genes and the patient’s clinical data with the possible 
development of GvHD could be attempted. 
Although the clinical utilisation of the findings of this study remain remote due to a 
large number of variables and lack of clinical data, the assay established can serve 
as an in vitro model to study several biological parameters of GvHD.  One such 
parameter is currently being studied in our laboratory and involves the potential role 
of HLA-G positive Tregs in suppressing GvHD. DNA methylation has a well-
established role in the generation, maintenance and regulation of the function of T-
regs (204).  Recently, it was shown that administration of hypomethylating agents 
(HAs) in mice prevented the development of GvHD through induction of FoxP3+ 
immunoregulatory cells (205). In vitro azacitidine (aza) induced suppressor function, 
was shown to be FoxP3 independent, suggesting that aza-induced suppressor 
function depends on the modification of other hypomethylated genes (206). Human 
leukocyte antigen-G (HLA-G) is a non-classical HLA-I immunoregulatory molecule, 
the expression of which is epigenetically regulated (207). In this study, we will 
address whether in vitro HAs can induce HLA-G+ immunoregulatory T-cells. Our 
collaborators have demonstrated that treatment of negative selected peripheral T-
cells of healthy individuals with HAs induces de novo HLA-G expression in HLA-G- 
CD4 T-cells as a result of hypomethylation of the HLA-G proximal-promoter. In vitro 
HA-induced HLA-G+ CD4 T-cells are FoxP3negative and exert potent 
immunosuppressive function, which is largely but not exclusively HLA-G dependent. 
The immunosuppressive functions of HLA-G+CD4+ cells is currently being studied in 
our laboratory using IDO, CCL8, CXCL9, CXCL10 and miR-155 gene expression. 
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Table A1. List of control genes used in gene expression studies 
YY1 YY1 transcription factor 
B2M Beta-2-microglobulin 
HPRT1 Hypoxanthine phosphoribosyltransferase 1 (Lesch-Nyhan syndrome) 
RPL13A Ribosomal protein L13a 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
ACTB Actin, beta 
 
 
Table A2. List of genes for which expression was tested using the “SuperArray’s 
RT2” template  
Symbol Description Gname 
IL17A Interleukin 17A CTLA8/IL-17 
CCL11 Chemokine (C-C motif) ligand 11 SCYA11 
CCL5 Chemokine (C-C motif) ligand 5 D17S136E/RANTES 
CCL7 Chemokine (C-C motif) ligand 7 FIC/MARC 
CCR2 Chemokine (C-C motif) receptor 2 CC-CKR-2/CCR2A 
CCR3 Chemokine (C-C motif) receptor 3 CC-CKR-3/CD193 
CCR4 Chemokine (C-C motif) receptor 4 CC-CKR-4/CD194 
CCR5 Chemokine (C-C motif) receptor 5 CC-CKR-5/CCCKR5 
CD28 CD28 molecule Tp44 
CD4 CD4 molecule CD4mut 
CD40LG 
CD40 ligand (TNF superfamily, member 5, hyper-IgM 
syndrome) CD154/CD40L 
IL23A Interleukin 23, alpha subunit p19 IL-23/IL-23A 
CD80 CD80 molecule CD28LG/CD28LG1 
CD86 CD86 molecule B7-2/B70 
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CEBPB CCAAT/enhancer binding protein (C/EBP), beta C/EBP-beta 
CREBBP CREB binding protein (Rubinstein-Taybi syndrome) CBP/KAT3A 
CSF2 Colony stimulating factor 2 (granulocyte-macrophage) GMCSF 
CTLA4 Cytotoxic T-lymphocyte-associated protein 4 CD152/CELIAC3 
CXCR3 Chemokine (C-X-C motif) receptor 3 CD182/CD183 
FASLG Fas ligand (TNF superfamily, member 6) APT1LG1/CD178 
GATA3 GATA binding protein 3 HDR 
GFI1 Growth factor independent 1 transcription repressor ZNF163 
GLMN Glomulin, FKBP associated protein FAP/FAP48 
GPR44 G protein-coupled receptor 44 CD294/CRTH2 
HAVCR2 Hepatitis A virus cellular receptor 2 KIM-3/TIM3 
ICOS Inducible T-cell co-stimulator AILIM/CD278 
IFNG Interferon, gamma IFG/IFI 
IGSF6 Immunoglobulin superfamily, member 6 DORA 
IL10 Interleukin 10 CSIF/IL-10 
IL12B 
Interleukin 12B (natural killer cell stimulatory factor 2, 
cytotoxic lymphocyte maturation factor 2, p40) CLMF/CLMF2 
IL12RB2 Interleukin 12 receptor, beta 2 RP11-102M16.1 
IL13 Interleukin 13 ALRH/BHR1 
IL13RA1 Interleukin 13 receptor, alpha 1 CD213A1/IL-13Ra 
IL15 Interleukin 15 IL-15 
IL18 Interleukin 18 (interferon-gamma-inducing factor) IGIF/IL-18 
IL18R1 Interleukin 18 receptor 1 CD218a/CDw218a 
IL1R1 Interleukin 1 receptor, type I CD121A/D2S1473 
IL1R2 Interleukin 1 receptor, type II CD121b/IL1RB 
IL2 Interleukin 2 IL-2/TCGF 
IL2RA Interleukin 2 receptor, alpha CD25/IDDM10 
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IL4 Interleukin 4 BSF1/IL-4 
IL4R Interleukin 4 receptor CD124/IL4RA 
IL5 Interleukin 5 (colony-stimulating factor, eosinophil) EDF/IL-5 
IL6 Interleukin 6 (interferon, beta 2) BSF2/HGF 
IL6R Interleukin 6 receptor CD126/IL-6R-1 
IL7 Interleukin 7 IL-7 
IL9 Interleukin 9 HP40/IL-9 
INHA Inhibin, alpha LOC388931 
INHBA Inhibin, beta A EDF/FRP 
IRF1 Interferon regulatory factor 1 IRF-1/MAR 
IRF4 Interferon regulatory factor 4 LSIRF/MUM1 
JAK1 Janus kinase 1 (a protein tyrosine kinase) JAK1A/JAK1B 
JAK2 Janus kinase 2 (a protein tyrosine kinase) JTK10 
LAG3 Lymphocyte-activation gene 3 CD223 
LAT Linker for activation of T cells LAT1/pp36 
MAF 
V-maf musculoaponeurotic fibrosarcoma oncogene 
homolog (avian) MGC71685 
MAP2K7 Mitogen-activated protein kinase kinase 7 Jnkk2/MAPKK7 
MAPK8 Mitogen-activated protein kinase 8 JNK/JNK1 
NFATC1 
Nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 1 NF-ATC/NFAT2 
NFATC2 
Nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 2 NFAT1/NFATP 
NFATC2IP 
Nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 2 interacting protein FLJ14639 
PCGF2 Polycomb group ring finger 2 MEL-18/RNF110 
PTPRC Protein tyrosine phosphatase, receptor type, C B220/CD45 
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SFTPD Surfactant, pulmonary-associated protein D COLEC7/PSP-D 
SOCS1 Suppressor of cytokine signaling 1 CIS1/CISH1 
SOCS2 Suppressor of cytokine signaling 2 CIS2/Cish2 
SOCS5 Suppressor of cytokine signaling 5 CIS6/CISH6 
SPP1 
Secreted phosphoprotein 1 (osteopontin, bone 
sialoprotein I, early T-lymphocyte activation 1) BNSP/BSPI 
STAT1 Signal transducer and activator of transcription 1, 91kDa 
DKFZp686B04100/ISGF-
3 
STAT4 Signal transducer and activator of transcription 4 STAT 4 
STAT6 
Signal transducer and activator of transcription 6, 
interleukin-4 induced D12S1644/IL-4-STAT 
TBX21 T-box 21 T-PET/T-bet 
TFCP2 Transcription factor CP2 CP2/LBP-1C 
TGFB3 Transforming growth factor, beta 3 ARVD/TGF-beta3 
TLR4 Toll-like receptor 4 ARMD10/CD284 
TLR6 Toll-like receptor 6 CD286 
TMED1 
Transmembrane emp24 protein transport domain 
containing 1 IL1RL1LG/Il1rl1l 
TNF Tumor necrosis factor (TNF superfamily, member 2) DIF/TNF-alpha 
CD27 CD27 molecule S152/T14 
TNFRSF8 Tumor necrosis factor receptor superfamily, member 8 CD30/D1S166E 
TNFRSF9 Tumor necrosis factor receptor superfamily, member 9 4-1BB/CD137 
TNFSF4 
Tumor necrosis factor (ligand) superfamily, member 4 
(tax-transcriptionally activated glycoprotein 1, 34kDa) CD134L/CD252 
TYK2 Tyrosine kinase 2 JTK1 
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Table A3. Mismatched MLC gene expression data analysis at 24 hours of 
incubation normalised to controls. Group 1 represents the mismatched MLC results 
while Control Group represents both individuals cells incubated alone under the same 
conditions in the same run. Results shown are from three different pairs experiments 
repeated in triplicate. MLCs set up using mismatched subject pairs as described in 
Chapter 2, Section 2.3. At 24 hours, cells were harvested and plated as described in 
Chapter 2, Section 2.5. using the SuperArray Th1-Th2-Th3 kit. Data was then analysed 
using the SuperArray software for this plate. 
Gene 
Symbol 
 
AVG ΔCt 2^-ΔCt 
Fold 
Change 
p-value 
Fold Up- or 
Down-
Regulation 
Group 
1 
Control 
Group 
Group 1 
Control 
Group 
Group 
1/Control 
P Value 
Group 
1/Control 
IL17A 6.06 6.04 0.014955 0.015187 0.98 0.942234   -1.02 
CCL11 10.31 10.04 0.000787 0.000948 0.83 0.707150   -1.21 
CCL5 1.37 1.30 0.387562 0.406875 0.95 0.819707   -1.05 
CCL7 6.12 6.97 0.014356 0.007976 1.80 0.321161   1.80 
CCR2 4.91 5.19 0.033308 0.027382 1.22 0.684660   1.22 
CCR3 5.58 5.98 0.020853 0.015832 1.32 0.684313   1.32 
CCR4 4.52 4.55 0.043457 0.042825 1.01 0.967224   1.01 
CCR5 6.99 7.28 0.007841 0.006415 1.22 0.863856   1.22 
CD28 7.50 7.60 0.005508 0.005151 1.07 0.967782   1.07 
CD4 3.93 3.68 0.065482 0.077832 0.84 0.338855   -1.19 
CD40LG 4.90 4.78 0.033474 0.036287 0.92 0.735456   -1.08 
IL23A 6.14 5.96 0.014190 0.016086 0.88 0.845730   -1.13 
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CD80 7.57 7.88 0.005249 0.004241 1.24 0.846440   1.24 
CD86 4.87 5.39 0.034285 0.023769 1.44 0.541778   1.44 
CEBPB 3.94 3.78 0.065244 0.072585 0.90 0.556002   -1.11 
CREBBP 6.57 6.27 0.010509 0.012955 0.81 0.065801   -1.23 
CSF2 10.52 11.11 0.000683 0.000453 1.51 0.596259   1.51 
CTLA4 6.43 6.62 0.011558 0.010143 1.14 0.785706   1.14 
CXCR3 5.73 5.47 0.018874 0.022562 0.84 0.345593   -1.20 
FASLG 6.61 6.49 0.010248 0.011116 0.92 0.787449   -1.08 
GATA3 6.45 6.56 0.011424 0.010626 1.08 0.845609   1.08 
GFI1 6.07 6.10 0.014872 0.014628 1.02 0.973588   1.02 
GLMN 5.68 5.76 0.019475 0.018405 1.06 0.871918   1.06 
GPR44 7.79 7.55 0.004517 0.005340 0.85 0.887958   -1.18 
HAVCR2 4.26 4.00 0.052269 0.062311 0.84 0.266161   -1.19 
ICOS 4.48 4.65 0.044712 0.039712 1.13 0.514584   1.13 
IFNG 8.92 8.98 0.002062 0.001982 1.04 0.940689   1.04 
IGSF6 2.68 2.95 0.155930 0.129627 1.20 0.588282   1.20 
IL10 5.08 4.92 0.029561 0.033033 0.89 0.608124   -1.12 
IL12B 7.52 7.94 0.005452 0.004073 1.34 0.884397   1.34 
IL12RB2 8.95 9.61 0.002027 0.001276 1.59 0.741789   1.59 
IL13 7.49 7.74 0.005578 0.004674 1.19 0.908789   1.19 
IL13RA1 4.10 4.09 0.058142 0.058921 0.99 0.946751   -1.01 
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IL15 9.96 10.30 0.001003 0.000794 1.26 0.350032   1.26 
IL18 8.11 8.04 0.003631 0.003811 0.95 0.864331   -1.05 
IL18R1 6.18 5.13 0.013791 0.028516 0.48 0.295600   -2.07 
IL1R1 5.40 5.13 0.023615 0.028499 0.83 0.331648   -1.21 
IL1R2 8.44 8.61 0.002882 0.002555 1.13 0.794745   1.13 
IL2 9.00 9.13 0.001950 0.001786 1.09 0.838539   1.09 
IL2RA 7.21 7.41 0.006733 0.005896 1.14 0.641252   1.14 
IL4 7.41 8.00 0.005893 0.003899 1.51 0.809728   1.51 
IL4R 4.68 4.54 0.039102 0.042883 0.91 0.343914   -1.10 
IL5 6.72 7.05 0.009477 0.007540 1.26 0.876420   1.26 
IL6 9.74 10.25 0.001171 0.000821 1.43 0.678247   1.43 
IL6R 4.91 4.46 0.033312 0.045303 0.74 0.146463   -1.36 
IL7 6.14 6.34 0.014183 0.012302 1.15 0.870917   1.15 
IL9 7.93 8.48 0.004110 0.002801 1.47 0.835299   1.47 
INHA 7.53 7.78 0.005401 0.004553 1.19 0.929723   1.19 
INHBA 7.46 8.02 0.005694 0.003843 1.48 0.773241   1.48 
IRF1 2.16 2.91 0.223059 0.133271 1.67 0.068071   1.67 
IRF4 4.67 4.61 0.039262 0.041069 0.96 0.867149   -1.05 
JAK1 1.69 1.47 0.310536 0.362128 0.86 0.330533   -1.17 
JAK2 7.12 7.51 0.007191 0.005499 1.31 0.277406   1.31 
LAG3 6.25 6.58 0.013167 0.010455 1.26 0.778388   1.26 
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LAT 3.26 3.30 0.104179 0.101654 1.02 0.904298   1.02 
MAF 5.16 5.15 0.027985 0.028243 0.99 0.966789   -1.01 
MAP2K7 7.69 7.36 0.004848 0.006091 0.80 0.603961   -1.26 
MAPK8 4.92 4.95 0.033066 0.032260 1.02 0.769448   1.02 
NFATC1 5.21 4.94 0.027100 0.032508 0.83 0.288384   -1.20 
NFATC2 5.55 5.69 0.021307 0.019318 1.10 0.734768   1.10 
NFATC2IP 4.62 4.49 0.040590 0.044556 0.91 0.524610   -1.10 
PCGF2 5.94 5.42 0.016287 0.023332 0.70 0.787274   -1.43 
PTPRC 1.12 1.36 0.460073 0.389341 1.18 0.126405   1.18 
SFTPD 11.87 12.75 0.000267 0.000146 1.83 0.220558   1.83 
SOCS1 5.52 5.63 0.021753 0.020218 1.08 0.869185   1.08 
SOCS2 7.12 7.26 0.007185 0.006526 1.10 0.955528   1.10 
SOCS5 4.84 4.89 0.034814 0.033677 1.03 0.959271   1.03 
SPP1 4.09 4.07 0.058800 0.059611 0.99 0.963341   -1.01 
STAT1 0.56 1.84 0.680201 0.279882 2.43 0.034023   2.43 
STAT4 5.22 5.06 0.026778 0.029969 0.89 0.597737   -1.12 
STAT6 3.13 2.73 0.114290 0.150941 0.76 0.104440   -1.32 
TBX21 4.96 4.95 0.032198 0.032335 1.00 0.990506   -1.00 
TFCP2 5.22 5.36 0.026831 0.024298 1.10 0.692005   1.10 
TGFB3 6.53 6.73 0.010828 0.009402 1.15 0.897039   1.15 
TLR4 7.72 7.97 0.004738 0.003986 1.19 0.495341   1.19 
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TLR6 4.41 4.49 0.047087 0.044360 1.06 0.895853   1.06 
TMED1 7.29 7.24 0.006375 0.006628 0.96 0.922609   -1.04 
TNF 4.44 4.91 0.045993 0.033336 1.38 0.325587   1.38 
CD27 7.02 6.95 0.007713 0.008111 0.95 0.856701   -1.05 
TNFRSF8 10.71 11.11 0.000599 0.000451 1.33 0.605515   1.33 
TNFRSF9 8.37 8.32 0.003016 0.003124 0.97 0.926086   -1.04 
TNFSF4 8.46 8.81 0.002843 0.002230 1.27 0.510942   1.27 
TYK2 4.96 4.69 0.032104 0.038779 0.83 0.287727   -1.21 
YY1 2.92 2.65 0.131838 0.159085 0.83 0.066946   -1.21 
B2M -3.66 -3.53 12.672243 11.521234 1.10 0.284941   1.10 
HPRT1 5.83 5.73 0.017601 0.018817 0.94 0.543717   -1.07 
RPL13A 0.37 0.43 0.774319 0.744541 1.04 0.726393   1.04 
GAPDH 0.60 0.51 0.661586 0.700953 0.94 0.543098   -1.06 
ACTB -3.13 -3.14 8.751923 8.838531 0.99 0.891728   -1.01 
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Table A4.  Mismatched MLC data analysis at 48 hours of incubation normalised to 
controls. Group 1 represents the mismatched MLC results while Control Group 
represents both individuals cells incubated alone under the same conditions in the same 
run. Results shown are from three different pairs experiments repeated in triplicate. 
MLCs set up using mismatched subject pairs as described in Chapter 2, Section 2.3. At 
48 hours, cells were harvested and plated as described in Chapter 2, Section 2.5. using 
the SuperArray Th1-Th2-Th3 kit. Data was then analysed using the SuperArray 
software for this plate. 
Gene 
Symbol 
AVG ΔCt 2^-ΔCt 
Fold 
Change 
p-value 
Fold Up- or 
Down-
Regulation 
Group 1 
Control 
Group 
Group 1 
Control 
Group 
Group 
1/Control 
P Value 
Group 
1/Control 
IL17A 12.38 11.64 0.000188 0.000314 0.60 0.686745   -1.67 
CCL11 11.68 11.05 0.000306 0.000470 0.65 0.729910   -1.54 
CCL5 1.99 1.99 0.251808 0.251571 1.00 0.994685   1.00 
CCL7 10.45 9.47 0.000715 0.001414 0.51 0.475410   -1.98 
CCR2 6.44 6.78 0.011483 0.009118 1.26 0.696770   1.26 
CCR3 7.01 6.80 0.007774 0.008945 0.87 0.813398   -1.15 
CCR4 5.77 5.60 0.018354 0.020687 0.89 0.775921   -1.13 
CCR5 4.09 4.21 0.058725 0.054086 1.09 0.473505   1.09 
CD28 9.54 9.80 0.001342 0.001125 1.19 0.856919   1.19 
CD4 4.87 4.63 0.034227 0.040311 0.85 0.524371   -1.18 
CD40LG 5.92 5.85 0.016509 0.017310 0.95 0.900360   -1.05 
IL23A 6.08 6.13 0.014746 0.014306 1.03 0.932054   1.03 
CD80 9.79 9.61 0.001130 0.001281 0.88 0.864991   -1.13 
CD86 6.72 6.70 0.009504 0.009636 0.99 0.974359   -1.01 
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CEBPB 4.07 3.93 0.059687 0.065635 0.91 0.758132   -1.10 
CREBBP 5.90 5.72 0.016746 0.018998 0.88 0.595213   -1.13 
CSF2 11.84 10.95 0.000272 0.000505 0.54 0.530552   -1.86 
CTLA4 7.82 8.03 0.004427 0.003818 1.16 0.705983   1.16 
CXCR3 6.15 5.94 0.014051 0.016280 0.86 0.568702   -1.16 
FASLG 7.87 7.74 0.004277 0.004665 0.92 0.848825   -1.09 
GATA3 7.14 6.90 0.007080 0.008354 0.85 0.607731   -1.18 
GFI1 8.36 7.90 0.003052 0.004188 0.73 0.542622   -1.37 
GLMN 6.65 6.54 0.009966 0.010711 0.93 0.836135   -1.07 
GPR44 10.09 9.76 0.000916 0.001155 0.79 0.776699   -1.26 
HAVCR2 4.98 4.67 0.031713 0.039189 0.81 0.409525   -1.24 
ICOS 6.04 6.12 0.015211 0.014332 1.06 0.775922   1.06 
IFNG 8.67 8.99 0.002461 0.001964 1.25 0.768465   1.25 
IGSF6 2.36 2.85 0.195200 0.138279 1.41 0.204593   1.41 
IL10 7.28 6.41 0.006429 0.011760 0.55 0.235347   -1.83 
IL12B 12.26 11.26 0.000203 0.000408 0.50 0.604613   -2.01 
IL12RB2 12.33 11.77 0.000195 0.000286 0.68 0.694677   -1.47 
IL13 11.53 10.79 0.000338 0.000565 0.60 0.645233   -1.67 
IL13RA1 4.58 4.83 0.041804 0.035233 1.19 0.257077   1.19 
IL15 6.02 6.62 0.015444 0.010140 1.52 0.210305   1.52 
IL18 6.31 6.10 0.012563 0.014595 0.86 0.572181   -1.16 
IL18R1 6.69 6.50 0.009693 0.011024 0.88 0.727055   -1.14 
IL1R1 5.65 5.05 0.019949 0.030154 0.66 0.274283   -1.51 
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IL1R2 9.42 9.08 0.001458 0.001843 0.79 0.714858   -1.26 
IL2 8.68 8.49 0.002433 0.002787 0.87 0.870982   -1.15 
IL2RA 6.11 5.84 0.014484 0.017453 0.83 0.662196   -1.20 
IL4 11.02 10.27 0.000483 0.000807 0.60 0.656435   -1.67 
IL4R 2.88 2.90 0.136014 0.134342 1.01 0.939792   1.01 
IL5 10.15 9.60 0.000879 0.001291 0.68 0.700234   -1.47 
IL6 8.39 8.83 0.002978 0.002200 1.35 0.742161   1.35 
IL6R 3.48 3.36 0.089341 0.097723 0.91 0.776510   -1.09 
IL7 7.11 7.31 0.007245 0.006298 1.15 0.791073   1.15 
IL9 12.10 11.67 0.000228 0.000307 0.74 0.809218   -1.35 
INHA 12.01 11.40 0.000243 0.000371 0.66 0.769175   -1.53 
INHBA 9.48 8.99 0.001399 0.001972 0.71 0.728553   -1.41 
IRF1 2.87 4.10 0.137201 0.058512 2.34 0.004118   2.34 
IRF4 5.21 5.12 0.027074 0.028695 0.94 0.788827   -1.06 
JAK1 1.74 1.78 0.299334 0.291161 1.03 0.634615   1.03 
JAK2 4.44 5.18 0.046200 0.027661 1.67 0.081394   1.67 
LAG3 8.20 8.00 0.003410 0.003903 0.87 0.815680   -1.14 
LAT 3.02 3.21 0.123695 0.107882 1.15 0.488653   1.15 
MAF 5.06 5.08 0.029969 0.029610 1.01 0.909613   1.01 
MAP2K7 7.30 7.20 0.006331 0.006809 0.93 0.905011   -1.08 
MAPK8 5.47 5.35 0.022588 0.024557 0.92 0.654127   -1.09 
NFATC1 5.57 5.48 0.021118 0.022451 0.94 0.821041   -1.06 
NFATC2 7.82 7.61 0.004420 0.005131 0.86 0.618052   -1.16 
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NFATC2IP 5.14 5.16 0.028296 0.027945 1.01 0.965126   1.01 
PCGF2 10.50 9.74 0.000689 0.001172 0.59 0.587589   -1.70 
PTPRC 0.43 0.72 0.743666 0.606748 1.23 0.041988   1.23 
SFTPD 12.42 12.00 0.000182 0.000244 0.75 0.706667   -1.34 
SOCS1 6.01 6.58 0.015487 0.010437 1.48 0.143626   1.48 
SOCS2 10.51 9.64 0.000686 0.001253 0.55 0.604956   -1.83 
SOCS5 5.29 4.93 0.025616 0.032827 0.78 0.511183   -1.28 
SPP1 3.89 3.17 0.067676 0.111449 0.61 0.281824   -1.65 
STAT1 0.39 2.25 0.762862 0.209856 3.64 0.000735   3.64 
STAT4 5.62 5.55 0.020294 0.021375 0.95 0.755205   -1.05 
STAT6 2.45 2.35 0.182491 0.195524 0.93 0.710527   -1.07 
TBX21 6.38 5.86 0.011966 0.017175 0.70 0.298699   -1.44 
TFCP2 5.10 5.28 0.029172 0.025814 1.13 0.591655   1.13 
TGFB3 7.14 6.90 0.007096 0.008388 0.85 0.759644   -1.18 
TLR4 3.97 4.11 0.063838 0.058018 1.10 0.461694   1.10 
TLR6 6.44 6.09 0.011541 0.014709 0.78 0.553658   -1.27 
TMED1 7.74 7.83 0.004677 0.004399 1.06 0.864896   1.06 
TNF 4.14 5.28 0.056840 0.025649 2.22 0.123504   2.22 
CD27 2.78 2.60 0.145746 0.164617 0.89 0.509815   -1.13 
TNFRSF8 9.16 8.56 0.001748 0.002654 0.66 0.638926   -1.52 
TNFRSF9 9.48 9.29 0.001405 0.001600 0.88 0.864498   -1.14 
TNFSF4 11.91 11.72 0.000260 0.000296 0.88 0.865970   -1.14 
TYK2 5.62 5.55 0.020325 0.021271 0.96 0.893112   -1.05 
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YY1 3.65 3.86 0.079687 0.069065 1.15 0.617631   1.15 
B2M -3.59 -3.36 12.053610 10.295819 1.17 0.166925   1.17 
HPRT1 5.19 5.11 0.027348 0.028864 0.95 0.290094   -1.06 
RPL13A 0.23 0.15 0.850565 0.900326 0.94 0.593915   -1.06 
GAPDH 0.96 0.83 0.515172 0.564405 0.91 0.408721   -1.10 
ACTB -2.79 -2.73 6.923141 6.622014 1.05 0.685425   1.05 
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Table A5.  Mismatched MLC gene expression data analysis at 72 hours of 
incubation normalised to controls. Group 1 represents the mismatched MLC results 
while Control Group represents both individuals cells incubated alone under the same 
conditions in the same run. Results shown are from three different pairs experiments 
repeated in triplicate. MLCs set up using mismatched subject pairs as described in 
Chapter 2, Section 2.3. At 72 hours, cells were harvested and plated as described in 
Chapter 2, Section 2.5. using the SuperArray Th1-Th2-Th3 kit. Data was then analysed 
using the SuperArray software for this plate. 
Gene 
Symbol 
AVG ΔCt 2^-ΔCt p-value 
Fold Up- or Down-
Regulation 
Group 
1 
Control 
Group 
Group 1 
Control 
Group 
Group 
1/Control 
P Value 
Group 
1/Control 
IL17A 11.74 10.27 0.000292 0.000811 0.36 0.419085   -2.77 
CCL11 11.11 9.26 0.000453 0.001631 0.28 0.319164   -3.6 
CCL5 2.47 2.41 0.180561 0.188433 0.96 0.793857   -1.04 
CCL7 10.8 9.61 0.00056 0.001283 0.44 0.390179   -2.29 
CCR2 6.35 7.08 0.01222 0.007384 1.65 0.176211   1.65 
CCR3 6.68 6.3 0.009737 0.012718 0.77 0.443706   -1.31 
CCR4 5.87 5.55 0.017073 0.021387 0.8 0.457082   -1.25 
CCR5 3.21 3.48 0.108427 0.089916 1.21 0.205879   1.21 
CD28 9.92 9.25 0.001032 0.001637 0.63 0.534396   -1.59 
CD4 5.17 4.86 0.02778 0.034535 0.8 0.570877   -1.24 
CD40LG 5.51 5.51 0.021994 0.021869 1.01 0.980321   1.01 
IL23A 6.39 6.17 0.011902 0.01388 0.86 0.615374   -1.17 
CD80 8.91 8.72 0.002081 0.002376 0.88 0.620749   -1.14 
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CD86 7 6.73 0.007833 0.009395 0.83 0.493658   -1.2 
CEBPB 5.27 5.84 0.025975 0.01751 1.48 0.588813   1.48 
CREBBP 5.88 5.73 0.016952 0.01879 0.9 0.581866   -1.11 
CSF2 9.49 9.1 0.001391 0.00182 0.76 0.663599   -1.31 
CTLA4 9.09 8.67 0.001834 0.002462 0.75 0.454212   -1.34 
CXCR3 8.3 8.03 0.003167 0.003829 0.83 0.682635   -1.21 
FASLG 7.5 7.5 0.005521 0.00553 1 0.995972   -1 
GATA3 8.34 7.86 0.00309 0.004308 0.72 0.470863   -1.39 
GFI1 9.26 8.68 0.001636 0.00243 0.67 0.601071   -1.48 
GLMN 7.05 6.89 0.007561 0.008423 0.7 0.752370   -1.11 
GPR44 10.72 9.06 0.000593 0.001878 0.32 0.179730   -3.17 
HAVCR2 5.44 5.19 0.022971 0.027488 0.84 0.416003   -1.2 
ICOS 7.26 7.48 0.006523 0.005598 1.17 0.486272   1.17 
IFNG 8.66 8.82 0.00247 0.002207 1.12 0.869345   1.12 
IGSF6 1.82 2.14 0.283475 0.226667 1.26 0.200939   1.26 
IL10 7.72 6.81 0.004731 0.008923 0.53 0.034417   -1.89 
IL12B 11.52 9.41 0.000341 0.001473 0.23 0.82308   -4.32 
IL12RB2 12.5 12 0.000173 0.000244 0.71 0.541048   -1.41 
IL13 9.8 9.05 0.00112 0.001882 0.6 0.625288   -1.68 
IL13RA1 4.11 4.33 0.057945 0.049789 1.16 0.145959   1.16 
IL15 5.91 6.22 0.016682 0.01341 1.24 0.486674   1.24 
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IL18 5.59 5.44 0.019424 0.023089 0.84 0.400531   -1.19 
IL18R1 6.56 6.67 0.010582 0.009845 1.07 0.833638   1.07 
IL1R1 6.14 5.69 0.014142 0.019318 0.73 0.342595   -1.37 
IL1R2 10.86 9.7 0.000538 0.001206 0.45 0.171866   -2.24 
IL2 7.8 6.94 0.004483 0.008116 0.55 0.344096   -1.81 
IL2RA 5.71 5.63 0.01905 0.020251 0.94 0.793342   -1.06 
IL4 10.55 9.44 0.000667 0.001438 0.46 0.427721   -2.15 
IL4R 3.46 3.37 0.090875 0.096939 0.94 0.761686   -1.07 
IL5 9.88 9.22 0.001058 0.001674 0.63 0.566308   -1.58 
IL6 6.85 7.81 0.008695 0.004448 1.95 0.164865   1.95 
IL6R 4.02 3.85 0.061842 0.069219 0.89 0.740722   -1.12 
IL7 7.17 7.5 0.006959 0.005532 1.26 0.541162   1.26 
IL9 11.29 9.72 0.000399 0.001183 0.34 0.368626   -2.96 
INHA 12.35 9.96 0.000192 0.001003 0.19 0.158315   -5.25 
INHBA 8.59 8.47 0.002604 0.002818 0.92 0.909447   -1.08 
IRF1 4.57 6.07 0.042219 0.014894 2.83 0.152291   2.83 
IRF4 5.91 5.77 0.01664 0.01802 0.91 0.646320   -1.1 
JAK1 1.84 1.78 0.278914 0.290382 0.96 0.686378   -1.04 
JAK2 4.72 5.33 0.037629 0.024856 1.51 0.053406   1.51 
LAG3 9.47 8.92 0.001411 0.002066 0.68 0.616707   -1.46 
LAT 3.9 3.95 0.067184 0.064695 1.04 0.869375   1.04 
 140 | P a g e  
 
MAF 5.65 5.18 0.019959 0.027551 0.72 0.053237   -1.38 
MAP2K7 8.63 8.21 0.002518 0.003385 0.74 0.711469   -1.34 
MAPK8 5.99 5.91 0.015722 0.016671 0.94 0.765296   -1.06 
NFATC1 6.36 6.33 0.012251 0.012425 0.99 0.972327   -1.01 
NFATC2 8.88 8.87 0.002118 0.002135 0.99 0.990847   -1.01 
NFATC2IP 6.91 7.11 0.008299 0.007235 1.15 0.788398   1.15 
PCGF2 10.55 9.45 0.000668 0.001432 0.47 0.439614   -2.15 
PTPRC 0.99 1.19 0.50464 0.439527 1.15 0.243817   1.15 
SFTPD 12.56 11.83 0.000165 0.000274 0.6 0.413317   -1.66 
SOCS1 6.27 7.16 0.012937 0.006995 1.85 0.024815   1.85 
SOCS2 10.5 8.64 0.000692 0.002515 0.28 0.103733   -3.64 
SOCS5 6.35 5.95 0.012295 0.016166 0.76 0.355735   -1.31 
SPP1 5.9 4.19 0.016777 0.05493 0.31 0.004051   -3.27 
STAT1 0.21 2.47 0.861901 0.180209 4.78 0.000930   4.78 
STAT4 5.58 5.3 0.02095 0.025421 0.82 0.655779   -1.21 
STAT6 2.94 3 0.130727 0.12472 1.05 0.901430   1.05 
TBX21 6.85 6.58 0.008648 0.010468 0.83 0.469257   -1.21 
TFCP2 6.05 5.85 0.015122 0.017293 0.87 0.508518   -1.14 
TGFB3 7.91 7.16 0.004145 0.006996 0.59 0.448391   -1.69 
TLR4 4.31 4.01 0.053244 0.062134 0.86 0.183907   -1.17 
TLR6 6.73 6.25 0.009451 0.013095 0.72 0.173323   -1.39 
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TMED1 9.11 9.17 0.001805 0.001734 1.04 0.932194   1.04 
TNF 4.77 5.28 0.036591 0.025724 1.42 0.093421   1.42 
CD27 2.66 2.35 0.158069 0.195945 0.81 0.231230   -1.24 
TNFRSF8 10.61 8.59 0.000638 0.00259 0.25 0.011375   -4.06 
TNFRSF9 8.74 8.43 0.002345 0.002895 0.81 0.707866   -1.23 
TNFSF4 11.85 11.34 0.00027 0.000386 0.7 0.453709   -1.43 
TYK2 6.78 6.86 0.009131 0.008582 1.06 0.905974   -1.06 
YY1 3.72 3.67 0.075968 0.078321 0.97 0.882244   -1.03 
B2M -3.69 -3.31 12.904121 9.951155 1.3 0.016701   1.3 
HPRT1 5.34 5.32 0.024606 0.02511 0.98 0.836253   -1.02 
RPL13A 0.69 0.57 0.62018 0.675012 0.92 0.465310   -1.09 
GAPDH 0.49 0.23 0.712812 0.850347 0.84 0.064060   -1.19 
ACTB -2.83 -2.8 7.124358 6.972152 1.02 0.853547   1.02 
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Table A6.  Mismatched MLC gene expression data analysis at 24 hours of 
incubation supplemented with LPS normalised to controls. Group 1 represents the 
mismatched MLC results while Control Group represents both individuals cells 
incubated alone under the same conditions in the same run. Results shown are from 
three different pairs experiments repeated in triplicate. MLCs set up using mismatched 
subject pairs as described in Chapter 2, Section 2.3. At 24 hours, cells were harvested 
and plated as described in Chapter 2, Section 2.5. using the SuperArray Th1-Th2-Th3 
kit. Data was then analysed using the SuperArray software for this plate. 
 
Gene 
Symbol 
AVG ΔCt 2^-ΔCt 
Fold 
Change 
p-value 
Fold Up- or 
Down-
Regulation 
Group 1 
Control 
Group 
Group 1 
Control 
Group 
Group 
1/Control 
P Value 
Group 
1/Control 
IL17A 10.66 8.85 0.000617 0.002174 0.28 0.389109   -3.52 
CCL11 10.56 9.05 0.000663 0.001882 0.35 0.504264   -2.84 
CCL5 1.65 1.69 0.319667 0.309775 1.03 0.889336   1.03 
CCL7 4.34 4.04 0.049332 0.060692 0.81 0.444923   -1.23 
CCR2 8.00 6.90 0.003906 0.008396 0.47 0.376754   -2.15 
CCR3 8.48 6.84 0.002806 0.008755 0.32 0.306719   -3.12 
CCR4 4.58 4.03 0.041786 0.061405 0.68 0.242618   -1.47 
CCR5 5.45 4.33 0.022846 0.049572 0.46 0.063764   -2.17 
CD28 9.50 8.08 0.001376 0.003686 0.37 0.504510   -2.68 
CD4 4.85 5.20 0.034610 0.027261 1.27 0.245112   1.27 
CD40LG 5.93 5.72 0.016366 0.018973 0.86 0.719984   -1.16 
IL23A 5.78 4.34 0.018160 0.049470 0.37 0.095997   -2.72 
CD80 7.23 7.00 0.006651 0.007801 0.85 0.779946   -1.17 
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CD86 8.62 8.90 0.002534 0.002099 1.21 0.723402   1.21 
CEBPB 3.98 3.63 0.063168 0.081051 0.78 0.325473   -1.28 
CREBBP 5.83 5.21 0.017612 0.027039 0.65 0.252644   -1.54 
CSF2 5.72 5.05 0.019007 0.030236 0.63 0.416710   -1.59 
CTLA4 5.52 6.16 0.021792 0.013993 1.56 0.124485   1.56 
CXCR3 4.87 4.82 0.034121 0.035428 0.96 0.859849   -1.04 
FASLG 6.32 6.08 0.012532 0.014737 0.85 0.708323   -1.18 
GATA3 7.06 6.19 0.007470 0.013744 0.54 0.246659   -1.84 
GFI1 5.89 5.76 0.016826 0.018449 0.91 0.846832   -1.10 
GLMN 5.62 5.17 0.020306 0.027802 0.73 0.521010   -1.37 
GPR44 9.53 8.33 0.001352 0.003099 0.44 0.550545   -2.29 
HAVCR2 5.89 6.12 0.016899 0.014405 1.17 0.742221   1.17 
ICOS 4.37 5.15 0.048342 0.028158 1.72 0.003501   1.72 
IFNG 7.47 6.62 0.005650 0.010174 0.56 0.474972   -1.80 
IGSF6 5.49 5.07 0.022263 0.029862 0.75 0.394582   -1.34 
IL10 4.57 4.53 0.042239 0.043321 0.98 0.916956   -1.03 
IL12B 6.75 5.68 0.009265 0.019497 0.48 0.391780   -2.10 
IL12RB2 9.56 8.75 0.001324 0.002323 0.57 0.538557   -1.75 
IL13 9.34 8.04 0.001539 0.003796 0.41 0.437126   -2.47 
IL13RA1 7.06 5.68 0.007504 0.019513 0.38 0.035300   -2.60 
IL15 5.29 4.62 0.025485 0.040750 0.63 0.217225   -1.60 
IL18 8.43 6.94 0.002890 0.008136 0.36 0.371594   -2.82 
IL18R1 5.70 4.84 0.019184 0.034956 0.55 0.309435   -1.82 
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IL1R1 5.13 4.23 0.028606 0.053129 0.54 0.106766   -1.86 
IL1R2 9.30 8.81 0.001585 0.002229 0.71 0.714447   -1.41 
IL2 8.37 7.33 0.003019 0.006198 0.49 0.535127   -2.05 
IL2RA 3.14 2.73 0.113824 0.150791 0.75 0.056986   -1.32 
IL4 9.98 8.23 0.000987 0.003335 0.30 0.385821   -3.38 
IL4R 2.26 2.28 0.208104 0.206507 1.01 0.963297   1.01 
IL5 8.62 7.28 0.002541 0.006454 0.39 0.408248   -2.54 
IL6 -0.04 -0.48 1.025343 1.395543 0.73 0.088449   -1.36 
IL6R 4.05 3.12 0.060445 0.114730 0.53 0.022485   -1.90 
IL7 3.97 3.30 0.063769 0.101701 0.63 0.074046   -1.59 
IL9 11.34 8.61 0.000385 0.002553 0.15 0.241052   -6.63 
INHA 9.87 7.52 0.001072 0.005463 0.20 0.246703   -5.10 
INHBA 3.70 3.24 0.076943 0.105685 0.73 0.148977   -1.37 
IRF1 1.56 2.36 0.338753 0.194646 1.74 0.043141   1.74 
IRF4 3.36 3.38 0.097299 0.096081 1.01 0.935635   1.01 
JAK1 1.52 1.55 0.348639 0.341485 1.02 0.835647   1.02 
JAK2 4.91 4.69 0.033164 0.038723 0.86 0.713444   -1.17 
LAG3 5.60 5.47 0.020589 0.022515 0.91 0.845529   -1.09 
LAT 2.49 2.58 0.177514 0.167571 1.06 0.757941   1.06 
MAF 5.59 5.41 0.020704 0.023500 0.88 0.717299   -1.14 
MAP2K7 6.30 5.03 0.012717 0.030527 0.42 0.194004   -2.40 
MAPK8 5.06 4.39 0.030072 0.047629 0.63 0.149451   -1.58 
NFATC1 4.73 4.13 0.037806 0.057031 0.66 0.205762   -1.51 
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NFATC2 5.96 6.44 0.016077 0.011487 1.40 0.338047   1.40 
NFATC2IP 4.36 4.64 0.048803 0.040223 1.21 0.337225   1.21 
PCGF2 9.30 7.63 0.001592 0.005040 0.32 0.328991   -3.17 
PTPRC -0.04 0.41 1.029355 0.753203 1.37 0.247347   1.37 
SFTPD 10.31 10.29 0.000790 0.000796 0.99 0.994030   -1.01 
SOCS1 2.83 3.52 0.140848 0.086929 1.62 0.021385   1.62 
SOCS2 10.28 7.67 0.000807 0.004920 0.16 0.257681   -6.10 
SOCS5 4.08 4.54 0.059292 0.042929 1.38 0.713492   1.38 
SPP1 10.19 8.23 0.000858 0.003340 0.26 0.190774   -3.89 
STAT1 0.98 1.28 0.505485 0.412132 1.23 0.538002   1.23 
STAT4 5.27 4.87 0.025849 0.034204 0.76 0.256023   -1.32 
STAT6 2.13 1.51 0.228802 0.351706 0.65 0.086321   -1.54 
TBX21 5.60 5.16 0.020616 0.027950 0.74 0.553312   -1.36 
TFCP2 5.14 4.88 0.028296 0.033873 0.84 0.533033   -1.20 
TGFB3 6.85 5.91 0.008696 0.016621 0.52 0.445071   -1.91 
TLR4 7.54 6.61 0.005379 0.010207 0.53 0.379923   -1.90 
TLR6 6.76 6.04 0.009209 0.015180 0.61 0.428328   -1.65 
TMED1 6.99 7.30 0.007864 0.006366 1.24 0.490656   1.24 
TNF 5.48 5.07 0.022363 0.029674 0.75 0.341534   -1.33 
CD27 3.58 2.86 0.083764 0.138109 0.61 0.066400   -1.65 
TNFRSF8 6.73 6.03 0.009436 0.015292 0.62 0.476827   -1.62 
TNFRSF9 6.92 6.08 0.008246 0.014766 0.56 0.375040   -1.79 
TNFSF4 9.03 8.85 0.001907 0.002165 0.88 0.863152   -1.13 
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TYK2 4.81 4.19 0.035666 0.054867 0.65 0.084581   -1.54 
YY1 3.19 3.49 0.109513 0.088923 1.23 0.376871   1.23 
B2M -3.22 -3.06 9.320926 8.342482 1.12 0.446909   1.12 
HPRT1 4.87 4.88 0.034250 0.033863 1.01 0.934418   1.01 
RPL13A -0.35 -0.01 1.272330 1.004001 1.27 0.072397   1.27 
GAPDH 1.37 0.43 0.386411 0.742421 0.52 0.009473   -1.92 
ACTB -2.67 -2.25 6.371383 4.748900 1.34 0.000541   1.34 
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Table A7. Mismatched MLC gene expression data analysis at 48 hours of 
incubation supplemented with of LPS normalised to controls. Group 1 represents 
the mismatched MLC results while Control Group represents both individuals cells 
incubated alone under the same conditions in the same run. Results shown are from 
three different pairs experiments repeated in triplicate. MLCs set up using mismatched 
subject pairs as described in Chapter 2, Section 2.3. At 48 hours, cells were harvested 
and plated as described in Chapter 2, Section 2.5. using the SuperArray Th1-Th2-Th3 
kit. Data was then analysed using the SuperArray software for this plate. 
Gene 
Symbol 
AVG ΔCt 2^-ΔCt 
Fold 
Change 
p-value 
Fold Up- or 
Down-
Regulation 
Group 1 
Control 
Group 
Group 1 
Control 
Group 
Group 
1/Control 
P Value 
Group 
1/Control 
IL17A 10.91 9.15 0.000521 0.001759 0.30 0.491290   -3.37 
CCL11 9.67 8.82 0.001224 0.002205 0.56 0.693653   -1.80 
CCL5 2.07 1.95 0.238250 0.258416 0.92 0.752726   -1.08 
CCL7 2.76 2.84 0.147926 0.139184 1.06 0.436056   1.06 
CCR2 7.21 6.43 0.006762 0.011600 0.58 0.552548   -1.72 
CCR3 6.88 6.34 0.008472 0.012384 0.68 0.573292   -1.46 
CCR4 4.89 4.39 0.033806 0.047683 0.71 0.167171   -1.41 
CCR5 4.15 4.09 0.056385 0.058657 0.96 0.912951   -1.04 
CD28 9.94 7.87 0.001016 0.004262 0.24 0.270195   -4.20 
CD4 5.09 4.68 0.029428 0.038912 0.76 0.123522   -1.32 
CD40LG 6.47 5.78 0.011279 0.018209 0.62 0.203120   -1.61 
IL23A 6.56 5.67 0.010590 0.019706 0.54 0.271568   -1.86 
CD80 8.20 6.93 0.003393 0.008199 0.41 0.136095   -2.42 
CD86 7.71 7.28 0.004765 0.006452 0.74 0.577497   -1.35 
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CEBPB 4.23 3.39 0.053383 0.095292 0.56 0.048447   -1.79 
CREBBP 5.82 5.70 0.017657 0.019183 0.92 0.804169   -1.09 
CSF2 7.57 7.01 0.005247 0.007776 0.67 0.383867   -1.48 
CTLA4 6.37 6.12 0.012095 0.014357 0.84 0.473151   -1.19 
CXCR3 6.24 5.42 0.013198 0.023297 0.57 0.132657   -1.77 
FASLG 7.08 6.13 0.007411 0.014311 0.52 0.011955   -1.93 
GATA3 7.76 6.70 0.004602 0.009606 0.48 0.116524   -2.09 
GFI1 7.11 5.75 0.007261 0.018546 0.39 0.044898   -2.55 
GLMN 6.27 5.32 0.012986 0.024951 0.52 0.045096   -1.92 
GPR44 9.78 7.92 0.001135 0.004134 0.27 0.266622   -3.64 
HAVCR2 6.79 6.04 0.009048 0.015158 0.60 0.207949   -1.68 
ICOS 5.08 4.91 0.029563 0.033236 0.89 0.316310   -1.12 
IFNG 7.61 7.01 0.005102 0.007761 0.66 0.508682   -1.52 
IGSF6 5.50 5.05 0.022117 0.030107 0.73 0.043531   -1.36 
IL10 6.15 5.42 0.014108 0.023333 0.60 0.217200   -1.65 
IL12B 8.99 7.18 0.001969 0.006877 0.29 0.217381   -3.49 
IL12RB2 11.44 9.41 0.000361 0.001474 0.24 0.220855   -4.08 
IL13 9.47 8.55 0.001412 0.002661 0.53 0.665900   -1.88 
IL13RA1 5.75 5.48 0.018528 0.022441 0.83 0.415707   -1.21 
IL15 5.92 5.21 0.016563 0.027099 0.61 0.034518   -1.64 
IL18 8.83 7.32 0.002193 0.006252 0.35 0.302908   -2.85 
IL18R1 6.00 5.08 0.015652 0.029515 0.53 0.113769   -1.89 
IL1R1 5.00 4.26 0.031268 0.052078 0.60 0.045240   -1.67 
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IL1R2 8.37 7.29 0.003021 0.006392 0.47 0.318273   -2.12 
IL2 7.86 7.11 0.004316 0.007257 0.59 0.647321   -1.68 
IL2RA 4.28 4.07 0.051502 0.059471 0.87 0.486700   -1.15 
IL4 10.05 8.28 0.000944 0.003214 0.29 0.380295   -3.41 
IL4R 2.68 2.31 0.156566 0.201401 0.78 0.045282   -1.29 
IL5 8.72 7.58 0.002370 0.005225 0.45 0.521798   -2.20 
IL6 1.01 1.23 0.496138 0.426412 1.16 0.650123   1.16 
IL6R 4.25 3.59 0.052699 0.083266 0.63 0.036238   -1.58 
IL7 5.18 4.29 0.027519 0.051025 0.54 0.137909   -1.85 
IL9 9.59 8.70 0.001301 0.002406 0.54 0.627424   -1.85 
INHA 11.01 7.55 0.000483 0.005343 0.09 0.137683   -11.06 
INHBA 4.54 4.38 0.043023 0.047903 0.90 0.715338   -1.11 
IRF1 2.92 2.72 0.132489 0.151501 0.87 0.715602   -1.14 
IRF4 4.69 4.19 0.038713 0.054646 0.71 0.061863   -1.41 
JAK1 1.77 1.91 0.292805 0.265769 1.10 0.110559   1.10 
JAK2 5.49 4.65 0.022181 0.039695 0.56 0.088369   -1.79 
LAG3 6.83 5.69 0.008771 0.019316 0.45 0.120396   -2.20 
LAT 2.90 2.54 0.133883 0.171653 0.78 0.326565   -1.28 
MAF 5.46 5.23 0.022641 0.026698 0.85 0.397288   -1.18 
MAP2K7 7.86 5.89 0.004313 0.016918 0.25 0.065273   -3.92 
MAPK8 5.54 4.86 0.021554 0.034333 0.63 0.063753   -1.59 
NFATC1 5.31 4.68 0.025133 0.038953 0.65 0.050586   -1.55 
NFATC2 7.12 6.10 0.007182 0.014612 0.49 0.019788   -2.03 
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NFATC2IP 5.44 4.69 0.023066 0.038621 0.60 0.038522   -1.67 
PCGF2 9.01 7.92 0.001933 0.004143 0.47 0.499075   -2.14 
PTPRC 0.79 0.55 0.579326 0.682592 0.85 0.456679   -1.18 
SFTPD 11.61 10.72 0.000320 0.000591 0.54 0.514176   -1.85 
SOCS1 3.97 3.80 0.063667 0.071910 0.89 0.585695   -1.13 
SOCS2 9.57 8.07 0.001318 0.003719 0.35 0.480770   -2.82 
SOCS5 5.85 5.01 0.017309 0.030993 0.56 0.318781   -1.79 
SPP1 8.65 7.87 0.002492 0.004266 0.58 0.476796   -1.71 
STAT1 1.86 1.97 0.276154 0.255301 1.08 0.879559   1.08 
STAT4 5.39 5.41 0.023865 0.023545 1.01 0.922811   1.01 
STAT6 2.49 2.06 0.178436 0.239653 0.74 0.021354   -1.34 
TBX21 6.60 5.40 0.010279 0.023679 0.43 0.045920   -2.30 
TFCP2 5.86 5.17 0.017175 0.027866 0.62 0.045071   -1.62 
TGFB3 7.30 5.89 0.006325 0.016808 0.38 0.167899   -2.66 
TLR4 7.26 6.48 0.006517 0.011229 0.58 0.407086   -1.72 
TLR6 7.27 6.25 0.006458 0.013153 0.49 0.276089   -2.04 
TMED1 7.48 6.84 0.005616 0.008719 0.64 0.343636   -1.55 
TNF 5.70 5.54 0.019275 0.021535 0.90 0.595425   -1.12 
CD27 3.12 3.17 0.114669 0.110759 1.04 0.797027   1.04 
TNFRSF8 6.10 5.62 0.014558 0.020358 0.72 0.536899   -1.40 
TNFRSF9 7.41 6.49 0.005868 0.011114 0.53 0.233017   -1.89 
TNFSF4 9.46 8.24 0.001419 0.003301 0.43 0.232317   -2.33 
TYK2 5.88 4.95 0.017029 0.032352 0.53 0.001394   -1.90 
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YY1 3.78 3.40 0.072860 0.094681 0.77 0.362713   -1.30 
B2M -3.18 -3.07 9.047881 8.421166 1.07 0.601603   1.07 
HPRT1 4.91 4.61 0.033158 0.040825 0.81 0.322917   -1.23 
RPL13A -0.12 -0.12 1.085565 1.085451 1.00 0.999404   1.00 
GAPDH 0.79 1.02 0.578684 0.492602 1.17 0.394471   1.17 
ACTB -2.41 -2.44 5.306081 5.439956 0.98 0.834521   -1.03 
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Table A8.  Matched MLC gene expression data analysis at 72 hours of incubation 
normalised to controls. Group 1 represents the mismatched MLC results while Control 
Group represents both individuals cells incubated alone under the same conditions in 
the same run. Results shown are from three different pairs experiments repeated in 
triplicate. MLCs set up using matched subject pairs as described in Chapter 2, Section 
2.3. At 72 hours, cells were harvested and plated as described in Chapter 2, Section 
2.5. using the SuperArray Th1-Th2-Th3 kit. Data was then analysed using the 
SuperArray software for this plate. 
Gene 
Symbol 
AVG ΔCt 2^-ΔCt 
Fold 
Change 
p-value 
Fold Up- or 
Down-
Regulation 
Group 
1 
Control 
Group 
Group 1 
Control 
Group 
Group 
1/Control 
P Value 
Group 
1/Control 
IL17A 5.78 9.11 0.018183 0.001814 10.02 0.066940   10.02 
CCL11 5.52 8.73 0.021793 0.002349 9.28 0.054491   9.28 
CCL5 1.02 0.62 0.491865 0.652340 0.75 0.223987   -1.33 
CCL7 6.20 8.21 0.013609 0.003379 4.03 0.144144   4.03 
CCR2 5.21 6.43 0.027011 0.011594 2.33 0.033823   2.33 
CCR3 4.97 6.63 0.032006 0.010067 3.18 0.077470   3.18 
CCR4 4.90 5.51 0.033434 0.021903 1.53 0.160356   1.53 
CCR5 4.00 4.33 0.062551 0.049725 1.26 0.132829   1.26 
CD28 5.85 8.23 0.017395 0.003331 5.22 0.039495   5.22 
CD4 3.16 3.57 0.112160 0.084343 1.33 0.286524   1.33 
CD40LG 4.91 5.59 0.033148 0.020808 1.59 0.260360   1.59 
IL23A 5.12 8.77 0.028785 0.002293 12.56 0.000736   12.56 
CD80 6.17 7.88 0.013929 0.004254 3.27 0.007439   3.27 
CD86 5.79 5.77 0.018113 0.018381 0.99 0.939690   -1.01 
CEBPB 4.53 4.33 0.043360 0.049881 0.87 0.520882   -1.15 
CREBBP 4.94 5.44 0.032557 0.023019 1.41 0.074707   1.41 
CSF2 6.60 8.78 0.010321 0.002269 4.55 0.044825   4.55 
CTLA4 6.80 7.89 0.008947 0.004210 2.13 0.061606   2.13 
CXCR3 6.57 6.94 0.010562 0.008117 1.30 0.357898   1.30 
FASLG 5.44 6.14 0.023048 0.014206 1.62 0.036479   1.62 
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GATA3 6.35 7.35 0.012300 0.006125 2.01 0.075666   2.01 
GFI1 5.66 6.75 0.019800 0.009311 2.13 0.030437   2.13 
GLMN 4.92 5.70 0.033003 0.019253 1.71 0.074300   1.71 
GPR44 5.49 8.26 0.022215 0.003263 6.81 0.022258   6.81 
HAVCR2 4.41 4.85 0.047160 0.034741 1.36 0.033385   1.36 
ICOS 6.47 6.83 0.011288 0.008802 1.28 0.471613   1.28 
IFNG 5.69 6.77 0.019351 0.009149 2.12 0.028352   2.12 
IGSF6 2.29 2.01 0.204211 0.249114 0.82 0.179898   -1.22 
IL10 5.84 6.54 0.017466 0.010765 1.62 0.150927   1.62 
IL12B 5.68 8.89 0.019441 0.002112 9.20 0.094242   9.20 
IL12RB2 8.08 10.19 0.003695 0.000854 4.33 0.090850   4.33 
IL13 5.54 6.87 0.021559 0.008577 2.51 0.413660   2.51 
IL13RA1 4.23 4.40 0.053205 0.047357 1.12 0.640638   1.12 
IL15 4.77 5.71 0.036606 0.019081 1.92 0.078534   1.92 
IL18 4.75 5.62 0.037104 0.020284 1.83 0.094224   1.83 
IL18R1 5.26 6.36 0.026142 0.012133 2.15 0.103054   2.15 
IL1R1 4.48 5.18 0.044751 0.027495 1.63 0.192507   1.63 
IL1R2 6.23 8.42 0.013283 0.002029 4.54 0.045721   4.54 
IL2 4.84 6.65 0.035004 0.009924 3.53 0.038665   3.53 
IL2RA 4.75 5.94 0.037104 0.016262 2.28 0.063549   2.28 
IL4 5.95 7.96 0.016182 0.004023 4.02 0.081704   4.02 
IL4R 2.88 3.08 0.136065 0.118418 1.15 0.372368   1.15 
IL5 5.42 7.38 0.023384 0.006021 3.88 0.059658   3.88 
IL6 6.05 8.13 0.015096 0.003561 4.24 0.073627   4.24 
IL6R 3.38 3.93 0.096230 0.065500 1.47 0.198834   1.47 
IL7 5.14 6.28 0.028445 0.012882 2.21 0.034448   2.21 
IL9 5.94 9.29 0.016268 0.001595 10.20 0.048763   10.20 
INHA 6.17 8.44 0.013850 0.002878 4.81 0.082674   4.81 
INHBA 5.44 7.64 0.023110 0.005007 4.62 0.118030   4.62 
IRF1 4.23 4.23 0.053330 0.053108 1.00 0.991936   1.00 
IRF4 4.49 4.88 0.044427 0.033965 1.31 0.225003   1.31 
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JAK1 2.18 2.20 0.220655 0.217441 1.01 0.923827   1.01 
JAK2 3.75 4.18 0.074269 0.055078 1.35 0.167139   1.35 
LAG3 5.54 6.29 0.021558 0.012790 1.69 0.194267   1.69 
LAT 3.39 3.58 0.095105 0.083700 1.14 0.717267   1.14 
MAF 4.10 4.65 0.058422 0.039798 1.47 0.279883   1.47 
MAP2K7 5.28 6.87 0.025807 0.008532 3.02 0.019185   3.02 
MAPK8 4.69 5.53 0.038712 0.021630 1.79 0.171684   1.79 
NFATC1 4.93 5.56 0.032899 0.021212 1.55 0.213641   1.55 
NFATC2 6.33 7.01 0.012402 0.007748 1.60 0.301800   1.60 
NFATC2IP 4.81 5.01 0.035694 0.030951 1.15 0.657014   1.15 
PCGF2 5.92 8.14 0.016522 0.003538 4.67 0.036618   4.67 
PTPRC 0.99 0.40 0.505214 0.757139 0.67 0.281170   -1.50 
SFTPD 8.83 10.57 0.002191 0.000659 3.32 0.100383   3.32 
SOCS1 5.84 6.35 0.017479 0.012269 1.42 0.123527   1.42 
SOCS2 5.62 8.20 0.020347 0.003398 5.99 0.131574   5.99 
SOCS5 4.80 5.74 0.035973 0.018674 1.93 0.149420   1.93 
SPP1 5.57 6.94 0.021088 0.008166 2.58 0.003846   2.58 
STAT1 1.97 1.99 0.254782 0.252545 1.01 0.987172   1.01 
STAT4 5.05 5.45 0.030096 0.022948 1.31 0.519169   1.31 
STAT6 2.15 2.50 0.226022 0.176476 1.28 0.389933   1.28 
TBX21 4.32 5.15 0.050156 0.028185 1.78 0.156186   1.78 
TFCP2 4.83 5.19 0.035145 0.027314 1.29 0.288372   1.29 
TGFB3 4.66 6.17 0.039629 0.013904 2.85 0.037562   2.85 
TLR4 3.36 3.44 0.097333 0.092019 1.06 0.754184   1.06 
TLR6 6.02 6.73 0.015442 0.009427 1.64 0.047824   1.64 
TMED1 6.97 7.08 0.007977 0.007387 1.08 0.735677   1.08 
TNF 4.36 4.63 0.048703 0.040389 1.21 0.432477   1.21 
CD27 2.73 3.20 0.151172 0.108758 1.39 0.096499   1.39 
TNFRSF8 5.67 7.45 0.019626 0.005731 3.42 0.018045   3.42 
TNFRSF9 5.68 8.01 0.019479 0.003883 5.02 0.015023   5.02 
TNFSF4 7.88 9.68 0.004254 0.001217 3.50 0.023612   3.50 
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TYK2 5.20 5.77 0.027162 0.018364 1.48 0.274201   1.48 
YY1 3.25 4.04 0.104785 0.060939 1.72 0.326215   1.72 
B2M -3.66 -3.60 
12.63540
5 
12.095764 1.04 0.598384   1.04 
HPRT1 4.75 4.83 0.037098 0.035244 1.05 0.628148   1.05 
RPL13A 0.41 0.32 0.751095 0.801105 0.94 0.737481   -1.07 
GAPDH 1.28 1.43 0.412186 0.371203 1.11 0.682322   1.11 
ACTB -2.78 -2.98 6.890936 7.888203 0.87 0.355071   -1.14 
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